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Abstract 
The Interferon (IFN) family of cytokines are produced in direct response to virus 
infection and they constitute the first line of defence against virus infection by 
inducing hundreds of interferon stimulated genes (ISGs) which act in concert to 
establish the so called “antiviral state”. Influenza A viruses and parainfluenza virus 
type 5 (PIV5) are both small negative strand RNA viruses that must circumvent their 
hosts’ interferon (IFN) response for replication. However, the ways in which these 
viruses interact with the IFN system are very different. Although PIV5 replication is 
initially severely impaired in cells in a pre-existing IFN-induced antiviral state, it 
manages to overcome the antiviral state by targeting an essential component of type I 
IFN signalling, STAT1, for degradation. Thus the cells cannot maintain the antiviral 
state indefinitely without continuous signalling. Consequently, the virus resumes its 
normal replication pattern after 24-48 hours post-infection. In clear contrast, influenza 
virus fails to establish its replication in the majority of infected cells (90-95%) with a 
pre-existing IFN-induced antiviral state, although a few cells are still able to produce 
viral antigens.  
To further investigate how influenza virus interacts with cells in a pre-existing IFN-
induced antiviral state, I have used in situ hybridization to follow the fate of input and 
progeny genomes in cells that have, or have not, been treated with IFN prior to 
infection. Here I show for the first time that IFN pre-treatment blocks the nuclear 
import of influenza A virus genome, which prevents the establishment of virus 
replication, but this can be overcome by increasing multiplicities of infection. Of 
those IFN-induced antiviral molecules, human MxA is an essential component of the 
IFN-induced antiviral state in blocking influenza virus genome import, as this block 
can be abolished by lentivirus-mediated knockdown of MxA. I also show that in cells 
constitutively expressing MxA the viral genome still manages to be transported into 
the nucleus, indicating that MxA might require an unidentified IFN-induced factor to 
block nuclear import of the influenza virus genome.  
These results reveal that IFN exerts its action at an early stage of virus infection by 
inducing MxA to interfere with the transport of viral genome into the nucleus, which 





1. Candidate’s declarations: 
 
I, Han Xiao, hereby certify that this thesis, which is approximately 44300 words in 
length, has been written by me, that it is the record of work carried out by me 
and that it has not been submitted in any previous application for a higher 
degree.  
 
I was admitted as a research student in Sept 2007 and as a candidate for the degree of 
Doctor of Phyilosophy (PhD) in Molecular Virology; the higher study for 
which this is a record was carried out in the University of St Andrews 
between 2007 and 2010.  
 
 
Date ……………… Signature of candidate ………….…  
 
2. Supervisor’s declaration: 
 
I hereby certify that the candidate has fulfilled the conditions of the Resolution and 
Regulations appropriate for the degree of Doctor of Phyilosophy (PhD) in 
the University of St Andrews and that the candidate is qualified to submit 
this thesis in application for that degree.  
 
 
Date ……………….. Signature of supervisor ……………… 
 
3. Permission for electronic publication:  
 
In submitting this thesis to the University of St Andrews I understand that I am 
giving permission for it to be made available for use in accordance with the 
regulations of the University Library for the time being in force, subject to any 
copyright vested in the work not being affected thereby.  I also understand that the 
title and the abstract will be published, and that a copy of the work may be made 
and supplied to any bona fide library or research worker, that my thesis will be 
electronically accessible for personal or research use unless exempt by award of an 
embargo as requested below, and that the library has the right to migrate my thesis 
into new electronic forms as required to ensure continued access to the thesis. I 
have obtained any third-party copyright permissions that may be required in order 
to allow such access and migration, or have requested the appropriate embargo 
below.  
 
The following is an agreed request by candidate and supervisor regarding the 
electronic publication of this thesis: 
 
Access to all of printed copy but embargo of all of electronic publication of thesis 
for a period of two years on the following ground(s): 
 
publication would be commercially damaging to the researcher, or to the 
supervisor, or the University;  
publication would preclude future publication;  




Date ………… Signature of candidate …..…  Signature of supervisor ……… 
	  
ACKNOWLEDGEMENTS 	  	  
This thesis would not have been possible without the support of many people who in 
one way or another contributed and extended their valuable help in the preparation 
and completion of my PhD project. 
First and Foremost, I would like to express my utmost gratitude to my supervisor 
Prof. Rick Randall for the continuous support of my Ph.D project, for his patience, 
motivation, enthusiasm, and immense knowledge. His guidance helped me in all the 
time of research and writing of this thesis. His insightful and critical thinking in 
scientific research, make a shining exemplary for me to grow to an independent 
researcher. I could not have imagined having a better supervisor and mentor for my 
Ph.D study. 
 
I am also extremely grateful to all members of the RER group for their constructive 
criticism, valuable discussion, excellent technical help, and genuine friendliness. 
Thank you David Jackson, Dan Young, Lena Andrejeva, Bernie Precious, Marian 
Killip, Claudia Hass, Hanna Norsted, John Short, Markus Schneider, and Shu Chen.	  	  
I also very grateful Prof. Peter Staeheli, Prof. Otto Haller and Dr. Georg Kochs from 
University of Freiburg for providing me the great opportunity to attend the 5th 
othomyxoviruses conference and a short research visit.	  	  
I also thank my friends Yaoqing Zhang, Xuejun Li, Lei Yang, Guogang Xu, Sijing 
Wang, Xiaoxuan Qi and many others due to the page limit I cannot list them all, you 
make my days in St Andrews very special and enjoyable. 	  	  
Last but not least, I am indebt to my family: my parents for their continuous 
emotional support. My wife Yan Li for your love, encouragement and always 
standing besides me no matter how hard the time is. I am also deeply grateful to my 






ADAR1 Adenosine deaminase. 
ATF-2 Activating transcription factor 2. 
bRSV Bovine respiratory syncytial virus. 
BSA Bovine serum albumin. 
BVDV Bovine Diarrhoea Virus. 
CARD Caspase activation and recruitment domain. 
CARDIF	   CARD	  Adaptor	  inducing	  IFN-­‐β 
CDV Canine distemper virus. 
CHX Cycloheximide. 
CPSF Cleavage and polyadenylation specific factor. 
CPE cytopathic effect. 
CPSF30 Cleavage and polyadenylation specificity factor. 
CRM1 Chromosome region maintenance 1 protein. 
cRNA Complementary RNA 
DAPI DNA-binding fluorochrome 4′,6′-diamidino-2-phenylindole. 
DDB1 DNA-binding protein 1. 
DIG Digoxigenin. 
DMEM Dulbecco’s modified Eagle’s medium. 
DMSO Dimethyl sulfoxide. 
DRBM  dsRNA binding motif. 
dsRNA Double strand RNA. 
DTT Dithiothreitol. 
ECL Enhanced luminol-based chemiluminescent. 
EDTA Ethylenediaminetetraacetic acid. 
eIF2α  alpha subunit of eukaryotic initiation factor 2. 
eIF4GI Eukaryotic translation initiation factor 4GI. 
EMCV Encephalomyocarditis virus. 
Epf Estrogen-responsive finger protein. 
ER Endoplasmic reticulum. 
FCS Fetal calf serum. 
FITC Fluorescein isothiocyanate. 
FLUAV Influenza A virus. 
FP Fusion peptide. 
GAS Gamma-activation sequence. 
GDP Guanosine diphosphate. 
GFP Green fluorescent protein. 
GTP Guanosine-5'-triphosphate. 
HA hemagglutinin. 
HCMV human cytomegalovirus. 
Herc5 interferon-induced HECT E3 enzyme. 
HeV Hendra virus. 
HGM I(Y) Non-histone high mobility group. 
hMPV Human metapneumovirus. 
hPIV Parainfluenza viruses. 
HPV human papillomavirus. 
HRP Horseradish peroxidase. 
hRSV Human respiratory syncytial virus. 
IFN Interferon.  
IFNAR IFN-α/β receptor. 
IFNGR IFN-γ receptor. 
IPS-1 IFN-­‐β	  promoter	  stimulator	  1.	  
IRF3  Interferon regulatory factor 3. 
IRFs Interferon regulatory factors. 
ISGF3 ISG factor 3. 
ISGs Interferon stimulated genes. 
iSH2 inter-SH2. 
ISRE IFN-stimulated response element. 
Jaks Janus activated kinases. 
JEV Japanese encephalitis virus. 
LCMV lymphocytic choriomeningitis virus. 
LGP2 Laboratory of genetics and physiology 2. 
MAVS Mitochondrial antiviral signalling protein. 
MDA-5 Melanoma differentiation-accociated gene 5. 
MeV Measles virus. 
MFSV Maize fine streak virus. 
MOI Multiplicity of infection. 
mRNA Messenger RNA. 
MuV Mumps virus. 
Mx1 Orthomyxovirus resistance gene 1. 
MxA Myxovirus resistant protein A. 
NA Neuraminidase. 
NAT N-acetyl trypsin. 
ND Newcastle disease. 
NDV Newcastle disease virus. 
NEP Nuclear export protein. 
NES Nuclear export signal. 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells. 
NiV Nipah virus. 
NLRs Nucloetide oligomerization domain-like receptors. 
NLSs Nuclear localization signals. 
NMR Nuclear magnetic resonance 
NOD nuclotide oligomerization domain. 
NoLS Nucleolar localization signal. 
NS1 non-structural protein 1. 
NS1B Influenza B virus NS1. 
NS2 non-structural protein 2. 
OAS Oligoadenylate synthetase. 
ORFs Open reading frames. 
p.i. post-infection. 
PABII poly(A)-binding protein II. 
PAMPs Pathgen associated molecular patterns. 
PBS Phosphate buffered saline. 
PCR Polymerase chain reaction. 
pfu Plaque-forming units. 
PI3K Phosphatidylinositol 3-kinase. 
PIP3 Phosphatidylinositol-3,4,5-trisphosphate. 
PKR dsRNA-dependent protein kinase. 
PRDs Positive regulatory domains. 
PRRs pattern-recognition receptors. 
PTEN Phosphatase and tensin homolog. 
PVDF Polyvinylidene difluoride. 
RBD RNA-binding domain. 
RIG-I Retinoic acid inducible gene I. 
RLRs Retinoic acid inducible gene-like receptors. 
RSV Respiratory Syncytial Virus. 
SDS Sodium dodecyl sulfate. 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
SeV Sendai virus. 
SH2 Src homology 2. 
SH3 Src homology 3. 
shRNA Small hairpin RNA or short hairpin RNA. 
SSC Saline-sodium citrate. 
ssRNA Single strand RNA. 
STATs Signal transducer and activator of transcription. 
SUMO Small ubiquitin-like modifier. 
SV5 Simian virus 5. 
TANK TRAF-associated NF-κB activator. 
TLRs Toll-like receptors. 
TM transmembrane. 
TMD Transmembrane domains. 
TNF Tumor necrosis factor. 
TPR tetratricopeptide. 
TRAF Tumor necrosis factor receptor-associated factor. 
TRIM Tripartite motif 
tRNAi Initiator transfer RNA 
ts Temperature sensitive. 
TYK2 Tyrosine kinase 2. 
UBE1L Ubiquitin-activating enzyme E1-like protein. 
Udorn Influenza A virus strain A/Udorn. 
viperin Virus inhibitory protein, ER-associated, interferon-inducible. 
VISA Virus-induced signalling adaptor 	  	  
VRC Vanadyl Ribonucloside Complex. 
vRNP Viral ribonucleocapsid. 
VV Vaccinia virus. 
W3 PIV5 strain W3. 
WHO World health organization. 
WSN Influenza A virus strain A/WSN/33. 






List of Contents 
 
CHAPTER 1: INTRODUCTION 
1.1 The Interferon system………………………………………………………………… 1 
1.1.1 Mechanisms of type I IFN induction………………………………………………………. 2 
1.1.1.1 Type I IFN induction…………………………………………………………….... 2 
1.1.1.2 IFN-β promoter………………………………………………………………….… 3 
1.1.2 Mechanisms of IFN signalling……………………………………………………….…..… 5 
1.1.2.1 Type I IFN signalling………………………………………………………….…... 5 
1.1.2.2 Type II IFN signalling………………………………………………………….…. 6 
1.1.3 IFN induced antiviral states……………………………………………………………...… 7 
1.1.3.1 dsRNA-dependent protein kinase (PKR) ……………………………………….… 7 
1.1.3.2 2’-5’OAS/RNase L system…………………………………………………….….. 9 
1.1.3.3 Mx GTPase……………………………………………………………………….... 10 
1.1.3.4 ISG15…………………………………………………………………………….... 12 
1.1.3.5 Viperin…………………………………………………………………………..… 13 
1.1.3.6 ISG56…………………………………………………………………………....… 14 
1.1.4 Virus encoded IFN antagonists……………………………………………………….……. 15 
1.1.4.1 Vaccinia virus E3L………………………………………………………….…….. 15 
1.1.4.2 Influenza A virus NS1……………………………………………………….……. 16 
1.1.4.3 Influenza B virus NS1…………………………………………………….………. 16 
1.1.5 Virus shut-off of host protein synthesis……………………………………………….…… 17 
 
1.2 The Paramyxoviridae………………………………………………………………….…… 18 
1.2.1 Introduction of paramyxoviruses……………………………………………………….….. 18 
1.2.2 Classification of paramyxoviruses…………………………………………………….…… 19 
1.2.3 Virion structure………………………………………………………………………….…. 21 
1.2.4 Genome organization………………………………………………………………….…… 22 
1.2.5 Paramyxoviridae genes and encoded proteins…………………………………….……….. 24 
1.2.5.1 The Nucleocapsid protein………………………………………………….……… 24 
1.2.5.2 The phosphoprotein…………………………………………………….…………. 24 
1.2.5.3 The V protein…………………………………………………………….………... 25 
1.2.5.4 The Matrix protein…………………………………………………………….…... 26 
1.2.5.5 The attachment protein………………………………………………………….… 27 
1.2.5.6 The fusion protein………………………………………..…………………….….. 28 
 
1.3 The Orthomyxoviridae…………………………………………………………….……….. 30 
1.3.1 Influenza A viruses………………………………………………………………….……... 30 
1.3.2 Virion structure…………………………………………………………………….………. 31 
1.3.3 Virus life cycle…………………………………………………………………….……….. 32 
1.3.3.1  Virus attachment and entry………………………………………………….……. 32 
1.3.3.2 vRNP nuclear import…………………………………………………………….... 33 
1.3.3.3 Transcription……………………………………………………………….……… 34 
1.3.3.4 Replication……………………………………………………………….………... 36 
1.3.3.5 Nuclear export…………………………………………………………………..…. 37 
1.3.3.6 Virion assembly………………………………………………………….………... 38 
1.3.3.7 Virion budding…………………………………………………………….………. 40 
1.3.4 Influenza A virus NS1 and host immune response……………………….…………… 42 
1.3.4.1 Synthesis of NS1 protein…………………………………………………….……. 42 
1.3.4.2 Sub-cellular localization of NS1 protein………………………………….………. 42 
1.3.4.3 NS1 and host immune response…………………………………………….……... 45 
1.3.4.3.1 NS1 Inhibits type I IFN production………………………………….…… 46 
(i) Pre-transcriptional limitation of IFN-β induction by NS1…………….…. 46 
(ii) Post-transcriptional limitation of IFN-β induction by NS1………….…… 47 
1.3.4.3.2 Ability of NS1 to limit IFN production is not absolute………………...… 48 
1.3.4.3.3 NS1 Inhibits OAS and PKR activity………………………………...…… 49 
1.3.4.3.4 NS1 activation of PI3K signalling……………………………………...… 50 
 
Aims of Thesis………………………………………………………………………………….… 52 
CHAPTER 2: MATERIALS AND METHODS 
2.1 Mammalian cells and tissue culture……………………………………………………… 53 
2.1.1 Cells types used in this study…………………………………………………………….… 53 
2.1.2 Cell maintenance…………………………………………………………………………… 54 
2.1.3 Cell stock preparation and resuscitation…………………………………………………… 54 
2.1.4 Treatment of cells………………………………………………………………..………… 54 
2.1.4.1 IFN treatment……………………………………………………………………… 54 
2.1.4.2 Transfections with plasmid DNA…………………………………………….…… 55 
 
2.2 Viruses and viruses infection…………………………………………….……….……….. 56 
2.2.1 Influenza viruses…………………………………….……….……….……….…………… 56 
2.2.2 Parainfluenza virus 5…………………………………………….……………….………… 57 
2.2.3 Virus infection…………………………………………….……………….…………….… 57 
2.2.4 Preparation of virus stocks…………………………………………….…………………… 58 
2.2.5 Titration of virus preparations…………………………………………….……………..… 58 
2.2.6 Immunostaining of influenza virus plaques………………………………………..….…… 59 
 
2.3 DNA subcloning………………………………………………….…………….……………. 61 
2.3.1 cDNA synthesis by reverse transcription…………………………………………….…..… 61 
2.3.2 Restriction enzyme digestion of DNA…………………………………………….……..… 61 
2.3.3 Transformation of competent cells…………………………………………….………...… 62 
2.3.4 Preparation of plasmid DNA…………………………………………….………………… 62 
2.3.5 Colony PCR screening…………………………………………….………….……….…… 62 
2.3.6 Agarose gel electrophoresis…………………………………………….………….…….… 63 
 
2.4 Protein analysis…………………………………………….……………….…………..…… 64 
2.4.1 SDS polyacrylamide gel electrophoresis…………………………………………….…..… 64 
2.4.2 Immunoblotting…………………………………………….……………….…………...… 64 
2.4.3 Immunofluorescence…………………………………………….……………….………… 65 
2.4.4 Preparation of radio-labelled antigen extracts, immunoprecipitation, and SDS-PAGE….... 67 
 
2.5 RNA analysis…………………………………………….…………………………………… 68 
2.5.1 RNA extraction…………………………………………….………………………………  68  
2.5.2 in situ hybridization…………………………………………….…………….…….……… 68 
2.5.2.1 Generation of single-stranded RNA probes………………………………..……… 68 
2.5.2.2 in situ hybridization…………………………………………….………………… 69 
 
2.6 Miscellaneous assays…………………………………………….…………….……………. 71 
2.6.1 Lentivirus-based shRNA plasmid preparation, virus production, and infection…………... 71 
2.6.1.1 Generation of shRNA constructs………………………………………….….…… 71 
2.6.1.2 Lentivirus production……….…………….…………….……....…………….…… 71 
2.6.1.3 Transduction of target cells……………………………………………………….. 72 
2.6.2 Lentivirus-based overexpression plasmid preparation, virus production, and infection…... 72 
 
2.7 Antibodies……………………………..…………………..…………………..………. 73 
2.8 Primers…………..…………………..……………………..…………………..……… 75 
2.9 Plasmids…………..…………………..……………………..…………………..…..… 77 
 
CHAPTER 3: RESULTS 
3.1 Comparing the mechanisms of Influenza A virus and PIV5 in dealing with the IFN 
response..……………………………………………………………………………………… 78 
3.1.1 Viral ability to overcome the IFN response is not absolute……………………………...… 78 
3.1.2 Comparison of FLUAV and PIV5 protein synthesis ……… ……………...……………… 80 
3.1.3 Study of the mechanism of host shutoff by Influenza A virus………………………..…… 81 
3.1.4 PIV5 can dismantle IFN-induced antiviral state…………………………………………… 83 
3.1.5 PIV5 could overcome the IFN-induced antiviral state in the presence of neutralizing 
antibodies…………………………………………………………………...……………… 84 
3.1.6 Influenza virus and the IFN-induced antiviral state……………………………………..… 87 
 
3.2 Characterization of influenza A virus replication in cells in an IFN-induced antiviral 
state…..………………………………………………………...……………………………… 88 
3.2.1 IFN treatment after virus infection failed to inhibit virus replication……………………… 88 
3.2.2 Multiplicity-dependent leakiness of the IFN-induced inhibition of virus replication……... 89 
3.2.3 Effects of IFN treatment upon vRNP import………………………………………………. 90 
3.2.4 Effects of MxA knockdown upon virus genome import………………………………...… 92 
3.2.5 Effects of MxA overexpression upon virus genome import………………………………. 94 
3.2.6 Effects of introducing MxA into MxA knockdown cells upon virus genome import…….. 95 
3.2.7 Effects of MxA in plaque reduction assay…………………………………………………. 98 
 
3.3 Identification of potential ISGs involved in the establishment of IFN-induced antiviral 
state. …………………………………………………………………………………………... 100 
3.3.1 Effects of viperin in plaque reduction assay……………………………………………….. 100 
3.3.2 Effects of ISG56 knockdown in plaque reduction assay…………………………………... 101 
3.3.3 Effects of ISGylation upon IFN-mediated plaque reduction………………………………. 102 
3.3.4 IFNγ does not have a significant effect on viral plaque reduction……………………….… 103 
 
CHAPTER 4: DISCUSSIONS 
4.1 Effects of IFN on the replication of PIV5……………………………….……...…… 104 
4.2 Comparison of PIV5 and FLUAV in dealing with the IFN response……………... 105 
4.3 Influenza A virus shut-off of host protein synthesis………………………………... 107 
4.4 Stages of influenza A virus replication blocked by IFN……………………………. 108 
4.5 MxA recognition of NP protein……………………………………………………… 109 
4.6 Cell type and virus strain specificity of the antiviral function of MxA…….…..….. 110 




A.1 Plasmid map of the pLKO.1 with shRNA construct…..………..……………… 143 
A.2 Plasmid map of the pdlNotI’IRESpuro vector…..………..………………..…… 145 
A.3 pGEM-T Easy Vector Map and sequence reference points…..………..………. 146 
	   1	  
1.1 The Interferon system 
The interferons (IFN) were initially discovered more than 50 years ago by Isaacs and 
Lindenmann as a molecule induced by heat-inactivated influenza virus, which were found 
to interfere with virus replication in previously uninfected cells (Isaacs and Lindenmann, 
1957; Lindenmann, Burke, and Isaacs, 1957). Half the century has passed since this 
discovery, and a lot more has been learned about IFN, including the discovery of 
cytoplasmic sensors of viruses infection leading to IFN induction, the IFN induced 
antiviral molecules and their mode of actions, as well as the underlying strategies evolved 
by viruses to coutermeasure the IFN system. 
The IFN superfamily are grouped according to their amino acid sequences, mode of 
induction and biological activities into three classes: type I, II and III IFNs. Type I IFNs  
are also known as viral IFNs and constitute a multi-gene family of 13 closely related 
IFNα genes, and a single IFN-β gene. Type I IFNs are synthesized by many cell types 
after infection by diverse group of viruses, and they bind to a common type I IFN 
receptor complex, IFNAR1 and IFNAR2.  
 
Type II IFN is also known as immune IFN and consists of a single gene encode IFN-γ 
that binds the IFNγ receptor complex (IFNGR). In contrast to type I IFNs, IFN-γ is not 
directly induced by viral infection but is produced later by immune cells, including 
natural killer (NK) cells, CD4 Th1 cells, CD8 cytotoxic suppressor cells and has an 
important role in the adaptive immune response. 
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Novel antiviral cytokines IFN-λ1, IFN-λ2, and IFN-λ3 (also referred to as IL-29, IL-28A 
and IL- 28B, respectively) are classified as type III IFNs. These cytokines are also 
induced in direct response to virus infection and have been shown to share many 
functional characteristics with type I IFNs. However, type III IFNs use a distinct set of 
receptors from type I or type II IFNs, comprising IL-28Rα and the IL-10Rβ [reviewed in 
(Ank and Paludan, 2009; Ank, West, and Paludan, 2006; Uze and Monneron, 2007)]. 
 
1.1.1 Mechanisms of type I IFN induction 
1.1.1.1 Type I IFN induction 
Induction of type I IFN begins with recognition of pathogen associated molecular 
patterns (PAMPs), foreign to host cells, by host pattern-recognition receptors (PRRs), 
which could distinguish self from non-self (Akira, Uematsu, and Takeuchi, 2006; 
Janeway and Medzhitov, 2002). A schematic representation of recognition of RNA 
viruses by cellular sensors is shown in Fig. 1.1. A major component of PAMPs are viral 
nucleic acids, typically double-strand or single-strand RNA and DNA, that can be 
recognized by three class of PRRs: cytoplasmic retinoic acid inducible gene (RIG-I)-like 
receptors (RLRs), endosomal Toll-like receptors (TLRs) that recognize PAMPs at the cell 
surface or inside endosomes, and nucleotide oligomerization domain (NOD)-like 
receptors (NLRs). The RLR family consists of three members, RIG-I (Yoneyama et al., 
2004), melanoma differentiation-associated gene 5 (MDA-5) (Andrejeva et al., 2004; 
Kang et al., 2002; Yoneyama et al., 2005) and laboratory of genetics and physiology 2 
(LGP2) (Rothenfusser et al., 2005; Yoneyama et al., 2005). RIG-I and MDA-5 share 
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structural homologies: they both contain two tandem caspase activation and recruitment 
domains (CARD) at their N-terminus, and a DExD/H Box helicase domain at their C-
terminus. However, LGP2 only contains a DexD/H Box helicase domain. RIG-I has been 
shown to recognize ssRNA bearing a 5’-triphosphate (Hornung et al., 2006; Pichlmair et 
al., 2006) and short double strand RNAs, whilst MDA-5 recognizes long dsRNAs (Gitlin 
et al., 2006) [For recent reviews, see (Meylan, Tschopp, and Karin, 2006; Takeuchi and 
Akira, 2009; Wilkins and Gale, 2010)].  
A common downstream signalling molecule shared by RIG-I and MDA-5 is MAVS (also 
called IPS-1, VISA and Cardif) [(Hiscott et al., 2006; Kawai et al., 2005; Meylan et al., 
2005; Seth et al., 2005; Xu et al., 2005), reviewed by (Hiscott et al., 2006)]. MAVS is 
localized at the outer mitochondria membrane by its C-terminal transmembrane domain, 
and its N-terminal CARD domain is essential for mediating the interaction of RIG-I with 
MAVS [reviewed in (Meylan, Tschopp, and Karin, 2006)]. The recruitment of MAVS by 
RIG-I/MDA-5 leads to the transmembrane (TM)-dependent dimerization of MAVS and 
subsequent recruitment and activation of the tumor necrosis factor (TNF) receptor-
associated factor (TRAF) family members, leading to signal transduction cascade and the 
activation of transcription factors NF-κB and IRF-3, which are both essential components 
for type I IFN induction (Baril et al., 2009).  
 
1.1.1.2 IFN-β promoter 
Induction of type I IFN requires the assembly of a higher order multi-component 
transcription factor enhancer complex, termed the enhanceosome [reviewed by (Thanos, 
	   4	  
1996)]. The IFN-β promoter consists of a set of cis regulatory elements designated 
positive regulatory domains (PRDs). PRDIV, PRD I/III and PRD II are recognized by 
activating transcription factor 2 (ATF-2)/C-Jun, IFN regulatory factors (IRFs), and NF-
κB respectively. These trans elements, together with the architectural protein non-histone 
high mobility group HGM I(Y), form the enhanceosome (Falvo, Thanos, and Maniatis, 
1995; Thanos and Maniatis, 1995). The cooperative assembly of the enhanceosome not 
only facilitates the binding of activators to promoter regions, but also stabilizes the 
interaction with basal transcription machinery to activate IFN-β gene transcription (Fig. 
1.2).  
All of these trans activators need to be phosphorylated by cellular kinases from the signal 
transmitted from RLRs/MAVS signalling pathway. NF-κB is normally held in a 
quiescent state in the cytoplasm by association with an inhibitory molecule IκB. The 
associated IκB masks the NF-κB nuclear localization signal (NLS) and thereby inhibits 
its nuclear translocation. Upon stimulation of a varity of stress signals, IκB is 
phosphorylated and targeted by proteasomal degradation thus leading to NF-κB nuclear 
translocation [reviewed in (Israel, 2000)]. IFN regulatory factor 3 (IRF-3) is 
constitutively expressed inside the cells and mainly localized in the cytoplasm. Upon 
virus infection, IRF-3 is hyperphosphorylated on a number of serine and threonine 
residues at its C-terminus, leading to its dimerization and translocation into the nucleus 
(Kumar et al., 2000).  
	   5	  
 
1.1.2 Mechanisms of IFN signalling 
IFNs are cytokines secreted by cells in response to virus infection, and induce the 
expression of IFN stimulated genes (ISGs) via the classical JAK-STAT signalling 
pathway. This pathway was originally discovered in the 1990s (Fu et al., 1992; Schindler 
et al., 1992; Silvennoinen et al., 1993), and has been well studied by many experimental 
approaches [reviewed by (Platanias, 2005; Randall and Goodbourn, 2008b)]. Key players 
in this pathway are protein tyrosine kinases of the Janus activated kinase (Jaks), activated 
by ligands binding to cell surface receptors and the signal transducer and activator of 
transcription (STATs) [reviewed by (Murray, 2007)]. JAK-STAT signalling pathway 
allows signal to be transmitted from cell surface to the nucleus, leading to the induction 
of hundreds of ISGs (de Veer et al., 2001; Der et al., 1998).  
 
1.1.2.1 Type I IFN signalling 
The large family of type I IFNs bind a common cell-surface hetero-dimeric receptor, 
which is known as the type I IFN receptor, composed of at least two distinct subunits: 
IFNAR1 and IFNAR2 [reviewed by (Mogensen et al., 1999)]. Each of these receptor 
subunits interacts with a member of the JAK family. IFNAR1 subunit is constitutively 
associated with tyrosine kinase 2 (TYK2), whereas IFNAR2 is associated with JAK1. 
Type I IFNs binding induce type I IFN receptor to oligomerize and brings the Jaks close 
enough for them to cross-phosphorylate each other. The resulting phosphorylation of 
IFNAR1 by Tyk2, allows the docking of STAT2, and phosphorylation of IFNAR2 by 
	   6	  
Jak1, allows the docking of STAT1. After STATs dock on specific phosphotyrosines on 
the receptor, the Jaks phosphorylate them, phosphorylated STATs dissociated from 
receptor and form heterodimer via their Src Homology 2 (SH2) domain. The STAT1-
STAT2 complex associates with a monomer of IRF-9 to form the ISG factor 3 (ISGF3) 
heterotrimer complex, translocates to the nucleus, and binds to IFN-stimulated response 
element (ISRE) located in the promoter region of most ISGs, thereby initiating their 
transcription (Fig. 1.3).  
 
1.1.2.2 Type II IFN signalling 
Signalling in response to IFN-γ follows very similar features to that in response to type I 
IFN. The IFN-γ receptor is also a heterodimeric glycoprotein, comprising at least two 
major subunits, IFNGR1 and IFNGR2 [reviewed by (Bach, Aguet, and Schreiber, 1997)]. 
In contrast to the type I receptor, the cytoplasmic domains of IFNGR1 and IFNGR2 are 
associated with a different set of JAKs, Jak1 and Jak2, respectively. Dimeric IFN-γ 
binding to the receptor subunits triggers receptor dimerization and activation of receptor 
associated Jak1 and Jak2, which subsequently phosphorylate a tyrosine residue (Y440) on 
IFNGR1 that serves as a docking site for STAT1 [Reviewed in (Bach, Aguet, and 
Schreiber, 1997)]. STAT1 is then activated by phosphorylation at tyrosine 701, resulting 
in the homo-dimerization of STAT1 and dissociation from the receptor. Dimerized 
STAT1s translocate to the nucleus and bind to gamma-activation sequence (GAS) that is 
present in the promoter region of certain ISGs (Fig. 1.3).   
Of the hundreds of known ISGs, some have either a GAS or ISRE elements in their 
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promoters, whilst others have both elements; thus the expression of certain ISGs are 
regulated by different sets of STATs. Indeed, there is some redundancy in IFN-γ and 
IFN-α/β signalling (Vilcek, 2003).  
1.1.3 IFN-induced antiviral state?
Type I IFNs are produced in direct response to virus infection and lead to the induction of 
the expression of a number of antiviral proteins, which are involved in the establishment 
of the “antiviral state” in infected cells and neighbouring cells, and thus to limit the extent 
of virus spread (van Boxel-Dezaire, Rani, and Stark, 2006). However, not all the IFN-
induced ISGs are involved in the establishment of the antiviral state, and probably 
different subset of genes are required to limit different type of viruses replication. Among 
them, three families of IFN-inducible genes have been extensively studied with respect to 
their antiviral activities. These genes encode the dsRNA-activated protein kinase (PKR) 
(Clemens and Elia, 1997), the 2’,5’-oligoadenylate synthetases (OAS), and the Mx 
protein(s) (Haller et al., 1980; Haller, Staeheli, and Kochs, 2007). Further more, recently 
other ISGs have been reported to be involved in IFN-induced antiviral responses 
(Discussed later in this session).  
 
1.1.3.1  dsRNA-dependent protein kinase (PKR) 
One of the best-characterized IFN-induced antiviral molecules is PKR. PKR is a 
ubiquitously expressed serine/threonine protein kinase that consists of two dsRNA 
binding motifs (dsRBM) at its N terminus and a conserved kinase domain at its C-
terminus (Meurs et al., 1990). PKR can be induced by IFN and activated by a variety of 
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signals such as dsRNA, pro-inflammatory stimuli, cytokines, growth factors and 
oxidative stress signals. PKR normally exists in a latent inactive form due to the auto-
inhibitory effect of its dsRBM. Upon binding to dsRNA, PKR undergoes conformational 
change to form homodimer (Dey et al., 2005) and autophosphorylate itself (Galabru and 
Hovanessian, 1987), leading to its activation.  
PKR was discovered from experiments showing that IFN pretreated cells infected with 
vaccinia virus (VV) have a translational inhibition of viral mRNAs. The cell extracts 
prepared from these IFN-treated VV-infected cells showed restricted translation of viral 
and cellular mRNAs (Friedman et al., 1972; Metz and Esteban, 1972). Later on it was 
shown that in rabbit reticulocyte system, protein translation is inhibited by 
phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2α) in the 
presence of hemin or low concentrations of dsRNA (Farrell et al., 1977). eIF2α is one of 
the best-known PKR substrates. The eIF2 complex, consisting of three subunits (α, β, γ), 
is involved in the recruitment of Met-tRNAi to the 40S ribosome subunit for initiation of 
protein synthesis [reviewed in (Hershey, 1991)]. eIF2 binds the Met-tRNAi in a GTP-
dependent manner to form a ternary complex Met-tRNAi/GTP/eIF2, which associates 
with the 40S subunit. After Met-tRNAi is delivered, hydrolysis of GTP to GDP promoted 
by eIF5, eIF2/GDP is released from the 40S subunit.  Inactive eIF2/GDP complexes are 
reactivated by the GDP-to-GTP exchange, catalyzed by eIF2B, thus allowing active 
eIF2/GTP to bind to Met-tRNA. However, PKR phosphorylation of eIF2α at S51 
increases the affinity of eIF2 and eIF2B (Sudhakar et al., 2000), leading to the PKR-
mediated down-regulation of translation initiation. 
In addition to phosphorylating eIF2α and the inhibition of translation initiation, PKR also 
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actively regulates diverse cellular processes in transcription, apoptosis, cell growth, 
differentiation by phosphorylation of downstream effectors such as NF-κB, IRF-1 
(Kumar et al., 1997), p53 (Cuddihy et al., 1999a; Cuddihy et al., 1999b), STATs (Deb et 
al., 2001; Wong et al., 1997), and ATF-3 (Guerra et al., 2006) [for reviews, see (Garcia, 
Meurs, and Esteban, 2007; Williams, 2001)].  
 
1.1.3.2 2’-5’OAS/RNase L system 
2'-5' oligoadenylate synthetases are a group of enzymes that are induced by IFNs in 
mammalian cells that catalyse the formation of 5'-triphosphorylated, 2'5'-phosphodiester-
linked oligoadenylates (2-5A) from ATP (Player and Torrence, 1998). 2-5A is relatively 
unstable and is degraded by the concerted action of phosphodiesterase and phosphatase 
shortly after formation. 2-5A is found in cells in the trimeric form (Knight et al., 1980), 
and the only well established function of 2-5A is activation of endoribonuclease RNase L 
[(Zhou, Hassel, and Silverman, 1993), reviewed by (Bisbal and Silverman, 2007)]. 
RNase L is expressed constitutively in most cells types and is normally hold in a 
quiescent state, but it is rapidly activated by the association of 2-5A. Activated RNase L, 
causes the degradation of single-stranded RNA as well as 28S ribosomal RNA, therefore 
leading to protein synthesis inhibition. Thus the level of 2-5A is believed to be a major 
factor that controls RNase L activity (Minks et al., 1979).  
2’-5’A/RNase L system has been suggested to have an important role in antiviral and 
antitumor functions [reviewed in (Hovanessian and Justesen, 2007)]. Overexpression of 
2′-5′OAS is sufficient to protect cells against infection with EMCV, Mengo viruses, and 
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HIV (Chebath et al., 1987; Coccia et al., 1990; Maitra and Silverman, 1998; Williams 
and Kerr, 1978). Despite the fact that RNase L could degrade cellular mRNA, it 
preferentially targets viral mRNA as a result of local activation of 2’-5’OAS by viral 
replication and transcription (Nilsen and Baglioni, 1979). 
 
1.1.3.3 Mx GTPases 
Mx proteins are key components of the antiviral state induced by type I IFN [reviewed in 
(Haller, Staeheli, and Kochs, 2007)]. In 1962, Lindenmann discovered that the inbred 
mouse strain A2G showed an unusually high degree of resistance towards infection with 
influenza A virus (FLUAV) (Lindenmann, 1962). Later on, it was found that the innate 
resistance depends on a single gene, named Mx1 (for orthomyxovirus resistance gene 1), 
which was the major mediator of innate immunity against influenza A virus in mice 
(Arnheiter et al., 1990; Horisberger, Staeheli, and Haller, 1983; Staeheli et al., 1986), 
whilst most inbred strains of mice carry defective Mx1 alleles and are highly susceptible 
to pathogenic influenza A virus strains (Staeheli et al., 1988). It was intriguing for the 
existence of an influenza virus resistance gene in mice because mice are not natural hosts 
for influenza viruses. However, subsequently it became clear that Mx1 is the first 
member of Mx gene family which exist in a variety of organisms, including yeast, fish, 
chicken, ducks, dogs, pigs, cows, sheep, horses, and humans (Horisberger, 1992; 
Horisberger and Gunst, 1991; Nakayama and Ishihama, 1992; Nakayama et al., 1991; 
Pitossi et al., 1993; Samuel, 1991; Staeheli, 1990), and inhibit a broad spectrum of 
viruses from different taxonomic groups [reviewed by (Haller, Staeheli, and Kochs, 
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2007)].  
Mx1 gene expression is normally undetectable, but is rapidly upregulated by type I or 
type III IFNs (IFNs) (Haller et al., 1980; Holzinger et al., 2007). Mx proteins belong to 
the dynamin family of large GTPase (Pavlovic et al., 1993; Staeheli, Pitossi, and Pavlovic, 
1993), which function in endocytosis, vesicle trafficking between intracellular membrane 
compartments, maintenance of mitochondria morphology and viral resistance (Danino 
and Hinshaw, 2001; Staeheli and Haller, 1985; van der Bliek, 1999). Mx proteins of 
human and mice can self-assemble into ring-structures and associate with intracellular 
membranes in solution (Hinshaw and Schmid, 1995; Kochs et al., 2005). Mx contains a 
highly conserved tripartite GTP binding motif within the N-terminal G domain. The less 
conserved C-terminal effector domain, which contains leucine zipper motifs, is involved 
in homo-oligomerization and association with other molecules.  
MxA, a human homolog of Mx1, accumulates in the cytoplasm and interferes with 
multiplication of orthomyxoviruses (Haller et al., 1995; Marschall et al., 2000; Pavlovic, 
Haller, and Staeheli, 1992), paramyxoviruses (Zhao et al., 1996), bunyaviruses (Frese et 
al., 1996), picornaviruses (Pavlovic et al., 1990a), hepatitis B virus (Netherton et al., 
2009), and Semliki Forest virus (Landis et al., 1998). Current evidence suggests that 
MxA exerts its antiviral activity by interacting with viral ribonucleoproteins. Human 
MxA inhibits Thogoto virus replication by recognizing and preventing the nuclear import 
of viral nucleocapsids, thereby inhibiting transcription of the viral genome (Kochs and 
Haller, 1999a) and inhibits La Crosse virus replication by binding and sequestering viral 
nucleoprotein in the perinuclear region, forming an elongated tubular structure resulting 
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in cytoplasmic bodies, thus preventing genome amplification, budding, and release (Frese 
et al., 1996; Kochs et al., 2002; Reichelt et al., 2004). 
1.1.3.4 ISG15 
ISG15, first identified more than 20 years ago, is a small ubiquitin-like protein 
(Blomstrom et al., 1986; Haas et al., 1987; Korant et al., 1984). It is expressed as a 17kDa 
precursor protein, and maturation involves cleavage at its C-terminus to generate a 15kDa 
protein, revealing di-glycine residues in the form of a LRLRGG motif (Potter et al., 
1999), which is essential for ISG15 conjugation to target proteins (ISGylation). 
ISGylation is accomplished through the concerted action of IFN-inducible conjugation 
cascade, includes an E1 (UBE1L), E2 (UbcH8, UbcH6), and two E3 ligases Efp 
(estrogen-responsive finger protein) and Herc5 (Dastur et al., 2006; Kim et al., 2004; 
Yuan and Krug, 2001a; Zou and Zhang, 2006). Efp is the ISG15 E3 ligase for 14-3-3σ 
protein, Herc5 is involved in the global regulation of ISGylation. USP18/UBP43 is the 
deconjugating enzyme, removing ISG15 from its target proteins (Malakhov et al., 2002).  
 
Recent publications have shown that ISG15 targets nearly 200 cellular proteins found in 
many important cellular pathways (Giannakopoulos et al., 2005; Zhao et al., 2005). Most 
targets are constitutively expressed and function in diverse cellular pathways, while a few 
targets are induced by IFN, including RIG-I, STAT1, PKR, MxA. Thus it has been 
speculated ISGylation plays an import role in IFN-induced antiviral immunity. Indeed, 
current evidence suggests that ISG15 alone, and/or its conjugation, has a broad-spectrum 
of antiviral activity against HIV-1(Bach, Aguet, and Schreiber, 1997), Ebola virus 
(Okumura, Pitha, and Harty, 2008), herpes virus, Sindbis virus and influenza virus 
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Viperin (virus inhibitory protein, endoplasmic reticulum-associated, IFN-inducible), also 
known as RSAD2, or cig5 in humans, is an IFN-inducible protein that is evolutionarily 
conserved. Viperin was initially discovered in human cytomegalovirus (HCMV) infected 
cells (Chin and Cresswell, 2001), and has a broad range of antiviral activities (Chin and 
Cresswell, 2001; Helbig et al., 2005; Rivieccio et al., 2006; Wang, Hinson, and 
Cresswell, 2007). siRNA-mediated knockdown of viperin enhances the replication of 
alphaviruses, Sendai virus, Sindbis virus (SIN) and HIV-1 (Chan et al., 2008; Chin and 
Cresswell, 2001; Jiang et al., 2008; Zhang et al., 2007).  
Viperin is localized to the ER through an N-terminal amphipathic α-helix (Brass et al., 
2002; Elazar et al., 2004; Hinson and Cresswell, 2009a; Hinson and Cresswell, 2009b), 
and interacts with the lipid biosynthesis enzyme farnesyl-diphosphate synthase, resulting 
in the disruption of lipid raft microdomains and inhibition of influenza virus budding 
from plasma membrane (Wang, Hinson, and Cresswell, 2007). Viperin is highly induced 
in neutrophils and macrophages by lymphocytic choriomeningitis virus infection 
(LCMV), and may contribute to the antimicrobial activity of neutrophils (Hinson et al., 
2010). It was also shown that it is targeted by Japanese encephalitis virus (JEV) for 
degradation through a proteasome-dependent mechanism (Chan et al., 2008). 
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1.1.3.6 ISG56 
The ISG56 family of proteins are induced strongly in response to virus infection, IFNs 
and dsRNA. In humans, this family comprises four members: ISG54, ISG56, ISG58 and 
ISG60. In mice, this family comprises three members: ISG49, ISG54 and ISG56 (de Veer 
et al., 1998; Lee et al., 1994; Levy et al., 1986). All of these proteins contain multiple 
tetratricopeptide (TPR) motifs that are known to mediate protein-protein interactions 
(Lamb, Tugendreich, and Hieter, 1995). ISG56 C-terminal region is responsible for 
interaction with eIF3e subunit to impair the ability of eIF3 to stabilize the eIF2·GTP·Met-
tRNAi ternary complex (Guo et al., 2000; Hui et al., 2003a; Terenzi et al., 2006). Mouse 
ISG54 and ISG56, as well as human ISG54, bind to eIF3c and eIF3e subunits to inhibit 
protein translation (Hui et al., 2005; Terenzi et al., 2006; Terenzi, Pal, and Sen, 2005).  
 
ISG56 was recently been reported to be an important antiviral molecule in IFN-induced 
antiviral state, it was reported to inhibit hepatitis C virus (Sumpter et al., 2005), Sindbis 
virus (Zhang et al., 2007), West Nile virus, lymphocytic choriomeningitis virus (LCMV) 
(Wacher et al., 2007) and human papillomaviruses (HPV) (Terenzi, Saikia, and Sen, 
2008). ISG56 exert its antiviral action against HPV by binding and translocating the 
DNA replication origin-binding protein E1 of HPV from the nucleus to the cytoplasm, 
thus mediating the inhibitory action of IFN on HPV DNA replication. Mutational studies 
showed that the interaction is mediated by TRP repeat 2 (TRP2) of ISG56 and the C-
terminal region of E1 (Terenzi, Saikia, and Sen, 2008).  
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1.1.4 Virus encoded IFN antagonists 
In order for viruses to survive the antiviral IFN response, viruses developed diverse 
strategies to counteract the IFN system. It is now becoming clear viral antagonistic 
strategies target virtually all aspect of IFN system. Viruses were found to interfere with 
induction of IFN production, IFN signalling, to suppress the activities of IFN-induced 
antiviral effector molecules, or a broad shut down of host protein synthesis [See extensive 
reviews in (Bonjardim, 2005; Goodbourn, Didcock, and Randall, 2000; Levy and Garcia-
Sastre, 2001; Randall and Goodbourn, 2008a; Weber, Kochs, and Haller, 2004)]. Viruses 
often encode one or more IFN antagonists and they are often multifunctional proteins to 
allow efficient evasion of host antiviral mechanims.  
 
1.1.4.1 Vaccinia virus E3L 
A typical IFN antagonist encoded by vaccinia virus is E3L. It blocks IFN induction and 
action by sequestering dsRNA and inhibiting IRF-3/7 activation (Xiang et al., 2002), and 
it has also recently been shown to inhibit the 5′-ppp-ssRNA- and dsDNA-induced 
activation of IFNβ even though it does not interact with these nucleic acids (Marq et al., 
2009). In addition, it was also reported to inhibit IFN-induced ISGs. It has been shown to 
bind and sequester viral dsRNA thus blocking the activation of PKR and 2’-5’ 
OAS/RNaseL pathway, inhibits IFN inducible RNA-specific adenosine deaminase 
(ADAR1) activity (Liu et al., 2001), and disables ISG15 function by direct binding 
(Guerra et al., 2008). 
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1.1.4.2 Influenza A virus NS1 
FLUAV encodes NS1 that is a multifunctional protein. It targets various points of IFN 
pathway. It was described in details in section 1.3.4.3. 
 
1.1.4.3 Influenza B virus NS1 
Influenza B virus NS1 protein (NS1B) contains 281 amino acids. NS1B forms 
homodimers and binds to single- and double-stranded RNAs in vitro (Wang and Krug, 
1996). It consists of an N-terminal RNA binding domain and a C-terminal effector 
domain, sharing less than 20% sequence identity with the influenza A virus NS1 protein. 
It accumulates in nuclear speckles domains and disrupts their normal functions, and this 
activity is independent of other viral proteins (Schneider et al., 2009). 
It has previously been shown to inhibit antiviral responses by blocking the induction of 
type I IFNs (IFN) (Dauber, Heins, and Wolff, 2004; Dauber, Schneider, and Wolff, 2006; 
Donelan et al., 2004), preventing the activation of PKR (Dauber, Heins, and Wolff, 2004; 
Dauber, Schneider, and Wolff, 2006; Donelan et al., 2004), blocking ISG15 conjugation 
(ISGylation) to its target proteins (Yuan and Krug, 2001b). Recently it was shown that 
the antagonistic activity against ISGylation of NS1B is species-specific, it prevents 
human but not mice or canine ISGylation (Sridharan, Zhao, and Krug, 2010; Versteeg et 
al., 2010).  
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1.1.5 Virus shut-off of host protein synthesis 
Virus infection of susceptible cells leads to a general inhibition of cellular protein 
synthesis, a phenomenon known as host shut-off. Different viruses employ very different 
mechanisms to shut-off host protein synthesis. The host shut-off can happen at different 
points in the pathway of eukayotic gene expression, such as transcription initiation, RNA 
maturation, nuclear-cytoplasmic transport, translation initiation and protein synthesis 
[Reviewed in (Aranda and Maule, 1998; Lyles, 2000)]. Adenoviruses block nucleo-
cytoplasmic transport of cellular mRNA. Herpes viruses degrade pre-existing cellular 
mRNAs. Piconaviruses inhibit host transcription by disruption of transcription initiation 
and translation by cleavage of translation initiation factor eIF4G. Poliovirus, a prototype 
of piconavirus, utilizes Cap-independent translation of viral mRNA that is of major 
importance shut-off of host protein synthesis after infection. VSV inhibits host translation 
by inhibiting eIF2. 
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1.2 The Paramyxoviridae 
1.2.1 Introduction of paramyxoviruses 
The family of Paramyxoviridae (from Greek para- beyond; -myxo-, mucus) are single- 
stranded, non-segmented, negative sense enveloped RNA viruses and are responsible for 
a number of human and animal diseases including measles, mumps, Newcastle disease 
and some emerging diseases caused by newly discovered Paramyxoviruses. 
Measles virus (MeV) belongs to the family of paramyxovirus and is one of the most 
contagious viruses known to human. It was targeted for eradication by the World Health 
Organization (WHO). However, it is still one of the leading causes of death among young 
children globally, even though a safe and cost-effective vaccine is available. An 
estimated 164, 000 people died from measles in 2008 (WHO, 2008). Human 
Parainfluenza viruses (hPIV) commonly cause a range of disease to children, from mild 
influenza-like symptom to bronchitis and pneumonia. Mumps virus (MuV) has been 
noted in history for a long time, with the description of parotitis and orchitis by 
Hippocrates dated back to the 5th century BC. Today, MuV still imposes a great impact 
on public health and zoonotic diseases. It is responsible for a very common childhood 
illness, with characteristic symptoms including fever, and hallmark symptom of parotid 
gland swelling prior to immunization. Occasionally, MuV infection results in serious 
complications including aseptic meningitis and infertility (Hviid, Rubin, and Muhlemann, 
2008).  
Among paramyxoviruses that infect animal species, Newcastle disease (ND) is a viral 
disease affecting many species of birds and causing severe economic losses in the poultry 
	   19	  
sector. The aetiological agent is Newcastle disease virus (NDV). The severity of avian 
disease depends on the pathotype of the NDV strain ranging from mild or asymptomatic 
infections (caused by lentogenic strains) to mesogenic strains of intermediate severity, 
and velogenic strains causing systemic infections with high mortality.  
Over the past few years, an increasing number of new paramyxoviruses have been 
discovered. Among those emerging paramyxoviruses, Hendra (HeV) and Nipah (NiV) 
viruses cause highly lethal central nervous system diseases.  
 
1.2.2 Classification of Paramyxoviruses 
The family Paramyxoviridae is part of the virus order Mononegavirales, and it is 
classified into two subfamilies: the Paramyxovirinae and the Pneumovirinae based on 
virion morphology, the organization of genome, activity of encoded proteins and 
relatedness of gene sequence. The two subfamilies are further sub-divided into different 
genera. Examples of the members of the Paramyxoviridae are shown in Table 1.1.  
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Table 1.1. Classification of the Paramyxoviridae family into subfamilies and genera 




 Subfamily Paramyxovirinae 
o Genus Rubulavirus 
 Mumps virus (Mu V) 
 Parainfluenza virus 5 [simian virus 5 (SV5)] 
 Human parainfluenza virus type 2, type 4a and 4b (hPIV2/4a/4b) 
 Porcine rubulavirus 
 Mapuera virus 
o Genus Avulavirus 
 Newcastle disease virus (avian paramyxovirus 1) (NDV) 
o Genus Respirovirus 
 Sendai virus (mouse parainfluenza virus type 1) (SeV) 
 Human parainfluenza virus type 1 and type 3 (hPIV1/3) 
 Bovine Parainfluenza virus type 3 (bPIV3) 
o Genus Henipaviruses 
 Hendra virus (HeV) 
 Nipah virus (NiV) 
o Genus Morbillivirus 
 Measles virus (MeV) 
 Rinderpest virus 
 Cetacean morbillivirus 
 Canine distemper virus (CDV) 
 Phocine distemper virus 
 Peste-des-petits-ruminants virus 
 Subfamily Pneumovirinae 
o Genus Pneumovirus 
 Human respiratory syncytial virus A2, B1, S2 (hRSV) 
 Bovine respiratory syncytial virus (bRSV) 
 Pneumonia virus of mice (PVM) 
o Genus Metapueumovirus 
 Human metapneumovirus (hMPV) 
 Avian metapneumovirus 
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1.2.3 Virion structure 
The virions of Paramyxoviridae are pleiomorphic, having typical spherical forms ranging 
from 150-350nm in diameter (see Fig. 1.4). The virions have a lipid bilayer envelope 
derived from the plasma membrane of the host cell. Inserted into the envelope are the 
attachment (HN, H or G) and fusion (F) glycoproteins that extend 8-12 nm from the 
surface of the membrane. The fusion genes are relatively well conserved among members 
of the Paramyxoviridae, whilst the attachment glycoproteins are more diverse. Members 
of the Respirovirus and Rubulavirus genera have an attachment glycoprotein with both 
haemagglutinin and neuraminidase activities (HN protein), while those of the 
Morbillivirus genus have a attachment protein with only haemagglutinin activity (H 
protein), and those of the Henipavirus genus and Pneumovirinae subfamily have 
attachment protein with neither activities (G protein).  
Underlying the envelope is the matrix (M) protein, playing an important role in 
maintaining the integrity and organization of the virus particle. Inside the viral membrane 
is the helical nucleocapsid core that contains the single-standed RNA genome. The viral 
genome is encapsidated by the nucleoprotein (N or NP), which is associated with the 
RNA-dependent RNA polymerase complex of phosphoprotein (P) and large (L) proteins.  
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?
1.2.4 Genome organization  
The genome of paramyxoviruses is single-stranded, non-segmented, negative-sense RNA 
ranging in length from 15 kb to 19 kb (see Fig. 1.5). Flanking the genome is a 3’ 
extracistronic region of ∼ 50 nucleotides known as the leader, and 5’ extracistronic region 
of 50 to 161 nucleotides known as the trailer. These regions are essential for virus 
transcription and replication. The genome contains 6 to 10 tandem linked genes, 
depending on species. At the beginning and end of each gene are conserved 
transcriptional control sequences that are transcribed into mRNA. These genes are 
separated by intergenic regions that vary in length depending on virus species.  
Paramyxovirus helical nucleocapsids, rather than the free RNA genome, are the template 
for all RNA synthesis. The genomic RNA complexed with the NP (or N), P and L 
proteins (Holonucleocapsids) are thought to have the capacity to transcribe mRNAs in 
vitro. A major characteristic used to help classify paramyxoviruses into different 
subfamilies and genera is the structure of P genes. In certain paramyxoviruses, P gene 
encodes more than one protein by overlapping open reading frames (ORFs) through 
“RNA editing” or pseudotemplated addition of nucleotides (Kolakofsky and Lamb, 
2001). In the genus Rubulavirus, PIV5, mumps virus P gene encodes both the P and V 
genes. The P and V proteins have a common N-terminal domain (1-164 aa), but after the 
editing site, viral polymerase could insert two additional non-templated G nucleotides 
into the mRNA that shift the translational reading frames (ORF) (Vidal, Curran, and 
Kolakofsky, 1990a; Vidal, Curran, and Kolakofsky, 1990b). As a result, the C-terminus 
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of P and V proteins are unique.  
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1.2.5 Paramyxoviridae genes and encoded proteins 
1.2.5.1 The Nucleocapsid protein 
The nucleocapsid protein (NP) is encoded by the first gene in the viral genome for all 
Paramyxoviruses, except the Pneumoviruses, and ranges in size from 489 to 553 amino 
acids. The NP protein serves several functions in the virus life cycle, including 
encapsidation of viral genome, interaction with the viral polymerase complex during viral 
RNA synthesis and interaction with the M protein during virus assembly. It was predicted 
that every copy of NP protein is associated with precisely six nucleotides of viral 
genome. Nevertheless, the protein does not seem to be a classical RNA-binding protein, 
as it does not contain any previously recognized RNA-binding motifs. Experimental data 
suggests that NP has two domains, a gobular amino-terminal body that represents 80% of 
the protein, and a highly variable tail-like carboxy-terminal domain that represents 20% 
of the protein [reviewed in (Portela and Digard, 2002a)]. 
 
1.2.5.2 The Phosphoprotein 
The phosphoprotein (P) is essential for viral RNA synthesis, and it is a core component of 
the viral polymerase complex. As indicated by its name, this protein is heavily 
phosphorylated at serine and threonine residues. The P protein has no enzymatic activity, 
but it acts as a transactivator of L, which is the catalytic subunit of the RNA polymerase. 
P protein is encoded by the P gene that always produces more than one polypeptide 
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species. The expression of P/V/C proteins involves “RNA editing” that alters the ORFs 
by insertion of G residues at a specific position in the mRNA. In the case of PIV5 P 
protein, it is the translation product from mRNA that is generated by the addition of two 
non-templated G residues at the editing site of the V/P gene that shift the ORFs at the site 
of insertion. 
The P protein C-terminal polymerase cofactor module is relatively well conserved, and is 
well studied for its role in viral RNA synthesis. P protein functions as a homo-oligomer, 
and the multimerization of P protein is mediated by its C-terminus domain. P protein also 
functions as a bridge to link L polymerase with the NP-RNA template. The C-terminal 
domain of P protein contains binding motif for interaction with L protein and for binding 
to the N-RNA complex (Bowman, Smallwood, and Moyer, 1999; Curran, Pelet, and 
Kolakofsky, 1994; Ryan, Morgan, and Portner, 1991). 
 
1.2.5.3 The V protein 
The V protein is encoded by the P/V gene and shares an N-terminal domain with the P 
protein but has a distinct C-terminal domain. The C-terminal domain of V protein is 
highly conserved and there is high sequence similarity among different paramyxoviruses. 
It contains a zinc-binding domain that binds two zinc molecules per V protein (Fukuhara 
et al., 2002; Li et al., 2006a). It has been proposed that the “Zinc-finger” domain is 
perhaps involved in interaction of V protein with other proteins. PIV5 V protein is a 
structural protein that is incorporated into the virion (approximately 350 copies of V 
protein per virion) and is associated with the nucleocapsids, whilst for respiroviruses and 
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morbilliviruses V protein is a nonstructural protein and it is absent from the virion. 
The V protein of PIV5 is a multifunctional protein and plays an essential role in viral 
pathogenesis. V protein limits IFN production by interacting with MDA-5 (Andrejeva et 
al., 2004), and this property is shared among all of paramyxoviruses (Childs et al., 2007; 
Childs et al., 2009). In addition, paramyxovirus V proteins can also block IFN signalling 
by targeting STAT1 for polyubiquitylation and proteasomal degradation (Didcock et al., 
1999; Young et al., 2000a). The 127 kDa cellular damage-specific DNA-binding protein 
1 (DDB1) (Andrejeva et al., 2002; Lin et al., 1998), and Cullin 4A, members of the 
Cullin family of ubiquitin ligase subunits, are essential for targeting STAT1 for 
degradation (Ulane and Horvath, 2002). In addition to commonly targeting STAT1 for 
degradation, paramyxoviruses differ in their specificity to target other STATs. PIV5 can 
only target STAT1 for degradation, PIV2 targets STAT2 (Parisien et al., 2001), and 
mumps virus V protein targets both STAT1 (Nishio et al., 2002; Ulane et al., 2003) and 
STAT3 (Parisien et al., 2001; Ulane et al., 2003). STAT2 act as a host range determinant 
for the virus and is required for STAT1 destruction (Parisien, Lau, and Horvath, 2002; 
Parisien et al., 2002). 
 
1.2.5.4 The Matrix Protein 
The paramyxovirus matrix (M) protein is the most abundant protein in the virion. The M 
proteins contain 341-377 amino acids with predicted molecular weight between 38kDa to 
43kDa. The M protein is quite basic and relatively hydrophobic, it is peripherally 
associated with membranes but it is not considered to be a membrane protein (Hirano et 
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al., 1992; Riedl et al., 2002). M protein also interacts with the cytoplasmic tails of the H 
and F glycoproteins (Cathomen et al., 1998; Cathomen, Naim, and Cattaneo, 1998; 
Spielhofer et al., 1998). M protein also interacts with the nucleocapsid (NP) protein 
components of RNPs (Hirano et al., 1993; Suryanarayana et al., 1994). Thus M protein 
plays a key role in virion assembly in bridging these elements (integral membrane 
proteins, lipid envelope and nucleocapsids) together and concentrating them at the plasma 
membrane for virion assembly and release [reviewed in (Takimoto and Portner, 2004)].   
 
1.2.5.5 The Attachment protein 
The Respirovirus and Rubulavirus attachment protein HN is a surface glycoprotein that 
contains both haemagglutinin and neuraminadase activities. The haemagglutinin activity 
of HN mediates virus attachment to sialic acid residues on cell surfaces, and the 
neuraminidase activity cleaves sialic acid from the surface of virions and the surface of 
infected cells to prevent self-aggregation of virus particles during budding at the plasma 
membrane, so that the assembled virus particles are efficiently released. In contrast, 
morbilliviruses attachment protein only contains haemagglutinin activity (H), whilst the 
henipaviruses and pneumoviruses have an attachment protein with neither activity (G).  
The HN protein ranges in size from 565 to 582 amino acids. HN is a type II integral 
membrane protein that spans the membrane once. It contains an N-terminal cytoplasmic 
tail, a single N-terminal transmembrane (TM) domain, a membrane-proximal stalk 
domain, and a large C-terminal globular head domain that contains the receptor binding 
and enzymatic activity. In addition to receptor binding, HN also promotes the fusion 
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activity of fusion proteins (F proteins). Co-expression of HN and F protein is required for 
virus-cell fusion [reviewed in (Lamb and Kolakofsky, 2001)]. Interaction between HN 
and F has been reported in several studies (Deng et al., 1999; Malvoisin and Wild, 1993; 
Stone-Hulslander and Morrison, 1997; Yao, Hu, and Compans, 1997). 
	  
1.2.5.6 The Fusion protein	  
Paramyxovirus penetration into host cells requires fusion of viral envelope with host 
plasma membrane, and this process is mediated by the fusion (F) protein. F protein 
expressed at the plasma membrane can also mediate fusion with neighboring cells to 
form syncytia late in infection, which may facilitate virus spread. F protein is synthesized 
as an class I inactive precursor protein (F0), which forms a trimer, and is proteolytically 
cleaved into its biologically active form F1 and F2 in a manner similar to other class I viral 
fusion proteins, such as influenza virus hemagglutinin (HA), HIV gp160, Ebola GP, and 
SARS CoV Spike protein (Colman and Lawrence, 2003; Dutch, Jardetzky, and Lamb, 
2000; Earp et al., 2005; Jardetzky and Lamb, 2004). F1 contains the N-terminal fusion 
peptide (FP), located at the new N-terminus after cleavage, and the hydrophobic stop-
transfer TM domain, and two heptad helical repeat regions, designated HRA and HRB.  
F protein initially folds as a metastable prefusion form. The fusion activity of F protein 
requires a receptor binding protein (HN, H, or G). Interaction of HN with F protein 
triggers the HRA to undergo a major conformational change into the pre-hairpin 
intermediate form that extends the fusion peptide outward, so that it is inserted into 
membranes (Crennell et al., 2000). HRB adjacent to the TM domain then binds to HRA, 
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forming the postfusion hairpin conformation. The structures of prefusion PIV5 F (Yin et 
al., 2006) and postfusion NDV and human PIV3 F proteins have been solved (Chen et al., 
2001; Yin et al., 2005).  
The mechanism for HN binding to its receptor to trigger F protein refolding is not known 
(Lamb, Paterson, and Jardetzky, 2006; Morrison, 2003). HN may serve as a clamp that 
retains the F protein in its prefusion state. After HN binds the target cell, F is released and 
undergoes conformational change to activate fusion (the "clamp model"). Alternatively, 
HN itself may undergo a conformational change after receptor binding that destabilizes 
the metastable F protein and causes F to trigger (the "provocateur model"). 
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1.3 The Orthomyxoviridae 
1.3.1 Influenza A viruses 
Influenza A viruses are significant human pathogens as they are highly contagious with 
often fatal outcomes. They are the causative agents of seasonal flu and due to their 
zoonotic characteristics can cause occasionally pandemic outbreaks such as those 
reported in 1918, 1957 and 1968 (Holmes et al., 2005). The current 2009 swine-origin 
H1N1 pandemic viruses have demonstrated how these viruses have great impact on 
public health worldwide and pose significant challenges to the scientific communities.  
Influenza A viruses (FLUAV) belong to the family Orthomyxoviridae that is defined by 
viruses which have a negative sense, segmented, single-strand RNA genome. There are 
five different genera in the family of Orthomyxovidae: the influenza A viruses, influenza 
B viruses, influenza C viruses, Thogotoviruses and Isavirus. 
FLUAV infect a variety of animal species, including humans, birds, pigs, horses, seals, 
dogs and cats, whilst influenza B and influenza C viruses have only been isolated from 
humans. All influenza A and B viruses have eight RNA segments, whilst influenza C 
viruses only have seven RNA segments. On the basis of the antigenicity of their 
haemagglutinin (HA) and neuraminidase (NA) molecules, influenza A viruses are 
classified into 16 HA subtypes (H1–H16) and 9 NA subtypes (N1–N9). The 
nomenclature given to each individual influenza A virus gives references to the host of 
origin (omitted if human), geographic location of isolation, strain number, year of 
isolation as well as the HA and NA subtype. For example, A/Udorn/307/1972(H3N2) is a 
type A influenza virus strain first isolated from humans in Russia in 1972. Of the 16 
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antigenically distinct HA subtypes and 9 NA subtypes, this virus has H3 and N2.  
 
1.3.2 Virion Structure 
Influenza A virus particles have a typical diameter of 80-160 nm. Each virion consists of 
three major sub-viral components: (i) on the outer most of the particle is the lipid bilayer 
derived from host cell membrane with three transmemberane proteins: HA, NA and M2; 
(ii) underneath the envelope is an intermediate layer of matrix protein (M1), and (iii) 
innermost within M1 shell is the viral ribonucleocapsid (vRNP) core formed by 8 
segmented genome wrapped-up with nucleocapsid proteins, and are associated with three 
viral polymerases, PB2, PB1 and PA, responsible for viral transcription and replication. 
A diagram represent the influenza A virus particle, together with viral genome and 
encoded proteins, is shown in Fig. 1.6.  
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1.3.3 Virus life cycle 
Virus replication inside the cells is a complicated process, requires not only viral 
proteins, but also a numbers of host factors to produce a large number of progeny viruses. 
A brief diagram illustrating the major steps of influenza virus life cycle is shown in Fig. 
1.7. 
1.3.3.1  Virus attachment and entry 
The initial step in the replication cycle of influenza virus begins with the attachment of 
virion HA to sialic acid residues that are present on either glycoproteins or glycolipids 
(Skehel and Wiley, 2000). The specific conformation of the sialic acid (α-2,3 vs α-2,6) 
has been established to control species tropism of the virus, with  human viruses 
preferentially interacting with an α2,6 linkage (SAα2,6 Gal) whereas avian viruses 
mostly bind to N-acetylsialic acid attached to the galactose with an α2,3 linkage (Martin 
et al., 1998; Suzuki et al., 2000).  
Hemagglutinin (HA) is the major surface glycoprotein. Besides receptor binding, it also 
mediates fusion between viral envelope and the endosomal membrane. In order for the 
fusion to occur, precursor HA must be cleaved into HA1 and HA2 subunits inside the 
endosome to expose the N-terminal hydrophobic region to bring the endosomal 
membrane in close contact with viral envelope. Most of the influenza strains have a single 
arginine at the HA cleavage site and HA is cleaved by trypsin-like proteases, which are 
restricted to certain tissues and cell types (Klenk et al., 1975; Lazarowitz and Choppin, 
1975), whilst the highly pathogenic avian virus subtypes H5 and H7 contain multiple 
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basic amino acids sequence R-X-R/K-R at the junction of HA1 and HA2 that can be 
cleaved by an intracellular subtilisin-type enzyme, such as furin or PC6 (Horimoto et al., 
1994; Kawaoka and Webster, 1988; Walker et al., 1994; Walker et al., 1992). Thus under 
experimental conditions trypsin usually needs to be added to the culture medium of 
influenza virus infected cells in order to make the virus infectious.  
 
1.3.3.2 vRNP nuclear import 
Influenza virus is one of the few RNA viruses that rely on the cell nucleus for viral 
transcription and replication (Herz et al., 1981b; Jackson et al., 1982). Inside the nucleus, 
cellular pre-mRNAs donate their 5’-caps and prime viral RNA transcription and only 
those mRNAs synthesized after infection are used as primers (Herz et al., 1981b). In the 
virion and in isolated ribonucleoproteins, viral genomes are never found in naked RNA 
form but exist in the form of a helix associated with viral nucleoprotein (Pistorius et al.). 
Three viral polymerases subunits PB2, PB1 and PA are also part of the RNP and 
localized at the partially complementary ends of viral RNA, creating a  “panhandle” 
structure (Hsu et al., 1987) (Fig. 1.8, panel B). Individual RNPs are approximately 15nm 
in diameter and between 50 and 130 nm long, depending on the length of the RNA 
(Compans, Content, and Duesberg, 1972; Heggeness et al., 1982; Jennings et al., 1983), 
and their diameters are close to the limit for movement through the nuclear pore complex, 
and thus vRNP import into the nucleus is a tightly regulated active transport process. 
NP has multiple independent NLSs, one is localized at the N-terminus of the protein 
(Wang, Palese, and O'Neill, 1997), the other is identified at the amino acid position 198-
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216 (Weber et al., 1998), having been shown to interact with nuclear import machinery, 
which is sufficient and necessary for the import of vRNP (Cros, Garcia-Sastre, and Palese, 
2005; O'Neill et al., 1995). Nuclear import of RNPs is regulated by the viral M1 protein, 
which must be disassociated from RNPs during the uncoating process to allow RNP 
nuclear import (Martin and Helenius, 1991). In addition, it is also suggested that 
phosphorylation of NP protein at a serine residue may have a regulatory role in NP 
nuclear import (Arrese and Portela, 1996).  
Although all the proteins of the vRNP complex (NP and polymerase subunits PB2, PB1 
and PA) contain nuclear localization signals (NLSs) capable of directing their own entry 
into the nucleus (Mukaigawa and Nayak, 1991; Nath and Nayak, 1990; Nieto et al., 1994), 
NP was shown to be sufficient to mediate the nuclear import of viral RNAs (Cros, 
Garcia-Sastre, and Palese, 2005; O'Neill et al., 1995). The mechanism of nuclear import 
and assembly of the polymerase subunits has been controversial. However, recent 
publications suggest that newly synthesized PB1 and PA form a dimer in the cytoplasm, 
which is imported into the nucleus separately from PB2. Once in the nucleus, the PB1/PA 
dimer associates with PB2 to form the trimeric polymerase complex (Fodor and Smith, 
2004; Huet et al., 2010). 
 
1.3.3.3 Transcription 
Once the vRNPs are imported into the nucleus, viral mRNA synthesis begins. Initiation 
of viral mRNA synthesis requires 5’-cap structures generated by cleavage of capped 
cellular pre-mRNAs, which is known as “cap snatching”. The initiation of transcription 
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begins with PB1 binding to the 5’ end of vRNA, which induces conformational change of 
PB2, and activates its cap-binding activity that binds the 5’ cap of host pre-mRNAs, 
produced by cellular RNA polymerase II. This in turn causes PB1 to interact with 3’ end 
of vRNA, which is also stabilized by the base pairing between 5’ and 3’ end sequences. 
This event stimulates vial polymerase endonuclease activity, which cleaves 10-13 
nucleotides after cellular pre-mRNA cap structure (Blaas, Patzelt, and Kuechler, 1982; 
Li, Rao, and Krug, 2001; Nakagawa et al., 1995; Ulmanen, Broni, and Krug, 1981). Viral 
endonuclease activity has long been thought to reside in the PB1 subunit. However, 
recent biochemical and structural studies showed that PA subunit contains the active 
endonuclease site (Dias et al., 2009). After endonuclease cleavage, the short-capped 
oligonucleotide is used by the viral polymerase as a primer for transcription initiation by 
PB1, with addition of a “G” residue to the primer, directed by the penultimate “C” 
nucleotide at the 3’ end of vRNP template (Plotch et al., 1981). As a result, the first 
nucleotide of the template is not transcribed. ?
Elongation of nascent viral mRNA is catalyzed by the polymerase function of PB1 until a 
stretch of uridine residues are met near the 5’ end of the vRNA. Synthesis of viral mRNA 
terminates by polyadenylation at an uninterrupted stretch of 5-7 U residues located 15-22 
nucleotides before the 5’ end of the vRNA (Robertson, Schubert, and Lazzarini, 1981). 
Initially it was proposed that the base-pairing region of 5’ and 3’ end vRNA causes a 
physical block so that viral polymerase cannot proceed across, resulting in reiterative 
copying of the U stretch (Luo et al., 1991; Robertson, 1979). However, the current model 
proposes that steric hindrance of polymerase causes it to stutter on the stretch of uridines, 
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which it reiteratively copies to produce a poly (A) tail (Poon et al., 1998; Pritlove et al., 
1998). A diagram illustrating major steps of virus transcription is shown in Fig. 1.8A.  
 
1.3.3.4 Replication 
Replication involves generation of full-length complementary positive sense copies 
(cRNA) of the genomic RNA, which are subsequently used as a template to direct vRNA 
synthesis [reviewed in (Elton et al., 2006; Portela and Digard, 2002b)]. cRNA is different 
from mRNA: firstly, it does not contains a 5’ cap derived from host mRNA by cap-
snatching nor a polyadenylated 3’ end; secondly, it is full-length complementary copy of 
vRNA, whilst mRNA is truncated at its 3’ end where polyadenylation occurs. vRNA 
serves as a template for synthesis of both mRNA and cRNA. Thus there must be a switch 
from a cap-dependent, endonuclease dependant mRNA synthesis to cRNA synthesis by 
viral polymerase. However, the mechanism of switch from mRNA transcription to cRNA 
synthesis is not well understood.  
Early studies suggest that viral replication requires de novo protein synthesis. If protein 
synthesis is blocked, vRNP is only capable of directing viral mRNA transcription but not 
genome replication (Hay et al., 1977). Unlike mRNA, much less cRNA is synthesized 
and constitutes only about 5-10% of the total positive sense viral RNA in infected cells 
(Barrett, Wolstenholme, and Mahy, 1979; Hay et al., 1977; Herz et al., 1981b). 
Additionally, in much the same way as vRNA, newly synthesized cRNAs need to be 
encapsidated by free NP proteins, synthesized from primary transcription and re-entering 
the nucleus and associate and stabilize cRNA (Shapiro and Krug, 1988). In the second 
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stage of replication, full-length positive sense antigenomic cRNA serves as a template for 
progeny vRNA synthesis. vRNA synthesis is also primer-independent, and generates full-
length copies progeny vRNAs.  
NP has been shown to be essential for virus replication and its potential role for switching 
from mRNA transcription to genome replication has drawn much attention. Several NP 
temperature sensitive (ts) mutants have been isolated that are defective for replication at 
the non-permissive temperature (Krug, Ueda, and Palese, 1975; Scholtissek, 1978; 
Thierry and Danos, 1982). Depletion of free NP by antibody in infected cells inhibits 
cRNA synthesis in vitro (Beaton and Krug, 1984; Shapiro and Krug, 1988). Thus NP is 
essential for virus replication. Currently there are three models that have been proposed 
for the role of NP in the switch between mRNA and cRNA synthesis. The encapsidation 
model proposes that NP may simply acts to coat the nascent cRNA molecules (Shapiro 
and Krug, 1988); the template modification hypothesis proposes that the interaction of 
NP with vRNA template alters its structure and therefore the mode of transcription 
initiation and termination (Hagen et al., 1994; Tiley et al., 1994); a third hypothesis 
proposes that NP modifies polymerase function to favor a replication polymerase over a 
transcription polymerase by directly binding to PB2 and PB1 (Biswas, Boutz, and Nayak, 
1998; Mena et al., 1999). A diagram illustrating major steps of virus replication is shown 
in Fig. 1.8A. 
 
1.3.3.5 Nuclear export 
Parental RNPs must be imported into nucleus to serve as template for transcription and 
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replication, whilst progeny RNPs must be exported out of the nucleus for progeny viruses 
assembly and budding. Therefore, premature exit from the nucleus is detrimental to viral 
gene expression. In fact, nuclear export of RNPs is a tightly regulated active process. M1 
and NEP (nuclear export protein), also known as non-structural protein 2 (NS2) (O'Neill, 
Talon, and Palese, 1998), were shown to be essential in the RNP nuclear export process. 
Both M1 and NEP are synthesized at late time during virus infection, M1 enters the 
nucleus through its own NLS (Ye, Robinson, and Wagner, 1995), binds to RNPs and 
inhibits their transcriptional activity (Perez and Donis, 1998; Zvonarjev and Ghendon, 
1980). NEP binds directly to M1 protein (Ward et al., 1995; Yasuda et al., 1993). It also 
contains a functional nuclear export signal (NES) and interacts with components of 
nuclear pore complex. Chromosome region maintenance 1 protein (CRM1) is a nuclear 
export receptor and was shown to interact directly with NEP (Neumann, Hughes, and 
Kawaoka, 2000). Thus it was proposed that NEP acts as an adapter molecule that links 
“M1-RNP cargo” to the nucleo-cytoplasmic transport machinery, and mediates the 
nuclear export of vRNPs. 
 
1.3.3.6 Virion assembly 
Virion assembly and budding is a tightly controlled process and requires a number of 
steps: firstly, all viral components (eight vRNPs and structural proteins, HA, NA, M2, 
M1) must be directed to the site of the assembly: apical plasma membrane of polarized 
cells or plasma membrane in non-polarized cells [reviewed in (Schmitt and Lamb, 
2005)]. Secondly, all viral components must interact in an orderly fashion to be packed 
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into infectious virion. Finally, concentration of virion components must induce the 
curvature of plasma membrane, and the separation of virions from the host cells.  
Following synthesis, each viral integral membrane protein, HA, NA and M2 is 
translocated across the membrane into the lumen of the endoplasmic reticulum (ER), 
where they are correctly folded and glycosylated. They are subsequently transported to 
the Golgi network where the furin cleavage of HA0 with the multi-basic cleavage site into 
HA1 and HA2 may occur. However, for HA molecules with only a single arginine residue 
at the cleavage site, HA cleavage can only occur in response to extra-cellular proteases, 
thus to ensure the production of infectious viral particles.  
These integral membrane proteins are directed to the apical surface of polarized cells via 
their apical sorting signals.  The sorting signals for HA and NA have been studied in 
detail and were shown to reside in their transmembrane domains (TMD), yet the apical 
sorting signal for M2 needs to be defined [reviewed in (Barman et al., 2001)].  
Evidence indicates that HA and NA, but not M2, are enriched in lipid rafts, which are 
non-ionic detergent-resistant lipid microdomains within the plasma membrane that are 
enriched in sphingolipids and cholesterol. Lipid rafts have been shown to play critical 
roles in many aspects of the virus life cycle, including viral entry, viral protein 
trafficking, and viral assembly and budding (Nayak and Barman, 2002; Nayak, Hui, and 
Barman, 2004; Ono and Freed, 2005; Schmitt and Lamb, 2004). Non-raft-associated 
proteins may be brought to lipid rafts by protein-protein interaction. For example, M1, 
non-raft associated protein, could be brought to lipid rafts by interacting with HA and NA 
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(Ali et al., 2000). M2 was recently been shown to bind cholesterol, which is proposed to 
target M2 to the raft periphery where it may bridge raft domains (Schroeder et al., 2005). 
For assembly and budding, both M1 and the vRNPs must be transported to the assembly 
site. The association of M1 with vRNP/NEP complex is well documented. It was 
believed that M1 is the major driving force in directing vRNPs to the plasma membrane. 
In the absence of M1, virus budding does not occur. M1 was shown to be a determinant 
for viral morphology and size, expression of M1 alone can form virus-like particles in 
transfected cells (Gomez-Puertas et al., 2000).  
 
1.3.3.7 Virion budding 
Influenza A virus release from the host cell is described as a “pinching-off”, which 
requires the local curvature of the host plasma membrane to form a bud, followed by the 
formation of a lipid stalk and then fission. As described above, viral integral membrane 
proteins HA, NA and M2 are concentrated at the lipid raft domains and form the outer 
spikes, interaction of M1 with the cytoplasmic tails of HA and NA could facilitate the 
assembly of vRNPs into the assembly sites. Incorporation of all eight vRNP segments is 
required for the formation of infectious virus particles. However, the mechanisms of how 
these segments are incorporated into virus particles remain elusive. Many negative sense 
virus matrix proteins contain late (L) domains which contain highly conserved motifs that 
are involved in recruiting the host proteins required for bud formation and virus release 
[see review (Freed, 2002)]. L domains can be grouped into three general classes, namely, 
PT(S)AP, PPPY (or PPXY), and YPDL (or YXXL), which have been shown to interact 
	   41	  
with a number of host proteins involved in endosomal sorting and endocytosis, such as 
TSG101 (Demirov et al., 2002; Garrus et al., 2001), Nedd4 (Demirov et al., 2002; Garrus 
et al., 2001; Kikonyogo et al., 2001) and ubiquitination machinery (Kikonyogo et al., 
2001; Vogt, 2000). Influenza A virus M1 helix 6 (H6) domain was reported to possess a 
L domain-like motif and may be involved in interaction with host proteins (Hui et al., 
2003b). However, the interaction of cellular protein with influenza late domain that is 
involved in budding has not been identified.  
Virus release is facilitated by the enzymatic activity of NA that catalyze the removal of 
sialic acid from the cell surface, because HA anchors the virus to the cell by binding to 
sialic acid-containing receptors. It also removes sialic acids from viral glycoproteins HA 
and NA to prevent virus self-aggregation.  
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1.3.4 Influenza A virus NS1 and host immune response 
1.3.4.1 Synthesis of the NS1 protein 
Influenza A virus genome segment 8 is transcribed into two separate mRNAs. The first 
encodes the non-structural protein (NS1) that is collinear with the viral RNA segment, 
and the second is derived from a spliced version of the mRNA primary transcript, which 
is translated into the 121 amino acid nuclear export protein (NEP). The 26 kDa NS1 
protein is 219-237 amino acids (aa) in length, which is species specific. All avian-origin 
influenza viruses have a putative NS1 sequence of 230aa (Suarez and Perdue, 1998), 
swine origin NS1 has 219aa. Human-origin NS1 showed some size variation. During the 
1940s the 230 aa NS1 protein of human H1N1 viruses gained an additional 7 aa at its C-
terminus. This extension was then retained in human viruses until the 1980s, when both 
co-circulating H1N1 and H3N2 viruses lost the extension and reverted to the original 
NS1 sequence. The significance of the extension and why it was subsequently lost is not 
entirely clear, although it has recently been implicated in the nuclear and nucleolar 
localisation of NS1 (Hale et al., 2008; Melen et al., 2007). 
 
1.3.4.2 Sub-cellular localization of NS1 protein 
The sub-cellular localization of NS1 protein appears to be dependent on many factors, 
including viral strain, cell type, time-post infection, and expression level. The differential 
localization of sub-cellular compartments of NS1 may contributes to its biological 
activity against host innate immune response. Generally, at early time point post infection 
(4-6 hours), NS1 is predominately found in cell nucleus, whilst, after 8-12 hours post-
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infection, NS1 is found not only in the nucleus, but also in the cytoplasm (Melen et al., 
2007). Nuclear localization of NS1 is mediated by its nuclear localization signals (NLSs) 
interacting with cellular importin-α families. Most influenza strains contain two NLSs 
(NLS1, amino acids 34-38; NLS2, amino acids 203-237), whilst certain strains appears to 
have only one NLS (Greenspan, Palese, and Krystal, 1988).  
Recently, a nucleolar localization signal (NoLS) has been identified in NS1 (Melen et al., 
2007). The nucleolus is a relatively large, highly organized non-membranous sub-
compartment of the nucleus, and is the site for rRNA synthesis, processing, and ribosome 
assembly. Recently, it has become apparent that nucleoli are dynamic structures 
composed of more than 700 different proteins and involved in cell cycle regulation, 
tumor suppression, and stress response (Olson, 2004; Olson, Hingorani, and Szebeni, 
2002), and nucleoli are often targeted by DNA viruses, retroviruses and RNA viruses 
[reviewed in (Hiscox, 2002; Hiscox, 2007)]. The nucleoli targeting of influenza virus 
NS1 appears to depend on viral strain and cell type infected. All NS1 proteins have an 
amino acid sequence forming a functional NoLS in avian cells, however, only a few viral 
strains NS1 showed nucleoli targeting in mammalian cells. A/Udorn NS1 contains the 
mammalian NoLS, in contrast, A/WSN/33 NS1 failed to accumulate in the nucleoli 
(Melen et al., 2007). It has been shown that many viruses, such as plant rhabdovirus 
maize fine streak virus (MFSV), Borna disease virus (Pyper, Clements, and Zink, 1998), 
and hepatitis delta virus (Li et al., 2006b), hijack the nucleolus for genome replication. 
However, the role of influenza A virus NS1 targeting the nucleolus is unknown. Mutant 
influenza A virus (A/Udorn/72) expressing a truncated NS1 protein (lacking of its C 
terminal 17 amino acids) that was unable to localize into the nucleolus was not attenuated 
	   44	  
for replication (Melen et al., 2007). Therefore, nucleolus localization of NS1 may be only 
affecting host functions and thus viral pathogenesis.  
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1.3.4.3 NS1 and host immune response 
Influenza virus NS1 protein is widely regarded as a multifunctional protein with 
regulatory activities that affect a variety of host cell functions. It plays a key role in the 
viral anti-host defense mechanisms (Hale et al., 2008; Li et al., 2006c; Noah and Krug, 
2005). It is only found in cells infected with influenza viruses and not in the virion 
structure (Krug and Etkind, 1973). NS1 contains two distinct structural/functional 
domains: (i) an N-terminal RNA-binding domain (residues 1-73aa), which binds with 
high affinity to double-stranded RNA (dsRNA) for which both NMR and crystal 
structures have been published (Chien et al., 2004; Qian et al., 1995). Mutational analysis 
has further demonstrated that dimer formation is crucial for RNA-binding, mutation in 
R38 and K41 abolish the dsRNA binding activity (Wang et al., 1999). (ii) C-terminal 
effector domain with the binding sites for poly (A)-binding protein II (PABII) and the 
30kDa subunit of cleavage and polyadenylation specificity factor (CPSF30) [reviewed in 
(Krug et al., 2003)]. NS1 has also been reported to interact with several other host 
factors, including the eukaryotic translation initiation factor 4GI (eIF4GI) (Aragon et al., 
2000; Burgui et al., 2003; Wolff, O'Neill, and Palese, 1996; Wolff, O'Neill, and Palese, 
1998), which mediates interactions with a number of host-cell proteins (Krug et al., 
2003).  
	   46	  
 
1.3.4.3.1 NS1 Inhibits type I IFN production 
Evidence that the NS1 protein of influenza A virus inhibits the expression of IFN 
stimulated genes came from experiments showing that infection with delNS1 virus, the 
recombinant influenza virus lacking the NS1 gene, resulted in significant stimulation of 
an ISRE-containing promoter at conditions in which this activation was not observed in 
cells infected with wild-type influenza A virus (Garcia-Sastre et al., 1998). Further more, 
wild type influenza virus induces far less IFN than does mutant delNS1 virus and this 
difference lies at the transcriptional level, which suggests that NS1 protein prevents the 
synthesis of type I IFN during influenza A virus infection (Talon et al., 2000; Wang et al., 
2000). A number of studies suggested that NS1 protein limits IFN induction by both pre-
transcriptional (cytoplasmic) and /or post-transcriptional (nuclear) events.  
 
(i) Pre-transcriptional limitation of IFN-β induction by NS1 
The transcriptional activation of IFN-β in response to virus infection is regulated by IFN 
enhanceosome that includes the transcription factors IRF-3, NF-κB and AP-1 (see Fig. 
1.2). Each one of these transcription factors has been shown to be inhibited in wild type 
(wt) influenza virus infected cells but not in mutant virus delNS1 infected cells which 
corresponds with the differential induction of IFN-β by these viruses (Ludwig et al., 
2002; Talon et al., 2000; Wang et al., 2000). 
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The precise mechanism for how NS1 inhibits IFN synthesis is still elusive but its dsRNA-
binding activity plays a key role. It is now evident that influenza virus ssRNA genome 
containing 5’-triphosphate is a potent agonist of RIG-I (Pichlmair et al., 2006; Rehwinkel 
et al., 2010). As such, recent publications indicate that NS1 may mediate its block on 
IFN-β induction by forming a complex with RIG-I (Guo et al., 2007; Mibayashi et al., 
2007; Opitz et al., 2007), and NS1 was shown to sequester the stimulatory RNA to 
prevent recognition by RIG-I. It has been demonstrated in vRNP reconstitutions that 
wtNS1 forms a trimolecular complex with the stimulatory RNA and RIG-I (Rehwinkel et 
al., 2010), and the complex formation is largely dependent on R38 and K41 residues in 
NS1 (Pichlmair et al., 2006; Rehwinkel et al., 2010).  
Not only does NS1 sequester stimulatory RNA, but also it inhibits tripartite motif (TRIM) 
proteins to prevent RIG-I activation. The ubiquitin ligase TRIM25 has recently been 
shown to induce Lys63-linked ubiquitination of the N-terminal CARD domain of RIG-I, 
resulting in a significant increase in RIG-I downstream signalling activity (Gack et al., 
2007). In virus-infected cells, NS1 specifically inhibits TRIM25 activity by physical 
interaction, thus blocking TRIM25 oligomerization and RIG-I ubiquitination (Gack et al., 
2009).  
 
(ii) Post-transcriptional limitation of IFN-β induction by NS1 
The nucleus is the site where the cellular mRNAs are synthesized, and their maturation 
involves the endonucleolytic cleavage of the primary transcripts, followed by 
polyadenylation of the cleaved products. Cellular mRNAs are targeted by FLUAV NS1 
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at various stages. It was firstly shown NS1 prevents the nucleo-cytoplasmic transport of 
poly(A)-containing mRNAs (Alonso-Caplen et al., 1992; Nemeroff et al., 1998; Qiu and 
Krug, 1994), and this inhibition results, at least partly, from the intervention of NS1 with 
the 30 kDa protein subunit of the cleavage and polyadenylation specificity factor 
(CPSF30) (Nemeroff et al., 1998) and poly(A)-binding protein II (PABPII) (Chen, Li, 
and Krug, 1999). As a consequence of the interaction, cellular pre-mRNAs that contain 
short (about 12 nucleotide) poly(A) tails are retained in the nuclei of influenza virus-
infected cells, providing a pool of cap-donors for viral polymerases. 
Besides targeting the 3’ end processing of cellular pre-mRNAs, the 5’ end cellular caps 
are also used by influenza virus to prime viral RNA transcription, and only those capped 
cellular RNAs synthesized after infection, and not those synthesized before infection, are 
used as primers (Herz et al., 1981a), thus these mechanisms provide an effective means to 
limit host antiviral responses.  
 
1.3.4.3.2 Ability of NS1 to limit IFN production is not absolute 
Several groups have demonstrated that type I IFN mRNA is induced and upregulated 
upon influenza virus infection in dendritic cells, macrophages and A549 cells (Huang et 
al., 2001; Matikainen et al., 2000; Ronni et al., 1997), implying that there is leakage in 
blocking IFN-β mRNA induction. Infection with wild-type influenza A virus resulted in 
both the activation of IRF-3 (Kim, Latham, and Krug, 2002) and the production of IFN-β 
mRNA albeit at low levels (Noah, Twu, and Krug, 2003). These results show that even 
though NS1 targets cellular pre-mRNA processing and transport by interacting with 
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CPSF30 and PABPII, some IFN-β pre-mRNA escapes the inhibition of post-
transcriptional processing mediated by this binding site. Some post-transcriptional 
processing of several other virus-induced cellular pre-mRNAs also occurs in wild-type 
influenza A virus-infected cells, as detected by microarray analysis, e.g., the production 
of cellular mRNAs involved in the STAT and apoptotic pathways (Geiss et al., 2001; 
Geiss et al., 2002; Huang et al., 2001). These observations suggest that the function of the 
NS1-binding site for 30-kDa CPSF and PABPII is regulated during wild-type virus 
infection. One possibility is that the inhibition of posttranscriptional processing of 
cellular pre-mRNAs is relieved as a result of the activation of the nuclear export signal 
(NES) by the NS1 protein (Chen, Li, and Krug, 1998). 
 
1.3.4.3.3 NS1 Inhibits OAS and PKR activity?
OAS and PKR are both activated by dsRNA, a putative by-product of virus replication. 
NS1 can indirectly inhibits OAS and PKR activation by binding and sequestering 
dsRNA, thereby inhibiting host antiviral defense. PKR expression is induced by IFN and 
therefore the NS1-induced block in IFN synthesis will reduce the level of PKR in 
infected cells. NS1 can directly inhibit the function of PKR (Min and Krug, 2006). NS1 
has also been observed to form a complex with PKR to block its activation (Tan and 
Katze, 1998). The other mode of PKR inhibition by influenza virus infection is to recruit 
the cellular p58(IPK), which interacts with the ATP-binding region of PKR in the C-
terminal catalytic domain (amino acids 244 to 296) and involves in PKR dimerization 
(Gale et al., 1996). The interaction of P58IPK with this region of PKR prevents PKR 
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dimerization and autophosphorylation (Tan and Katze, 1998), thus interfering with PKR's 
ability to phosphorylate eIF2α and inhibiting translation initiation in response to viral 
infection. 
 
1.3.4.3.4 NS1 activation of PI3K signalling 
Influenza A virus infections induce a variety of pro- and antiviral-acting signalling 
processes (Ludwig et al., 2003; Ludwig et al., 2006). Very recently the 
phosphatidylinositol 3-kinase (PI3K) and its downstream effector Akt/protein kinase B 
have been added to the list of influenza A virus-induced signalling mediators (Hale et al., 
2006; Shin et al., 2007). PI3K signalling contributes to many processes, including cell 
metabolism, cell cycle progression, cell proliferation, survival and migration, and 
intracellular vesicular transport [reviewed in (Vanhaesebroeck et al., 2010)]. Class IA 
PI3K is a heterodimeric protein/lipid kinase that consists of a regulatory subunit (usually 
p85α, p85β, or p55γ), and a p110 catalytic subunit (Talon et al., 2000). The p85β 
regulatory subunit is made up of five domains: an N-terminal Src homology 3 (SH3) 
domain, a GTPase activating protein domain, and two SH2 domains (nSH2 and cSH2), 
separated by an inter-SH2 (iSH2) domain (Okkenhaug and Vanhaesebroeck, 2001).  
 
PI3K is activated upon influenza virus infection in a short and transient manner, followed 
by a second stage of prolonged activation later in the infection cycle (Ehrhardt et al., 
2006). Furthermore, it was reported NS1 effector domain is responsible for activating 
PI3K by interacting with iSH2 domain of p85β subunit (Hale et al., 2006; Hale et al., 
	   51	  
2008; Shin et al., 2007). Recently, the crystal structure of the NS1 effector domain in 
complex with the inter-SH2 (coiled-coil) domain of p85β has been solved (Hale et al., 
2010), and it was proposed that NS1 acts by physically blocking normal inhibitory 
contacts between the p85β nSH2 domain and p110. 
Activation of PI3K causes the generation of the second messenger PIP3, which acts to 
recruit pleckstrin homology (PH) domain-containing effectors to the membrane, and is 
involved in a wide variety of cellular events, generating lipid signals downstream of 
receptors and influencing diverse cellular pathways. Activated PI3K is regulated by a 
negative feedback loop mediated by phosphatase PTEN (Carracedo and Pandolfi, 2008).  
Activation of PI3K is involved in phosphorylation and activation of IRF-3 (Sarkar et al., 
2004) but the role of PI3K in influenza virus infection was proposed to support effective 
virus uptake in early stages as well as preventing apoptosis late in infection (Ehrhardt et 
al., 2006; Hale et al., 2006). However, recent results from recombinant mutant viruses 
with loss of function of NS1 that is unable to activated PI3K was shown to promote 
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Aims of Thesis 
The overall aim of this study is to compare influenza A viruses (FLUAV) and PIV5 in 
dealing with cells in a pre-existing interferon-induced antiviral state. Since the 
mechanisms of PIV5 in dealing with the IFN response is well characterized, the 
knowledge of PIV5 may shed lights on understanding how FLUAV deals with the IFN 
response. It may facilitate better understanding of viral pathogenesis and epidemiology. 
In particular, it is of interest to study which stages of influenza A virus life cycle is 
inhibited by IFN, and to identify the key antiviral molecules induced by IFN in 
establishing the antiviral state. To achieve this, it requires us to be able to look into each 
stage of virus life cycle in details and to be able monitor the fate of incoming genome. 
Since MxA was reported to be an important antiviral molecule induced by IFN and 
inhibit a number of viruses, it would also be of interest to characterize the antiviral 
mechanisms of MxA against influenza virus infection. 
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2.1 Mammalian cells and tissue culture 
2.1.1 Cell types used in this study  
A549 cells - Human lung epithelial cells. 
Vero cells – fibroblast-like cell line originating from kidney cells of African Green 
monkey. 
Vero-MxA – Vero cells constitutively expressing human MxA (kindly provided by 
Prof. Otto Haller, Freiburg). 
MDCK cells – canine kidney cells. 
MDCK/V cells – MDCK cells stably expressing the V protein of PIV5 (Precious et 
al., 2005b). 
293T cells – Human embryonic kidney cells constitutively expressing SV40 large T 
antigen. Kindly provided by Prof. Richard Iggo, University of St Andrews. 
A549/BVDV-Npro cells – A549 cells constitutively expressing Bovine Diarrhoea 
Virus (BVDV) Npro protein, which targets IRF-3 for degradation. 
A549/shMxA cells – A549 cells transducted with lentivirus overexpressing shRNA 
against MxA. 
A549/IFNβ-GFP cells – A549 cells overexpressing GFP under the control of IFNβ 
promoter, generated by Ms. Shu Chen (University of St Andrews). 
A549/shUbcH8 cells – A549 cells transducted with lentivirus over-expressing 
shRNA against ISG15 conjugating enzyme E2 (UbcH8). 
A549/MxA cells – A549 cells constitutively over-expressing MxA. 
A549/pk-MxA cells – A549 cells constitutively overexpressing pk-tagged MxA. 
A549/shMxA/wMxA cells – A549 cells with MxA knockdown constitutively over-
expressing wobble MxA. 
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A549/NS1B cells – A549 cells constitutively overexpressing pk-tagged influenza B 
virus NS1 protein. 
A549/FLAG-E3L cells – A549 cells constitutively overexpressing FLAG-tagged 
vaccinia virus E3L protein. 
 
2.1.2 Cell maintenance  
Cell monolayers were maintained in 25cm2 or 75cm2 tissue culture flasks (Greiner) in 
DMEM (Dulbecco’s modified Eagle’s medium; Invitrogen) supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum (FBS; Biowest) and incubated at 37°C/5% CO2 
incubator. Cells were routinely passaged using trypsin/EDTA (Becton Dickinson Ltd.), at 
a frequency dictated by the rate of cell growth. 
 
2.1.3 Cell stock preparation and resuscitation  
Adherent cells were trypsinised, resuspended in DMEM/10% FBS, and centrifuged at 
~500×g for 5mins. Pelleted cells were resuspended in DMEM supplemented with 20% 
FBS and 10% DMSO and aliquoted into cryovials. Cell stocks were frozen at 70oC before 
long-term storage in liquid nitrogen. For resuscitation of cells, cryovials were thawed at 
37°C before centrifugation at ~500×g. Pelleted cells were then resuspended and grown in 
DMEM/10% FBS at 37°C/5% CO2. Medium was replaced after 24 hours in order to 
remove traces of DMSO.  
 
2.1.4 Treatment of cells  
2.1.4.1 IFN treatment  
Cells were treated overnight (at least 16 hours, unless where otherwise stated) with media 
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supplemented with Roferon recombinant human IFNα-2a (Roche Diagnostics) or IFN-γ 
(Invitrogen) at a concentration of 103 units/ml.  
 
2.1.4.2 Transfections with plasmid DNA  
Mutant viruses were generated by substituting the pHH-NS “rescue” plasmid for mutated 
versions in the rescue transfection (plasmids were kindly provided by Robert A. Lamb, 
Northwestern University). These plasmids (pHH-NS1-Y89F, pHH-NS1-P164/7A, pHH-
NS1-P162/4/7A, pHH-NS1-R38A, pHH-NS1-123/4, pHH-NS1-184-8, pHH-NS1-
103/106, pHH-NS1-Δ99) were generated by site-directed mutagenesis of pHH-NS using 
the QuikChange mutagenesis kit (Stratagene) and specific primers. The sequence of the 
mutated plasmids was confirmed by DNA sequencing. Transfection of cells with plasmid 
DNA was carried out using FuGENE 6 transfection reagent (Roche) according to the 
manufacturer’s instructions. 
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2.2 Viruses and viruses infection 
2.2.1 Influenza viruses 
1. rWSN: Recombinant wild-type influenza A virus (A/WSN/33) generated and 
provided by Dr. Dave Jackson (University of St Andrews). 
2. rUd: Recombinant wild-type influenza A virus (A/Udorn/72) generated and 
provided by Dr. Dave Jackson (University of St Andrews). 
3. rUd-Y89F: recombinant Udorn virus expressing NS1 with the Y89F amino-acid 
substitution. Generated and provided by D. Jackson, Northwestern University, 
USA (Hale et al., 2006).  
4. rUd-P164/7A: The NS1 protein carries two amino acid substitutions at positions 
164 and 167 that are reported to abrogate PI3K binding (Shin et al., 2007). 
5. rUd-P162/4/7A: The NS1 protein carries three amino acid substitutions at 
positions 162, 164 and 167. Virus isolation took much longer than for other 
mutants, and was initially a mixed population of virus, also containing rUd NS1-
Δ99. 
6. rUd-Δ99: This virus encodes an NS1 protein carrying only amino acids 1-98, and 
was isolated during rescue of the rUd-P162/164/167A virus. 
7. rUd-184-8(L): At positions 184-188, five amino acids, GLEWN have been 
substituted for RFLRY. This mutation eliminates the binding site for CPSF30 
(Noah et al., 2003). This virus took much longer to rescue than other mutants, and 
isolated virus was initially a mixed population, also containing rUd -184-8(P).  
8. rWSN-Y89F: recombinant WSN virus expressing NS1 with the Y89F amino acid 
substitution. Generated and provided by D. Jackson Northwestern University, 
USA (Hale et al., 2006). 
9. rUd-184-8(P): Isolated during the rescue of rUd-184-8(L). rUd-184-8(P) differs 
from rUd-184-8(L) at position 186, where it carries a proline instead of a leucine 
residue.  
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10. rUd-103/106B: The NS1 protein carries F103L and M106I amino acid 
substitutions. Residues 103 and 106 are important for stabilizing the NS1:CPSF30 
interaction (Kochs, Garcia-Sastre, and Martinez-Sobrido, 2007; Twu et al., 2007).  
11. rUd-123/4: The binding site for PKR (residues 123-127) is mutated in the NS1 
protein. Mutation of this site abrogates the ability of NS1 of inhibit PKR during 
virus infection (Min et al., 2007).  
12. rUd-R38A: The NS1 protein carries an amino acid substitution at position 38. 
This residue is absolutely required for the dsRNA binding activity of NS1, and 
replacement of arginine with alanine abrogates this activity (Wang et al., 1999). 
 
2.2.2 Parainfluenza virus 5 
1. W3 Wild-type laboratory strain of PIV5 (Choppin, 1964)  
2. CPI- canine isolate of PIV5 unable to block IFN signalling. (Baumgartner, 
Krakowka, and Blakeslee, 1987; Baumgartner et al., 1982; Baumgartner et al., 
1981) 
 
2.2.3 Virus infection 
To infect with paramyxovirus isolates, monolayers were inoculated with virus diluted in 
DMEM supplemented with 2% fetal bovine serum (FBS) at an appropriate multiplicity of 
infection (MOI), or DMEM only (for mock infections). For virus infections in 6-well 
plates, cells were inoculated in a volume of 1ml per well and placed on a rocking 
platform at 37°C for an adsorption period of 1-2 hours. Virus inoculum was then 
removed and replaced with DMEM/2% FBS. Cells were incubated at 37°C/5% CO2 until 
harvested.  
FLUAV infections were carried out in serum-free DMEM. Monolayers were washed in 
DMEM prior to infection to remove all traces of serum. Cell monolayers were infected 
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with 400μl virus (per well of a 6-well plate) diluted in serum-free DMEM at an 
appropriate MOI (or DMEM only for mock infections). Cells were incubated for 1hr at 
37°C, with gentle agitation at regular intervals. Virus inoculum was removed and 
replaced with serum-free DMEM. Cells were incubated at 37°C/5% CO2 until harvested.  
 
2.2.4 Preparation of virus stocks 
Stocks of PIV5 isolates were kindly maintained and provided by Dan Young (University 
of St. Andrews).  
To prepare stocks of influenza A virus, 100% confluent MDCK or MDCK/V monolayers 
in T75 cm2 flask were washed twice in serum-free DMEM. Cells were inoculated at an 
MOI of ~ 0.001 plaque-forming units (PFU)/cell in 5ml serum-free DMEM. After a 1 
hour adsorption period with constant rocking at 37°C, virus inoculum was removed and 
monolayers were washed with serum-free DMEM. 12 ml (per 75cm2 flask) of serum-free 
DMEM supplemented with 2.5µg/ml N-acetyl trypsin (NAT) were added to the 
monolayers and cells were incubated in incubator at 37°C, 5% CO2. Supernatants were 
harvested when 80-90% CPE (cytopathic effect) was observed (about 2 days). Cell debris 
was removed by centrifugation (~3000 ×g for 10mins) and aliquots were frozen at -70°C. 
Virus titers were determined by plaque assay as described below.  
 
2.2.5 Titration of virus preparations 
Titration of FLUAV was carried out on confluent MDCK monolayers in 6-well plates. 
The procedure was carried out essentially as described elsewhere (Takeda et al., 2002). 
Cells were washed twice in serum-free DMEM in order to remove all traces of serum. 
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Confluent monolayers of cells were inoculated with 0.5 ml 10-fold serial dilution of 
viruses and were incubated at 37°C/5% CO2. Plates were agitated every 10 minutes to 
ensure even adsorption of the virus among the monolayers. During this period, 2× 
overlay medium (13.4g DMEM, 3.7g NaHCO3, and 10mM HEPES pH 7.4 per 485ml 
water) supplemented with 2 µg/ml N-actetyl trypsin (NAT, Sigma) was incubated at 
37°C. 2% agarose (NuSieve® GTG®) in water was melted in a microwave oven and 
placed in a 55°C water bath until required. After an adsorption period of 2 to 3 hours, 
virus inoculum was removed, monolayers were washed with FBS free DMEM, the 2× 
overlay medium and the 2% agarose were mixed in a 1:1 ratio, and 2ml of this molten 
agarose was added into each well. After the overlay had solidified (after about 30 
minutes), plates were inverted and incubated at 37°C incubator with 5% CO2 until 
distinct plaques had formed (2 to 3 days). Cells were fixed by adding 2ml 5% 
formaldehyde/1% sucrose in PBS on top of the agarose plugs, and the monolayers were 
left to fix for 2 hours. Agarose plugs were then removed and washed with PBS, plaques 
were stained with crystal violet (0.1% crystal violet, 3.6% formaldehyde, 1% methanol, 
20% ethanol in H2O) or visualized by immunostaining as described below.  
 
2.2.6 Immunostaining of influenza virus plaques 
To stain the plaques for immunological specificity, the monolayers were fixed with 5% 
formaldehyde (in PBS) for at least 2 hours and the agarose overlay were removed, cell 
monolayers were washed with PBS and blocked with 500µl of PBN (PBS, 1% BSA, 
0.02% sodium azide) for one hour. Then the cells were incubated for 1 h with first 
antibody: goat anti-A/Udorn/72 virus serum in PBN (1:1000). The monolayers were then 
washed with PBS and incubated for 1 h with peroxidase-conjugated donkey anti-goat 
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immunoglobulin G (Santa Cruz Biotechnology, UK, sc-2022) in PBN. After the 
monolayers were washed with PBS, the peroxidase-conjugated antibody was reacted with 
fast red BCIP/NBT (Sigma) that is dissolved in water for 1-2 hours. 
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2.3 DNA subcloning 
2.3.1 cDNA synthesis by reverse transcription 
To clone IFN-induced genes, total cellular RNA were extracted using Trizol (Ambion) 
from A549 cells treated with IFNα (1000u/ml) and used as a template in a reverse 
transcription reaction for synthesis of cDNAs with M-MLV Reverse Transcriptase 
(Sigma). The procedures were carried out according to manufacture’s instruction 
(Promega). 0.5µg Oligo(dT)15 were mixed with 1µg of total RNA and heated at 70°C for 
5min to melt any secondary structure with the template. Samples were then immediately 
immersed on ice. The annealed primer/template were added with 5× M-MLV RT reaction 
buffer, 10mM dNTP and M-MLV reverse transcriptase and incubated at 40°C for the 
initial 10 mins, then 42°C for the final 50 mins. After that, the reaction was inactivated by 
heating for 15min at 70°C, and the cDNA was used as a template for amplification by 
PCR with gene-specific primers. 
 
2.3.2 Restriction enzyme digestion of DNA 
DNA backbone vectors and purified PCR products (typically 2-3µg) were mixed with 5 
units of the desired restriction enzymes, enzyme buffers, in a reaction mixture made up to 
30µl with de-ionised water. Reactions were incubated for 2 to 4 hours at the appropriate 
temperature. All restriction reagents were purchased from Promega or New England 
Biolabs. Where a single enzyme was used for digestion of backbone vector to create 
cohesive ends, Calf intestinal Alkaline Phosphatase (CIAP, Promega) was added into 
reaction tube following digestion to prevent vector self-ligation.?
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2.3.3 Transformation of competent cells  
0.1μg plasmid was added directly to 50μl of thawed, chemically competent cells 
(Invitrogen). After incubation on ice for 30min, cells were heat-shocked at 42°C in water 
bath for 30sec before being immediately immerged in ice for a further 2min. Cells were 
resuspended in 1ml LB broth and incubated at 37°C for 1h. The cell suspension was 
plated out onto LB-agar plates supplemented with ampicillin (90 mm-diameter Petri 
dishes; Scientific Laboratory Supplies Ltd., U.K.). Plates were inverted and incubated at 
37°C overnight.  
 
2.3.4 Preparation of plasmid DNA  
For small-scale preparations, bacterial cell cultures of 10 ml (in LB broth containing 
100μg/ml ampicillin) were grown overnight in a 37°C shaking incubator. DNA was 
extracted from cells and purified using the QIAGEN DNA mini-prep kit according to the 
manufacturer’s instructions (QIAGEN). To produce larger-scale DNA preparations, 100 
– 500 ml of bacterial culture was grown overnight in a 37°C shaking incubator. DNA was 
extracted from cells using the QIAfilter Plasmid Maxi Kit according to the 
manufacturer’s instructions (QIAGEN). 
 
2.3.5 Colony PCR screening 
Colony PCR screening was used to quickly test for the presence of a target DNA 
fragment in E.coli without the need for growth and mini-prep of transformed bacterial 
colonies. Basically, a master mix of PCR reaction with primers for gene of interest was 
prepared and dispensed into PCR tubes. Bacterial colonies were picked up individually 
and resuspended into the PCR reaction tube, and PCR amplification was performed at 
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appropriate time and temperature for the primerts and PCR product expected for ~25 
cycles according to the manufacturer’s protocol (Promega). PCR products were analysed 
by agarose gel electrophoresis and bacterial colonies corresponding to positive PCR 
product were used for plasmids mini-prep. 
 
2.3.6 Agarose gel electrophoresis 
Plasmids preparations and PCR digestions were analysed by agarose gel electrophoresis 
in 1% (w/v) agarose (Sigma-Aldrich) gel in 1× TAE buffer added with ethidium bromide. 
DNA samples were mixed with appropriate volume of 6× DNA loading buffer (Promega) 
and electrophoresis was performed in 1× TAE buffer at 100V. Resolved DNA bands of 
interest were visualized on a UV transluminator.  
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2.4 Protein analysis 
2.4.1 SDS polyacrylamide gel electrophoresis 
Cell lysates were prepared by adding 2× disruption buffer (6M Urea, 2M β-
mercaptoethanol, 4% (w/v) SDS, with bromophenol blue colouring) to cells in a 1:1 ratio. 
Viscosity of samples was reduced by sonication (2 × 20s) or digestion with Benzonase 
(Novagen). Polypeptides were separated through 4-12% NuPAGE polyacrylamide 
gradient gels (Invitrogen) by electrophoresis (200V for 50 min) in 1×MOPS buffer [3-(N-
morpholino)propanesulphonic acid] (Invitrogen). 
 
2.4.2 Immunoblotting 
Protein lysates were subjected to SDS-PAGE as described above, and transferred to 
polyvinylidene difluoride (PVDF) membrane using the XCell II Blot Module according 
to the manufacturer’s instructions (Invitrogen). After transfer, membranes were blocked 
for one hour in 5% (w/v) skimmed milk powder, 0.1% (v/v) Tween 20 in PBS (blocking 
buffer), and incubated for either 1h or overnight with primary antibody diluted (in 
blocking buffer) according to the manufacturer’s instructions. After 3 washes with PBS/ 
0.1% Tween 20, interactions between protein and antibody were detected by incubating 
the membrane for 1h with horseradish peroxidase (HRP)-conjugated antibody raised 
against the appropriate species, diluted appropriately in blocking buffer. Unbound 
antibody was washed away with PBS/ 0.1% Tween 20, and specific polypeptide bands 
were visualised using western blotting chemiluminescence luminal reagent according to 
the manufacturer's instructions (Santa Cruz).  
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2.4.3 Immunofluorescence 
For immunofluorescence analysis, cells were grown on 10mm-diameter coverslips 
(General Scientific Co. Ltd., Redhill, United Kingdom) in individual wells of 6-well 
plates. Treatment with exogenous IFN was as mentioned above. Cells were infected with 
FLUAV or PIV5, and the inoculum was adsorbed for 1 h. At various times p.i., coverslips 
were removed and incubated in fixing solution (5% formaldehyde and 2% sucrose in 
PBS) for 30 min at room temperature, then permeabilized (0.5% Nonidet-P40, 0.5% 
Triton X-100, and 2% sucrose in PBS) for 15 min, and washed three times in PBS 
containing 1% fetal calf serum and 0.1% azide. After that, monolayers of cells were 
blocked with 5% FBS. To detect the proteins of interest, cell monolayers on coverslips 
were incubated with 20-30 μl of appropriately diluted primary antibody for 1 h. The 
antibodies used to detect PIV5 proteins were the MAbs NP and P. To detect influenza 
viral proteins, purified sheep anti-NS1 or monoclonal anti-NP antibody (Abcam) was 
used. Cells were subsequently washed (1% fetal calf serum, 0.1% azide in PBS) several 
times, and the antibody-antigen interactions were detected by indirect 
immunofluorescence (1 h incubation) with a secondary Texas Red-conjugated goat anti-
mouse immunoglobulin, or FITC-conjugated goat anti-Rabbit IgG (Seralab, United 
Kingdom). In addition, cells were stained with the DNA-binding fluorochrome 4ʹ′,6-
diamidino-2-phenylindole (DAPI, 0.5 μg/ml; Sigma-Aldrich) for nuclear staining. 
Following staining, monolayers were washed with PBS, mounted with Citifluor AF-1 
mounting solution (Citifluor Ltd., United Kingdom), and examined under a Nikon 
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Microphot-FXA immunofluorescence microscope. For images that were meged with 
DAPI, SPOT software (version 4.6) was used. 
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2.4.4 Preparation of radio-labelled antigen extracts, immunoprecipitation, and SDS-
PAGE 
At various times after the addition or no addition of IFN, cells grown in T-25 flasks were 
metabolically labelled for 1 h with 2µl L-[35S]methionine (500 Ci/mmol; Amersham 
International Ltd., United Kingdom) in methionine-free tissue culture medium. At the end 
of the labelling interval, cells were washed with ice-cold phosphate-buffered saline (PBS) 
and lysed in immunoprecipitation buffer (10 mM Tris-HCl, pH 7.8, 5 mM EDTA, 0.3% 
Nonidet P-40, and 0.65 M NaCl) by sonication with an ultrasonic probe. 50µl of total cell 
antigen extract sample was kept as a control to examine total cellular protein synthesis. 
Soluble antigen extracts were prepared by subjecting the remainder of the cell lysates to 
centrifugation at 12, 000 ×g for 30min to remove insoluble material. To detect PIV5 viral 
proteins, immune complexes were formed by incubating 1ml samples of the soluble 
antigen extracts with a pool of monoclonal antibodies (MAbs) to the NP, P, M, and HN 
proteins of PIV5 and a polyclonal antiserum to the P/V proteins of PIV5 for 2 h at 4°C. 
To detect influenza viral proteins, immune complex were formed by incubating with 1ml 
of the soluble antigen extract with polyclonal anti-FLUAV antibody. The immune 
complexes were isolated by incubation with protein G-Sepharose 4B Fast Flow (Sigma) 
(1 h at 4°C). The proteins in the immune complexes were dissociated by heating in 2× 
disruption buffer (6M Urea, 2M β-mercaptoethanol, 4% sodium dodecyl sulphate) at 
100°C for 5 min and analyzed by SDS-PAGE. After electrophoresis, gels were fixed, 
stained, and dried. The resolved labelled polypeptide bands were visualized by 
autoradiography and quantitated by phosphorimager analysis.  
	   68	  
 
2.5 RNA analysis 
2.5.1 RNA extraction  
Monolayer of cells grown on 6-well plates were washed twice with ice-cold PBS and 
lysed directly in the culture dish by addingin 1ml Trizol (Ambion) and incubated for 5 
minutes at room temperature. Cell suspension was then transferred into an eppendorf tube 
and mixed with 200µl chloroform. Samples were vortexed vigoriously for 15sec and 
incubated at room temperature for 5 minutes. The solution was then subject to 
centrifugation for 20min at 4°C, and total RNA was pelleted from supernatant by mixing 
with 0.5ml isopropanol. Finally the pellet was washed with 70% enthanol and dissolved 
in DEPC-treated water. 
2.5.2 in situ hybridization 
2.5.2.1 Generation of DIG-labelled probes 
To generate Digoxigenin (DIG)-labelled ssRNA probes against FLUAV segment 8, we 
have to firstly generate a probe construct. Briefly, PCR amplicon was synthesized with 
primers sequence of A/Udorn Segment 8 (nucleotides169-610), and cloned into pGEM-T 
easy vector according to the manufacturer’s instructions (Promega, see A.3 for more 
details). The construct was then linearized by digestion with NdeI or NcoI and purified 
with QIAquick PCR purification kit (QIAGEN). T7 or SP6 polymerase was used to 
generate the digoxigenin (DIG)-labelled “run-off” transcript probes against the negative-
sense vRNA or positive-sense RNA antigenome, respectively, using DIG RNA labelling 
kit (Roche). DIG-labelled RNA probes were subjected to LiCl/ethanol precipitation to 
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remove unincorporated DIG nucleotides, and the yield of DIG-labelled RNA probes was 
estimated using a spot test. 
2.5.2.2 in situ hybridization  
For in situ hybridization analysis of viral RNA localization, cells were grown on 10mm-
diameter coverslips (General Scientific Co. Ltd., Redhill, United Kingdom) pre-coated 
with poly-L-lysine (sigma) in individual wells of 6-well plates. Cells were infected with 
FLUAV at 4oC on ice for one hour to allow virus attachment to cells before the cells were 
incubated at 37oC to synchronize the process of infection. At various times p.i., 
monolayers were fixed with 5% formaldehyde and 2% sucrose in PBS for 30 min at room 
temperature and washed three times in PBS. 
Deproteinization was carried out with Proteinase K solution (2µg/ml Proteinase K, 
20mM Tris pH7.5, 2mM CaCl2) at 37 oC for 15min. Cells were then rinsed with 0.1% 
Tween-20 in PBS and post-fixed in 5% paraformaldehyde in PBS for 20 minutes 
followed by permeabilization in 0.5% Triton X-100 in PBS with 2mM Vanadyl 
Ribonucloside Complex (VRC, Sigma) for 15 min at RT. After washing for 3 times with 
PBS, cells were allow to equilibrate for 5 minutes in 2× sodium chloride–sodium citrate 
(SSC) with 0.025% Tween-20 at 37oC. DIG-labelled probes (1ng/µl) in hybridization 
buffer (50% deionised formamide; 1mg/ml sonicated salmon sperm; 1mg/ml tRNA; 
0.1M Tris-HCl, pH8.0; 1.6mg/ml NaH2PO4; 1.4mg/ml Na2HPO4; 0.2mg/ml Ficol; 
0.2mg/ml polyvinyl-Pirrdidone; 1mM DTT; 1×SSC and 20× RNasin) were heated for 5 
minutes at 80°C on a heating block, and quenched on ice before being applied to the 
cells. Hybridization was allowed to proceed overnight at 55 oC in a humidified chamber.  
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After overnight hybridization, sections were thoroughly washed once for 15 minutes with 
2×SSC/10mM Tris pH7.5 at room temperature, twice in 0.1×SSC for 15 minutes (room 
temperature), and once with stringent buffer (30% Formamide/0.1%×SSC/10mM Tris, 
pH 7.5) for 30 minutes at 55 oC. Cells were subsequently washed 3 times with TBST 
buffer (150mM NaCl; 10mM KCl; 50mM Tris-HCl pH7.5; 0.1% Tween-20) and blocked 
for one hour at room temperature with 2% blocking reagent (Roche) in TBST 
supplemented with 20% heat inactivated sheep serum. 
For detection of hybridization, cells were incubated with alkaline phosphatase conjugated 
anti-DIG Fab fragments (Roche) diluted 1:1000 in TBST with 2% blocking reagent 
(Roche) and 1% heat-inactivated sheep serum for two hours at room temperature. After 
three washes with TBST buffer, viral RNAs and bound anti-DIG antibody complex was 
then detected with the highly sensitive Fast Red tablet (Roche) dissolved in 0.4M 
NaCl/Tris-HCl 0.1M, pH8.2 for two hours at room temperature. The reaction was 
stopped by washing of cells with 0.1% Tween-20 in PBS, followed by several washes 
with PBS. Cells nuclei were then stained with 4',6-Diamidino-2-phenylindole (DAPI) for 
10 minutes at room temperature. Finally, cells were washed in PBS and coverslips were 
mounted onto microscope slides with Mowiol mounting medium (CALBIOCHEM). 
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2.6 Miscellaneous assays 
2.6.1 Lentivirus-based shRNA cell line construction 
2.6.1.1   Generation of shRNA constructs 
The lentivirus-based small hairpin RNA (shRNA) transfer plasmids targeting human 
MxA at positions 1325 to 1349 (CCA GGA CUA CGA GAU UGA GAU UUC G) 
(pLKO/shMxA) was constructed, this sequence showed efficient MxA gene silencing 
(Oelschlegel, Kruger, and Rang, 2007). Briefly, the double strand hairpin oligos were 
synthesized by annealing two single strand DNA sequence, MxA Forward 
(GATCCCCAGGACTACGAGATTGAGATTTCGTTCAAGAGACGAAATCTCAATCTCGTAGTCCT
GGTTTTTCCCGGGCTAGAG) and MxA reverse (AATTCTCTAGCCCGGGAAAAACCAGGACTA 
CGAGATTGAGATTTCGTCTCTTGAACGAAATCTCAATCTCGTAGTCCTGGG) and ligated into 
the backbone vector pLKO.1 (see A.1 for more details), which was digested with EcoRI 
and BamHI. SmaI sequence was introduced into the hairpin oligos to allow screening of 
constructs by restriction digestion after transformation into E.coli. MxA sequence and its 
reverse complement sequence were marked in red color; SmaI (underlined) sequence was 
introduced into the hairpin oligos to allow screening of constructs by restriction digestion 
after transformation into E.coli.  
 
2.6.1.2 Lentivirus production 
Recombinant lentiviruses expressing MxA shRNA was prepared by transfecting 293FT 
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cells (Invitrogen) with the lentivirus vector plasmids (pLKO/shMxA) together with 
plasmids pCMVR8.91 (that expresses the gag/pol, tat, and rev genes of human 
immunodeficiency virus) and pMD_VSVG (that expresses the envelope gene of vesicular 
stomatitis virus) using FuGENE6 according to the manufactory’s protocol (Roche). Two 
days after transfection, the culture media containing the lentiviruses were harvested, and 
new medium was added into the cells and harvested 24 hrs later. Medium from day 2 and 
day 3 after transfection was pooled and cell debris was removed by centrifugation at 
3000×g for 10 minutes. The supernatant was filtered through a 0.45 µm Tuffryn 
membrane filters (Invitrogen) and stored at -70°C.  
 
2.6.1.3 Transduction of target cells 
30% confluent A549 cells were transduced with the lentivirus stock A549 cells in the 
presence of 8 µg/ml Polybrene (Sigma-Aldrich, UK). Selection with Blasticidin 
(InvivoGen; 10µg/ml) was carried out 2 days after infection. Stocks of stable cell line 
were frozen at -70°C. The cell line generated was verified by immunofluorescence and 
western blot assay.  
 
2.6.2 Lentivirus-based overexpression cell line construction 
The procedure of overexpressing lentivirus-based target gene is very similar to lentivirus-
based shRNA knockdown system, except that the pdlNotI’IRESpuro vector is used (the 
map of the vector is attached at the Appendix section), and lentivirus transducted cells 
were selected in the presence of puromycin (2µg/ml) or Blasticidin (10µg/ml). 
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Antibodies 
Antibodies were used in immunoblotting, immunostaining and immunofluorescence as 
described in the according section. The primary antibodies specific for viral proteins and 
cellular proteins used in this study are shown in table 2.1. 
Table 2.1: Primary antibodies and target proteins: 
Antibody Target Protein Source 
PIV5-NP-a (mAb) PIV5 NP (Randall et al., 1987) 
PIV5-P-e (mAb) PIV5 P (unique C 
domain) 
(Randall et al., 1987) 
PIV5-P-k (mAb) PIV5 V and P 
(common N domain) 
(Randall et al., 1987) 
Influenza A virus anti-NP 
(mAb) 
Influenza NP Abcam 
Ab20343 
Polyclonal Anti X-31 
(Sheep) 
Influenza A virus Diagnostics Scotland 
Polyclonal anti -NS1 
(Sheep) 


















MxA Kindly provided by Georg Kochs 
(University of Freiburg, Germany) 
 
The following antibodies were used as secondary antibodies to detect primary antibodies: 
• Donkey anti-Goat IgG-AP alkaline phophatase conjugated (Santa Cruz 
Biotechnology, UK, sc-2022) 
• Donkey anti-Goat IgG: Texas Red® conjugated (Santa Cruz Biotechnology, UK, 
sc-2783) 
• Donkey anti-Sheep IgG-AP alkaline phospatase conjugated (Abcam, UK, ab6898) 
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• Goat anti-mouse IgG-AP alkaline phosphatase conjugated (Santa Cruz 
Biotechnology, UK, sc-2008) 
• Goat anti-mouse IgG: FITC conjugated (AbD Serotec, UK, 103002) 
• Goat anti-mouse IgG: Texas Red® conjugated (AbD Serotec, UK, 103007) 
• Goat anti-rabbit IgG-AP alkaline phosphatase conjugated (Santa Cruz 
Biotechnology, UK, sc-2007) 
• Goat anti rabbit IgG-HRP linked (Santa Cruz Biotechnology, UK, sc-2004) 
• Goat anti-rabbit IgG+IgM: Texas Red® conjugated (AbD Serotec, UK, 401007) 
• Goat anti-rabbit IgG: Cyanine5 conjugated (kindly provided by Dan Young, 
University of St. Andrews 
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2.8 Primers 
PRIMERS DESCRIPTION SEQUENCE  
MxA5’(BamHI) 5’-CGGGATCCATGGTTGTTTCCGAAGTGGAC-3’ 
MxAr(NotI) 
Primers used for 
cloning of human 








































IFITM3-fwd to amplify IFITM3 
and clone into 
5’-GGACTAGTATGAATCACACTGTCCAAACC-3’ 
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used for knocking 




MxA Wobble 5’ 5’-CGGGATCCATGGTGGTGTCTGAAGTCGATATTG 
MxA Wobble 3’ 
Primers used for 
cloning of 
synthetic wobble 
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2.9 Plasmids 
PLASMIDS DESCRIPTION 
pMD-VSVG Expressing the vesicular stomatitis virus glycoprotein (VSV-G), used 
in lentivirus production, provided by Y-H. Chen. 
pCMVR 8.91 Expressing the gag/pol, tat and rev genes of HIV-1 (used in 
lentivirus production, provided by Y-H. Chen). 
pdl'BVDV/NPro(N'V5) Lentivirus vector expressing the N-terminally V5-tagged  
BVDV/NPro; provided by M. Galliano, University of St Andrews. 
pLKO/shMxA(Bla) Lentivirus vector expressing shRNA against MxA, cloned from 
backbone vector, pLKO-STAT1, which is kindly provided by Dr. 
Lena Andrejeva, University of St Andrews. 
pLKO/shUbcH8(Bla) Lentivirus vector expressing shRNA against ISGylation E2 
conjugation enzyme UbcH8, cloned from backbone 
pLKO/shMxA(Blasticidin resistance). 
pLKO/shHerc5 Lentivirus vector expressing shRNA against ISGylation E3 ligase 
gene Herc5. 
pLKO/shIFITM3(puro) Lentivirus vector expressing shRNA against IFITM3, cloned from 
backbone vector pLKO-TLR3(puro), provided by Dr. Andrejeva. 
pdl’MxA(puro) MxA gene was cloned into pdlNotI-IRESpuro plasmid (generated by 
Y.H. Chen) from pTM/MxA (kindly provided by Dr. Gjon Blakqori, 
University of St Andrews).  
pdl’pk-MxA(puro) Lentivirus vector expressing pk-tagged MxA. MxA gene were 
amplified from pTM-MxA, and cloned into pdl’SeV-V N-pk 
digested with SpeI/BamHI. 
pHH/NS1 Influenza A virus segment 8 (strain A/Udorn) was cloned into pHH 
plasmid in reverse orientation (kindly provided by Dr. D., Jackson). 
pdl’pk-Viperin(Bla) Viperin gene were amplified from puro-viperin vector (provided by 
Dr. Andrejeva), digested with SpeI/NdeI, and cloned into pdl’pk-
Npro(Bla) (provided by Dr. M., Killip). 
pdl’FLUBV/NS1 
(N’term-V5) 
Lentivirus vector expressing influenza B virus NS1 gene (strain 
Yamagata/73), provided by Dr. Benjamin Hale, University of St 
Andrews. 
pdl’FLAG-E3L Lentivirus vector expressing vaccinia virus E3L gene, N-ter FLAG 
tagged, provided by Mara Galliano, University of St Andrews.  
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3.1 Comparing the mechanisms of influenza A virus and PIV5 in overcoming the 
IFN response 
Type I interferon (IFN) constitutes the first line of defence against virus infection. IFN 
exert its antiviral function by induction of IFN-stimulated genes, which inhibit virus 
replication through a range of mechanisms. However, viruses have evolved different 
mechanisms to overcome the IFN response. Previous work has shown the 
paramyoxyvirus PIV5 can dismantle the IFN-induced antiviral state by targeting STAT1 
for degradation, thus blocking IFN-signalling (Young et al., 2000b). Influenza A virus 
encodes the NS1 protein which antagonizes various steps of interferon induction and 
signalling pathways. It was of interest to compare the strategies employed by influenza A 
viruses (FLUAV) and PIV5, which may allow better understanding viral pathogenesis 
and epidemiology, and may also facilitate improved vaccine design and drug discovery. 
 
3.1.1 Viral ability to overcome the IFN response is not absolute 
Even though PIV5 and FLUAV encode powerful IFN antagonists, V and NS1 
respectively; their ability to overcome the IFN response is not absolute (Carlos, Fearns, 
and Randall, 2005; Carlos et al., 2009). This is demonstrated by comparison of plaque 
size of both influenza A virus and PIV5 in A549 cells which could produce and respond 
to IFN is smaller compared with that in A549/BVDV-Npro cells (Fig. 3.1A), which can 
only respond to IFN but not produce IFN, because they were designed to constitutively 
overexpress BVDV N-terminal protease fragment (Npro), which targets IRF-3 for 
degradation (Hilton et al., 2006). A possible explanation for smaller plaques in naive 
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A549 cells is that, IFN released from cells in the developing plaque induce an antiviral 
state in neighboring cells, thus limiting virus spread.  
Further evidence to support that influenza A virus is unable to completely block IFN 
production is demonstrated by double staining with anti-NS1 and anti-MxA antibody 
using immunofluorescence in A549 cells infected at low multiplicity with A/Udorn (MOI 
= 0.1pfu/cell) (Fig. 3.1B). MxA expression is only seen in uninfected cells surrounding 
those infected cells, indicating that uninfected cells responded to IFN released from 
infected cells and induced the expression of MxA, even though influenza A virus NS1 
protein is a multifunctional protein involved in many aspects of antagonizing the IFN 
response. 
 
Nevertheless, the effects on virus replication, when IFN induces an antiviral state within 
a cell, are not known. To address this question, PIV5 and FLUAV plaque formation was 
examined in cells in a pre-existing antiviral state induced by IFN. Plaque assays were 
performed in A549/BVDV-Npro cells that were or were not pretreated with IFN. IFN 
pre-treatment reduces not only FLUAV plaque sizes, but also its plaque numbers by a 
factor of about 100. In contrast, IFN pre-treatment significantly reduced PIV5 plaque size 
but not plaque numbers (Fig. 3.1A). These preliminary results suggest that IFN treatment 
does not completely inhibit the replication of both PIV5 and FLUAV, and these viruses 
still manage to form plaques even through the cells are in an IFN-induced antiviral state. 
However, the viruses respond to IFN very differently, IFN does not prevent PIV5 from 
initiating plaque development, instead it slows down the spread of virus to neighboring 
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cells. In contrast, IFN not only significantly slows down FLUAV spread to neighboring 
cells, but also prevents FLUAV development from an initial focus of infection. ?
 
3.1.2 Comparison of FLUAV and PIV5 protein synthesis 
To understand how PIV5 and FLUAV deal with the IFN response in detail, viral protein 
synthesis was examined by radioactive labelling at various time post-infection. A549 
cells were, or were not, pretreated with IFN, then mock infected or infected with PIV5 or 
FLUAV at MOI of 5pfu/cell, and at various time post-infection, the cells were 
metabolically labeled with [35S] methionine for one hour and the total cell lysate were 
prepared and protein synthesis were visualized by phospho-imaging (Fig. 3.2). The 
results from this analysis revealed that PIV5 viral proteins were efficiently expressed in 
cells untreated with IFN, and there was a significant overexpression of PIV5 NP protein 
(Fig. 3.2A). In cells pretreated with IFN (Fig. 3.2B), the effect of IFN on different viral 
proteins was selective, the relative expression levels of NP, P and V proteins were similar 
in IFN-treated compared to non-treated cells. However, there was an obvious reduction in 
the relative protein levels of HN, M, and L.  
In case of influenza virus, the synthesis of viral proteins in cells untreated with IFN is 
very rapid, and is accompanied by a dramatic inhibition of host cell protein synthesis 
(Fig. 3.2C), termed host cell shut-off. However, the synthesis of all detectable viral 
proteins is impaired in IFN-treated cells, and it is also evident that host cell shut-off is 
prevented by IFN-treatment.  
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3.1.3  Study of the mechanism of host-cell shut-off by Influenza A virus 
Unlike PIV5, influenza virus infection of host cells leads to a progressive decline in the 
synthesis of cellular proteins, known as host-cell shut-off. The rapid synthesis of viral 
RNA and proteins requires the diversion of cellular resources away from cellular events. 
Several stages of host-cell mRNA translation stages are altered by influenza virus, which 
may lead to host-cell shut-off. It has been shown that an essential component of host cell 
transcriptional machinery, RNA polymerase II (pol II), was degraded in influenza virus-
infected cells (Vreede et al., 2010). Previous studies have shown that the NS1 protein 
selectively promotes translation of viral mRNAs rather than cellular mRNAs (de la Luna 
et al., 1995), and it was also shown it targets cellular pre-mRNA processing and transport 
by interacting with CPSF30 and PABPII (Chen, Li, and Krug, 1999; Fortes, Beloso, and 
Ortin, 1994; Nemeroff et al., 1998), I therefore asked whether the interaction and 
inhibition of these factors by NS1 could lead to host-cell shut-off.  
To address the question whether influenza NS1 protein is involved in shutting-off host 
protein synthesis, a panel of recombinant influenza A viruses generated by Dr. D. 
Jackson were used. These viruses contained mutations in the NS1 protein that have 
previously been shown to prevent interactions with dsRNA, PI3K, CPSF30 and PKR 
(Hale et al., 2006; Jackson et al., 2010; Nemeroff et al., 1998; Shin et al., 2007). Amino 
acid mutations were introduced into the NS1 protein of A/Udorn/72 by a plasmid-based 
reverse genetics system. The mutations introduced into NS1 and the functions inhibited 
by each mutant are summarized in Table. 3.1, and the relative position of each mutation 
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within NS1 is illustrated in Fig. 3.3. Two mutant viruses rUd-NS1-184-8(L) and rUd-
NS1-103/106 were created in which the interaction of NS1 with CPSF30 is inhibited. 
Interestingly, a third mutant [rUd-184-8(P)] was generated during the recovery of rUd-
NS1-184-8(L) virus, and these two viruses were separated by plaque purification. The 
rUd-NS1-123/4 mutant was created to prevent the binding of NS1 to PKR. The rUd-NS1-
R38A mutant was designed to prevent NS1 binding to dsRNA. The mutant rUd-Δ99 was 
created that the effector domain of NS1 is deleted. Three mutant viruses were created to 
prevent the interaction with the p85β subunit of PI3K: (i) rUd-Y89F, (ii) rUd-NS1-
P164/7A, and (iii) rUd-NS1-P162/4/7A. 
The expression of cellular and viral genes in cells infected with these mutant viruses was 
studied. A549 cells were infected with mutant viruses, wt A/Udorn or WSN strain at a 
MOI of 5 pfu/cell and labelled by incorporation of [35S] Met for 1 hour at 12 h post-
infection. Total cell lysates were separated by SDS-PAGE, and the proteins were 
visualized by phosphoimaging. The synthesis of cellular proteins was significantly 
inhibited in cells infected by both wild type and mutant viruses. Despite the loss of NS1 
functions for interactions with dsRNA, PI3K, CPSF30 and PKR, mutant viruses induced 
a shut-off similar to that observed after wild-type influenza virus infection, as seen by the 
diminished labelling and disappearance of prominent cellular bands (Fig. 3.4). Therefore, 
it was concluded that influenza virus induced host shut-off is independent of NS1 
function.  
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3.1.4 PIV5 can dismantle the IFN-induced antiviral state 
Even though the IFN response could limit virus spread to neighboring cells as 
demonstrated in above figures, PIV5 was still able to overcome the IFN-induced antiviral 
state. This was demonstrated by examining the effect of IFN pretreatment on the 
distribution of virus proteins in infected cells. A549 cells were, or were not pretreated 
with IFN for 16 h and then infected at a high MOI with PIV5. Cell monolayers were 
fixed at one, and two days p.i. and examined by immunofluorescence using a mixture of 
monoclonal antibodies against NP and P proteins (Fig. 3.5). In cells untreated with IFN, 
NP and P proteins were distributed diffusely throughout the cytoplasm during the time 
course of virus infection (Panels A and B). However, virus replication is severely 
impaired in cells pretreated IFN at one day post infection, as NP and P proteins are seen 
as inclusion bodies in the majority of infected cells, although in a few cells, NP and P 
were distributed throughout the cytoplasm (Panel C). However, by two days p.i., the size 
of the inclusion bodies increased slightly, and the proportion of the cells strongly positive 
for virus antigen was much higher (Panel D) and the distribution of NP and P became 
closer to that observed in untreated cells, i.e. localized throughout the cytoplasm. 
Therefore, even in the continuous presence of IFN, PIV5 could still gradually overcome 
the inhibitory effects of IFN treatment. 
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3.1.5 PIV5 could overcome the IFN-induced antiviral state in the presence of 
neutralizing antibodies 
In the above experiments, it was demonstrated that, in cells in a pre-existing IFN-induced 
antiviral state, PIV5 could gradually overcome the inhibitory effects of IFN. There are 
two explanations for this. PIV5 could initiate multiple cycles of replication with the 
functional attachment and fusion proteins and thus progeny viruses released from cells 
that were strongly positive for viral antigens could infect cells that were not strongly 
positive for viral antigens, or in cells that NP were seen as cytoplasmic bodies the viral 
genome was gradually recovered, and expressed high level of viral antigens. To address 
this issue, neutralizing antibody was used to prevent PIV5 virus from initiating multiple 
cycles of replication.  
Firstly, the ability of neutralizing antibodies against F and HN proteins to prevent 
multiple cycles of replication of PIV5 was tested. A549 cells were inoculated at low MOI 
(0.1pfu/cell) of PIV5, 3 hours after virus adsoption, the inoculum was removed, cells 
were washed twice with PBS and then serum free DMEM was added in the presence 
(+antibody) or absence (-antibody) of neutralizing antibody. Cells were fixed at different 
times p.i. and stained with anti-NP/P antibodies (Fig. 3.6). In the absence of neutralizing 
antibody, only a few cells were positive for viral antigens at early times post infection (16 
h; p.i; Panel A), but the virus managed to spread to neighboring cells, and by 48 hrs p.i, 
all the cells were positive for viral antigens (Panel C). In contrast, in the presence of 
neutralizing antibody, the virus was unable to undergo multiple cycles of replication, and 
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the majority of cells remained negative for viral antigens at 48 hrs p.i (Panel D). 
Therefore, this demonstrated that neutralizing antibody was able to block PIV5 multiple 
cycles of replication.  
Given that neutralizing antibody could neutralize PIV5, it was of interest to then ascertain 
whether the ability of PIV5 to undergo multiple cycle growth accounts for the 
breakthrough of IFN-induced antiviral effects. A549 cells pretreated or untreated with 
IFN were infected with PIV5 at high MOI to ensure all cells were infected, at 3 hours p.i., 
neutralizing antibody was added, or not added into the medium. Cells were fixed and 
stained with anti-NP/P antibodies at different times p.i (Fig. 3.7). As a control, in the 
absence of neutralizing antibody, all untreated cells were positive for NP and P proteins, 
while in cells pretreated with IFN, NP and P were strongly positive in a minority of cells, 
and localized in cytoplasmic bodies in the majority of cells at one day post infection. As 
discussed above, PIV5 was able to overcome the IFN-induced antiviral state at late times 
post infection. By 3 days, all the cells were strongly positive for NP and P (Panel A). 
Surprisingly, even in the presence of neutralizing antibody, PIV5 was still able to 
overcome the IFN-induced antiviral state, at 3 days p.i., NP and P proteins were diffusely 
distributed throughout the cytoplasm in all cells (Panel B), indicating that the ability of 
PIV5 to undergo multiple cycle of replication is not responsible for dismantling the pre-
existing IFN-induced antiviral state. Since PIV5 can eventually degrade STAT1 in cells 
that have entered an antiviral state (Didcock et al., 1999), those cells cannot maintain an 
antiviral state in the absence of continuous signalling. Consequently, although the PIV5 
viral genome was initially relatively quiescent in cells in an IFN-induced antiviral state, 
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activity gradually recovered when the cells left the antiviral state, and subsequently 
achieved high level of antigen expression at late times post-infection. 
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3.1.6 Influenza virus and the IFN-induced antiviral state 
Knowing that PIV5 can dismantle the pre-existing IFN-induced antiviral state, it was of 
interest to study whether influenza virus can overcome the antiviral state. A549 cells, 
untreated or treated with IFN, were infected at an MOI of 5pfu/cell to ensure all cells 
were infected. Cells were fixed at different times post-infection and analyzed for 
expression of NS1 by indirect immunofluorescence (Fig. 3.8A). In untreated cells, 
virtually all were positive for NS1 expression. By contrast, only a small fraction of IFN-
treated A549 cells expressed detectable levels of NS1 protein in the cytoplasm (Fig. 
3.8A). Even at two days post-infection, the majority of infected cells remain negative for 
NS1 expression, suggesting that in these cells, the influenza virus genome could not 
recover from the inhibitory effects of IFN treatment. 
 It is worthwhile to note that the inhibition, by IFN treatment, of virus replication is not 
100%, and a small fraction of cells were positive for NS1 expression. It seemed very 
likely that this minority of cells had lost their antiviral state, and could account for the 
positive expression for viral antigens. To address this question, A549 cells, untreated or 
treated with IFN were infected with FLUAV and double stained with sheep anti-NS1 
antibody and MxA monoclonal antibody (Fig. 3.8B). MxA is an IFN-induced antiviral 
molecule with a broad spectrum of antiviral activities, thus it is often used as a marker for 
the IFN-induced antiviral state. As seen in panel B, NS1 was strongly positive even in 
cells where MxA was also strongly positive. These findings clearly argue that FLUAV 
could overcome the antiviral state in a small percentage of cells.  
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3.2 Characterization of influenza A virus replication in cells in an IFN-induced 
antiviral state 
Although the antiviral function of interferon was discovered using UV-inactivated 
influenza virus, the mechanism of IFN-inhibition of influenza virus replication is still 
elusive. The IFN-induced antiviral state is considered to result from the concerted action 
of a number of IFN-induced proteins. It is of particular interest to identify the stage(s) of 
virus replication cycle that are/is inhibited by the action of IFN and to identify the key 
antiviral molecules induced by IFN that are responsible for the inhibition of influenza 
replication.  
 
3.2.1 IFN treatment after virus infection failed to inhibit virus replication 
It has been demonstrated above that influenza A virus replication is severely impaired in 
IFN-pretreated cells, but it is not known at which stage of influenza virus life cycle 
inhibition occurs. To address this issue, A549 cells were infected at high MOI (5 pfu/cell) 
with influenza A virus,  IFNα was added into the culture medium of infected cells one 
hours after infection and the cells were fixed and immunostained with anti-NS1 antibody 
at 8 and 24 hours post-infection (Fig. 3.9). In contrast to IFN-pretreatment, treatment 
after virus infection has no inhibitory effects on virus replication, all the infected cells 
showed positive staining for NS1 antigen. This result suggests that the late event of virus 
life cycle, such as viral protein synthesis, virion assembly and budding may not be 
affected. Therefore there may be a block before the expression of any viral functions, 
such as virus binding, endocytosis, uncoating, or transport to the nucleus. Alternatively, 
some early viral function, such as transcription and replication might be inhibited. Since 
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these events occur only at the beginning of an infection, delayed IFN treatment would be 
ineffective against virus infection. 
 
3.2.2 Multiplicity-dependent leakiness of the IFN-induced inhibition of virus 
replication 
If the early events of influenza virus life cycle are inhibited, this raised the question as to 
whether the IFN-induced antiviral state could be swamped by high multiplicity of 
infection (MOI). To answer this, monolayers of A549 cells were, or were not pretreated 
with IFN then infected with FLUAV at different MOI, the cells were fixed at 12h p.i. and 
immunostained with anti-NS1 antibody. The percentage of cells positive for NS1 antigen 
was calculated by counting cells positive for NS1 versus the total number of cells per 
field of view under the microscope. As shown in Fig. 3.10, the degree of inhibition does 
depend on the virus MOI. The number of IFN-pretreated cells which were positive for 
viral antigens is only about 5% at MOI of 0.5pfu/cell, the degree of protection by IFN 
gradually decreases with increasing MOI and the percentage of cells positive for viral 
antigens increased to about 35% at MOI of 50 pfu/cell (Fig. 3.10A). These results 
indicate that the inhibition of all the known early events of FLUAV can be overcome by 
infecting the cells at a higher multiplicity. 
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3.2.3 Effects of IFN treatment upon vRNP import 
Previous results on the effects of IFN treatment on influenza virus replication have shown 
that I, IFN-mediated inhibition only occurs when treatment with IFN precedes influenza 
A virus infection and treatment after virus infection has no inhibitory effect and II, that 
the degree of protection decreases with increasing MOI. The conclusion from these 
results is that inhibition by IFN can be narrowed down to early event(s) in the virus life 
cycle. If these early events are blocked, this can explain both the requirement for 
pretreatment with IFN and the decreased inhibition at higher multiplicity of infection. For 
instance, if the cell has only a few molecules induced by IFN which can block the early 
events, they could be overwhelmed by high amount of input virus. 
Given that FLUAV is one of the few RNA viruses that rely on the host cell nucleus for 
viral transcription and replication, it was of interest to study whether viral genome import 
into the nucleus is blocked in IFN-treated cells. To undertake this study, it was necessary 
to be able to monitor the fate of incoming (parental) nucleocapsids. This was 
accomplished in two ways: by using immunofluorescence with antibody specific for viral 
NP protein, and by in situ hybridization using Digoxigenin (DIG)-labelled probe to 
FLUAV genome. The accumulation of parental vRNP in infected cell nuclei was 
evaluated at a time before the onset of viral protein synthesis (2h after inoculation). A549 
cells that were, or were not treated with IFN were inoculated with very high MOI of 
influenza virus (500 pfu/cell) in the presence or absence of cycloheximide (CHX) at 4oC 
to allow the viruses to bind to the cells. 45 mins after inoculation, pre-warmed (37oC) 
serum-free medium was added to synchronize the process of virus infection. The infected 
cells were fixed and immunostained at 2h p.i. with anti-NP antibody. To ensure that we 
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were detecting only the incoming vRNP, a control group of cells were added with protein 
synthesis inhibitor cycloheximide (CHX) at the time of infection. No detectable synthesis 
of NP protein occurred under these conditions as judged by radioactive labelling of 
proteins (data not shown), so that the only NP protein detected in the infected cells was 
that associated with parental viral nucleocapsids. In cells not treated with IFN, viral NP 
proteins were readily detected in the nuclei. However, only a few cells showed nuclear 
staining of NP protein in cells pretreated with IFN (Fig.3.11a). 
It was not clear where the viral nucleocapsids were localized in those cells pretreated 
with IFN but without nuclear staining of NP. To address this issue, in situ hybridization, 
using ssRNA probes specific for sequences within the FLUAV segment 8 gene, was used 
to detect negative-sense viral RNA genome. The procedure for infection was basically 
the same as carried out above. In the absence of IFN treatment, virus genomes were 
readily seen inside the nuclei (Panel A). As expected, in cells pretreated with IFN, very 
few cells showed nuclear staining of FLUAV vRNA. In the majority of cells, vRNA was 
localized outside the nucleus at the perinuclear region (Panel B).  
Taken together, by immunofluorescence it was shown that parental NP protein was 
prevented from entering the cell nucleus in IFN-pretreated cells, and by in situ 
hybridization it was also shown that negative-sense viral genomes were localized at the 
perinuclear region and prevented from entering the nucleus in IFN-pretreated cells, thus 
IFN-pretreatment must inhibits at the stage of nuclear import of viral genome.  
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3.2.4 Effect of MxA knockdown upon virus genome import 
Previous reports have shown that MxA is an important antiviral molecule induced by IFN 
which inhibits replication of a number of DNA and RNA viruses. In particular, MxA has 
been shown to block the replication of La Crosse virus, hantaviruses, Dugbe virus, and 
Crimean-Congo hemorrhagic fever virus (CCHFV) by interacting with the viral 
nucleocapsid proteins. It has also been shown that MxA targets influenza virus NP 
protein in minireplicon systems, and that over-expression of NP effectively rescues viral 
transcriptional activity from the MxA inhibition (Turan et al., 2004). In light of the 
observations above, that IFN-treatment inhibits FLUAV viral genome import, it was of 
interest to study whether MxA plays a major role in blocking influenza viral genome 
import within cells in an IFN-induced antiviral state. To address this question, an MxA-
knockdown cell line was generated using a lentivirus-based shRNA system. The 
procedures for generation of MxA-knockdown cells are described in detail in Materials 
and Methods. 
Western blot analysis and immonofluorescence were used to determine whether MxA 
was efficiently depleted in cells transduced with lentivirus expressing shRNA against 
MxA (Fig. 3.12). Naïve A549 cells and MxA-knockdown cells were treated with 1000 
u/ml IFNα. 16 h later, cells were fixed and immunostained with monoclonal anti-MxA 
antibody or lysed and subjected to SDS-PAGE and western blot analysis. As shown in 
Panel A, by western blot analysis MxA expression was seen only in IFNα-treated naïve 
A549 cells but was not detectable in cells not treated with IFNα. In contrast, MxA was 
not detectable in lentivirus-transduced MxA-knockdown cells (shMxA) even if the cells 
were treated with IFNα. As a control, the expression of STAT1 was upregulated in both 
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naïve A549 cells and MxA-knockdown cells following IFN treatment. By 
immunofluorescence analysis MxA was strongly expressed in the cytoplasm in naïve 
A549 cells treated with IFN, but it was undetectable in cells not treated with IFN (Panel 
B). In contrast, in MxA-knockdown cells, MxA was down regulated in almost 100% of 
the cell population even after treatment with IFN, although a few cells showed weak 
staining of MxA. 
To follow the fate of influenza viral nucleocapsids in cells in a pre-existing IFN-induced 
antiviral state in the absence of MxA expression, control cells and shMxA cells that were, 
or were not treated with IFN were infected at very high multiplicity with influenza virus 
(500pfu/cell). To selectively stain incoming nucleocapsids, cells were incubated in the 
presence of CHX to block de novo viral protein synthesis. Fig. 3.13 showed that in 
control cells in the absence of IFN treatment, NP almost completely moved into the 
nucleus of control cells at 2 hour post-infection, whilst in the presence of IFN treatment, 
there was no obvious nuclear staining of NP. In contrast, irrespective the presence or 
absence of IFN-treatment in shMxA cells, the viral nucleocapsids were efficiently 
imported into the nucleus, suggesting that MxA plays an essential role in blocking viral 
genome import in IFN-treated A549 cells. 
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3.2.5 Effects of MxA over-expression upon virus genome import 
Previous studies have shown that avian strain of influenza virus (FPV-B) replication was 
severely impaired in murine 3T3 cells over-expressing MxA, and it was suggested that 
MxA inhibits a poorly defined step after primary transcription (Pavlovic, Haller, and 
Staeheli, 1992). To demonstrate the role of MxA, MxA-over-expression cell line was 
generated by transducing A549 cells with lentivirus encoding human MxA and 
subsequently selected in the presence of puromycin. The procedure for generation of 
MxA-over-expression cell line is described in details in Materials and Methods.	  Over-
expression of MxA in A549 cells was tested by western blot and immunofluorescence 
(Fig. 3.14). By western blot analysis, in control A549 cells, MxA is only expressed in 
cells treated with IFN, whilst in A549 cells over-expressing MxA (A549-MxA), MxA 
was shown to be strongly positive even in the absence of IFNα treatment (Panel A). By 
immunofluorescence analysis, MxA accumulated in the cytoplasm of A549-MxA cells 
and showed a granular staining pattern similar to MxA pattern observed in that of A549 
cells treated with human IFNα (Panel B). It was clear that MxA was expressed in more 
than 95% of the total cell population as judged by immunofluorescence. 	  
The fate of incoming nucleocapsids in MxA-over-expressing cells was also investigated 
(Fig. 3.15). The procedure was basically the same as previously described. Nucleocapsids 
moved into the nucleus of naive A549 cells, leaving the cytoplasm virtually clear at 2 
hours post-infection. In A549-MxA cells, the transport of parental nucleocapsids into the 
nucleus was similar to control cells, suggesting that MxA over-expression alone is 
insufficient to block incoming genome import.  
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3.2.6 Effects of introducing MxA back into MxA-knockdown cells upon virus 
genome import 
It has been demonstrated above that without IFN pretreatment, over-expression of MxA 
in naïve A549 cells does not block FLUAV genome import. Two possible explainations 
for the observations in the above experiment are, firstly, that exogenously expressed 
MxA (by lentivirus transduction) is nonfunctional, or secondly, that whilst MxA is 
required to block the nuclear import of FLUAV genome. To do so, it requires additional 
auxiliary molecules induced by IFN. In IFN-pretreated A549-MxA cells, the MxA 
population constitutes the endogenously expressed IFN-induced MxA and exogenously 
expressed lentivirus-transduced MxA. To determine whether exogenously expressed 
MxA was nonfunctional, “wobble” MxA (kindly provided by Prof. Peter Staeheli) was 
introduced into the MxA-knockdown cells (shMxA). The amino acid sequence of the 
wobble MxA gene is identical to endogenous MxA. However, no shRNA-complementary 
sequences are present due to the introduction of synonymous substitutions. As a 
consequence, even after IFN-treatment of these cells, only the “wobble” MxA would be 
expressed. If the expression of the wobble MxA restored the ability to block the nuclear 
import of FLUAV genome in the shMxA cells, it would demonstrate that whilst MxA is 
essential in blocking viral genome nuclear entry, additional IFN-induced factors are 
required for its functionality.  
Briefly, wobble MxA was cloned into lentivirus backbone vector, then MxA-knockdown 
cells were transduced with lentivirus encoding wobble MxA and subsequently selected in 
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the presence of puromycin. Immunofluorescence analysis showed that MxA was strongly 
expressed in the cytoplasm in naïve A549 cells treated with IFN, but was not detected in 
A549 cells that had not been treated with IFN. As previously shown, MxA was not 
detected in shMxA cells regardless of whether the cells had or had not treated with IFN. 
In contrast, in shMxA/wMxA cells, MxA was detected in the cytoplasm of a proportion 
of shMxA cells and showed a granular staining pattern similar to the pattern observed in 
A549 cells treated with IFN (Fig. 3.16). Therefore, wobble MxA was successfully 
expressed in shMxA cells even though the cells constituively express shRNA against 
endogenous MxA.  
The fate of incoming nucleocapsids in shMxA/wMxA cells was then investigated. The 
procedure was basically the same as previously described. As seen in Fig. 3.17B, in naïve 
A549 cells, in the absence of IFN treatment, NP almost completely moved into the 
nucleus at 2 hour p.i., whilst in the presence of IFN treatment, there was no obvious 
nuclear staining of NP, and NP was seen as cytoplasmic bodies inside the cytoplasm. In 
MxA-knockdown cells (shMxA), irrespective of the presence or absence of IFN-
treatment, NP was efficiently imported into the nucleus (Panel C). In contrast, in 
shMxA/wMxA cells, in the absence of IFN treatment, NP was imported into the nucleus 
even if the cells are positive for MxA expression. However, in the presence of IFN 
treatment, NP nuclear import was blocked (Panel D). This result showed that the ability 
of IFN to block the nuclear import of influenza virus genome could be restored by 
introducing MxA back into MxA knockdown cells.?
Taken together, these experiments showed that influenza viral genomes were efficiently 
imported into the nucleus in cells in a pre-existing antiviral state in the absence of MxA 
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expression. However, over-expression of MxA alone is insufficient to account for the 
observed blockage of genome import, implying that there must be other molecules 
induced by IFN which function together with MxA to restrict genome import, or that 
MxA function requires modification by IFN.  
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3.2.7 Effects of MxA in plaque reduction assay 
It has been demonstrated above that MxA is an essential molecule in blocking viral 
genome import in cells in a pre-existing IFN-induced anti-viral state, but failed to confer 
resistance of viral genome import in stable cell lines by following the fate of incoming 
parental nucleocapsids using immunofluorescence and in situ hybridization. These 
studies also suggested that there are other ISGs which act in concert with MxA to block 
viral genome import. Plaque reduction assays were performed to confirm the role of MxA 
in blocking FLUAV genome import, in addition, and to identify potential ISGs in 
modulating MxA activities.  
Naïve A549 cells, MxA-knockdown cells and MxA-over-expressing cells, pre-treated or 
left untreated with IFN, were infected with 10-fold serial dilutions of influenza A viruses, 
after virus attachment to cells, unbound virus was removed and monolayers of cells were 
overlaid with agarose. Virus plaques were allowed to develop for 4 days, and plaque 
numbers were counted (Fig. 3.18). The number of plaques was reduced by 100-fold in 
A549 cells pretreated with IFN compared with untreated cells. Reduction in plaque 
numbers were partially relieved in MxA-knockdown cells pretreated with IFN, 
suggesting that MxA is an important antiviral molecule in the IFN-induced antiviral state. 
However, there is still about a 10-fold reduction in plaque numbers, suggesting the 
existence of other molecules induced by IFN that contribute to the IFN-induced antiviral 
state. Immunofluorescence studies above have shown that there is no restriction in 
blocking viral genome import in MxA-expressing A549 cells, this is also supported by 
plaque reduction assays. There was only a slight reduction in plaque numbers in MxA-
expressing A549 cells compared to that in naïve A549 cells, suggesting that over-
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expression of MxA alone is insufficient to confer resistance to influenza virus in stable 
cell lines. However, surprisingly, IFN treatment proved to be more effective in MxA-
expressing A549 cells than naïve A549 cells, reduction in plaque numbers following 
IFN-treatment were 1000-fold and 100-fold respectively, suggesting that stable 
expression of exogenous MxA in A549 cells enhances IFN-mediated resistance against 
influenza virus replication. Furthermore, this also points out a role of IFN treatment in 
enhancing MxA antiviral activity either by the modification of MxA itself, or modulation 
by other molecules induced by IFN.  
Overall, from the observations presented above, it is clear that MxA is essential but is not 
the only molecule in IFN-mediated antiviral resistance, and its activity strongly depends 
on IFN treatment. 
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3.3 Identification of potential ISGs involved in the establishment of IFN-induced 
antiviral state 
Over-expression and small interfering RNA (siRNA)-mediated knockdown of ISG 
expression are two common approaches to identify ISGs involved in the establishment of 
an antiviral state by IFNs. It has been shown that the activity of MxA against FLUAV 
depends on IFN treatment, suggesting that there are other auxiliary ISGs induced by IFN 
which act in concert with MxA to bring about its full functionality. It will be important to 
identify those molecules essential for MxA function. I aimed to clone ISGs and over-
express them either alone or in combination with MxA, but because of the time limit, I 
did not have enough time to screen all the ISGs.  
 
3.3.1 Effects of viperin in plaque reduction assay 
Viperin was recently reported to be an important antiviral molecule and showed a broad 
spectrum against viruses. In particular, viperin has been reported to inhibit influenza virus 
release by perturbing lipid-rafts (Wang, Hinson, and Cresswell, 2007). The lentivirus 
system was used to generate A549 cell lines that stably express N-terminal Pk-tagged 
viperin by selection with blasticidin. The viperin gene was cloned with specific primers 
by RT-PCR using total RNA extracted from A549 cells treated with IFNα. As seen in 
Fig. 3.19, over-expression of viperin was able to reduce plaque numbers by 10-fold 
compared to naïve A549 cells. However, IFN treatment of viperin-expressing A549 cells 
and naïve A549 cells, compared with untreated cells, resulted in reduction in plaque 
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numbers both around 100-fold, suggesting that IFN treatment does not enhance the 
antiviral function of viperin. These results clearly suggest that viperin is an important 
molecule in establishing the antiviral state induced by IFN.  
 
3.3.2 Role of ISG56 in plaque reduction assay 
In search of the ISGs that are able to inhibit FLUAV infection and potentially modulate 
MxA function, my colleague Dr. Lena Andrejeva was also looking for ISGs that are able 
to inhibit PIV5. She identified ISG56 was an important antiviral molecule against PIV5 
infection. Thus her cell line was used to investigate whether ISG56 also has antiviral 
activity against FLUAV. The role of ISG56 upon PIV5 was demonstrated in Fig. 3.20, 
PIV5 only formed pinpoint plaques in Hep2 cells, which could respond and produce IFN, 
whilst the plaque size was significantly bigger in Hep2/Npro cells, that cannot produce 
IFN because they constitutively express BVDV-Npro, which targets IRF-3 for 
degradation. In Hep2 cells with ISG56 knockdown mediated by lentivirus expressing 
shRNA, the plaque size was in between that in Hep2 and Hep2/Npro cells (Panel A).  
To examine whether ISG56 has antiviral activity against influenza A virus, plaque 
development was observed in naïve A549 cells and A549 cells with ISG56 knockdown. 
As seen in Panel B, FLUAV plaque size and numbers were comparable in naïve A549 
cells and ISG56 either pretreated with IFN or left untreated, suggesting that ISG56 is not 
involved in inhibiting FLUAV replication in IFN-induced antiviral state. 
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3.3.3 Effects of ISGylation on IFN-mediated plaque reduction 
ISG15 is an IFN-induced antiviral molecule and mediates the ISGylation of hundreds of 
proteins in IFN-treated cells. It has also been reported that a few IFN-induced molecules, 
RIG-I, PKR and MxA are targeted for ISGylation (Zhao et al., 2005). To understand the 
role of ISGylation in the IFN-induced antiviral state, the knockdown approach was used 
to generate cell lines expressing shRNA against the E3 ligase, Herc5, a component of the 
ISGylation pathway. An NS1B-over-expressing cell line was also genenated, as it has 
been reported influenza B virus NS1 protein (NS1B) inhibits ISGylation. These cell lines, 
treated or left untreated with IFNα, were infected with FLUAV, and virus plaques were 
allowed to develop for 4 days. As seen in Fig. 3.21, in NS1B-over-expressing cells, the 
size of viral plaques were significantly larger, although there was no increase in plaque 
numbers compared to naïve A549 cells. This suggests NS1B over-expression could 
facilitate FLUAV spread to neighbouring cells. However, it was not clear whether the 
inhibition of ISGylation by NS1B accounts for the increase in plaque size. In IFN-treated 
Herc5 knock down cells (shHerc5), there was a slight reduction in plaque numbers 
compared to IFN-treated naïve A549 cells. This result is perplexing, and it is in conflict 
with previous publications that ISGylation negatively regulates FLUAV replication 
(Tang et al., 2010). Thus further studies need to be carried out to understand the role of 
ISGylation in cells in a pre-existing IFN-induced antiviral state. 
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3.3.4 IFNγ  does not have a significant effect on viral plaque reduction 
Both type I and types II IFNs activate antiviral defence mechanisms by inducing the 
expression of antiviral genes. Although the signalling pathways and genes activated by 
IFN-α/β and IFN-γ partially overlap, there are genes selectively regulated by distinct 
IFNs (Der et al., 1998). It has been shown that IFN-α and IFN-γ reduce Hantaan virus 
replication with same efficiency (Oelschlegel, Kruger, and Rang, 2007), thus it was of 
interest to compare the consequences of addition of each of the two types of IFN on 
influenza virus plaque formation to see whether IFN-γ reduces plaque numbers to same 
extent as IFN-α.  
Monolayers of A549 cells were treated with 1000 u/ml IFN-α or IFN-γ for different times 
before inoculation with influenza virus, after adsoption, cell monolayers were washed 
with PBS and agarose overlay medium were added onto the cells to allow the plaques to 
grow. Cells were fixed and immunostaining with polyclonal antibody against influenza 
virus, and plaque numbers were counted. As shown in Fig. 3.21, IFN-γ, in contrast to 
IFN-α, did not significantly reduce plaque numbers. Rather, the plaque numbers in IFN-γ 
treated cells was very similar to that observed in untreated cells. It has been reported that 
no MxA protein and only minimal amount of MxA mRNA were detected in IFN-γ-
treated cells (Andersson et al., 2006), thus the difference seen with IFN-α and IFN-γ-
treated cells suggests that only those ISGs induced by type I IFN are responsible for the 
observed inhibition, and this correlation might be useful to identify potential effectors 
responsible for the IFN-induced block of influenza virus. 
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Discussions 
Experimental data presented in this thesis revealed important observations that have 
contributed to understanding how PIV5 and FLUAV interact with the IFN system. 
Moreover, these findings have contributed to elucidating the mechanism by which IFN 
inhibits influenza virus replication.  
 
4.1 Effect of interferon on the replication of PIV5 
Studies on PIV5 replication in cells in a pre-exisiting IFN-induced antiviral state showed 
that IFN treatment had at least two effects on viral proteins. First, experimental data from 
the analysis of virus proteins isolated by immunoprecipitation from infected cells showed 
that the relative expression levels of NP, P, and V proteins were not significantly 
different between IFN-treated and untreated cells. However, IFN-treatment did cause an 
obvious reduction in the relative levels of M, HN, and L proteins (Figure 3.2, Panel B). 
These results suggest that IFN causes a specific down-regulation in the expression of 
genes that are downstream of the V/P gene (Carlos, Fearns, and Randall, 2005). Second, 
results presented in this thesis also showed that IFN alters the intracellular distribution of 
the viral proteins synthesized. In cells pretreated with IFN, the NP and P proteins rapidly 
became localized in cytoplasmic inclusion bodies, whilst in the absence of IFN treatment, 
the majority of NP and P proteins were more evenly distributed throughout the cytoplasm 
(Fig. 3.5). Therefore, PIV5 virus replication is severely impaired within cells in a pre-
existing IFN-induced antiviral state. 
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4.2 Comparison of the mechanisms of PIV5 and FLUAV in dealing with the IFN 
response 
The co-evolution of viruses with their hosts has resulted in diverse mechanisms, 
employed by viruses, to evade the host anti-viral immune system. Viruses infection of in 
vivo system results in the production of large amounts of IFN to mount an effective 
defence against viral replication. As a result, viruses will ultimately encounter cells that 
are already in an IFN-induced antiviral state at some stage during an ongoing infection. 
In this thesis, it has been shown that PIV5 and FLUAV have evolved strikingly different 
strategies in dealing with cells in a pre-existing IFN-induced antiviral state. Although the 
IFN response significantly slows down PIV5 spread to neighbouring cells [Fig. 3.1A, see 
also (Young et al., 2003)], PIV5 manages to limit the amount of IFN induction, as well as 
to block IFN signalling by targeting STAT1 for proteasome-mediated degradation 
(Andrejeva et al., 2004; Didcock et al., 1999). However, to survive, PIV5 must maintain 
its genome in a functional state within cells in an IFN-induced antiviral state until those 
cells exit the antiviral state. This is corroborated by plaque reduction assays, which 
showed that IFN pretreatment did not significantly reduce PIV5 plaque numbers, but 
rather reduce plaque size (Fig. 3.1). Our working model is that upon infection of cells in 
an IFN-induced antiviral state, although virus replication is initially severely impaired, 
PIV5 targets STAT1 for proteasome-mediated degradation. Without continuous IFN 
signalling, the cells cannot maintain their antiviral state indefinitely. When the cell exits 
the antiviral state, normal virus replication is restored and a diffuse cytoplasmic 
distribution of the nucleocapsid and P proteins is observed [Fig. 3.5, see also (Carlos et 
al., 2009)]. However, the virus has to wait for 24-48 hours to dismantle the pre-existing 
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antiviral state, thus the plaque size in IFN-pretreated cells is significantly smaller 
compared to untreated cells.  
FLUAV also employs mechanisms to antagonize the IFN response. The expression of 
IFN-induced antiviral molecules is blocked in virus-infected cells (Fig. 3.1B). However, 
FLUAV replication is severely impaired within cells, which are in a pre-existing IFN-
induced anti-viral state. Thus by plaque reduction assays, it was shown that there was a 
significant reduction in plaque numbers in IFN-pretreated cells, however, the plaque size 
was comparable regardless whether the cells were or were not pretreated with IFN (Fig. 
3.1A). Thus it is reasonable to postulate that IFN pretreatment of naïve A549 cells 
inhibits FLUAV by preventing that one infectious virus particle from developing into a 
plaque at the initial foci of infection, so that only around 1% of the virus population is 
able to initiate productive infection in cells in a pre-existing IFN-induced antiviral state. 
Once virus replication is established in infected cells, a large number of progeny viruses 
can be produced in a short time and they are able to infect neighbouring uninfected cells 
by swamping the pre-existing IFN-induced antiviral state (Fig. 3.10). As a result, the size 
of plaques developed is compable regardless whether the cells were, or were not, 
pretreated with IFN (Fig. 3.1A). By immunofluorescence, it was shown that in the 
majority of infected cells in a pre-existing antiviral state, FLUAV failed to establish a 
productive infection (Fig. 3.8), and in those cells that are negative for viral antigens, the 
virus was unable to resume normal replication even if IFN was washed away and the 
infection was allowed to proceed. This led onto an investigation into the fate of FLUAV 
genomes within cells in an IFN-induced antiviral state.  
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4.3 Influenza A virus shut-off of host protein synthesis 
Currently, there is no consensus on the strategies utilized by influenza viruses to shut-off 
host protein synthesis. Beloso et al reported that a role of cellular mRNA degradation 
during infection maybe responsible for protein synthesis shut-off (Beloso et al., 1992). 
NS1 is a multifunctional protein has been implicated in a number of functions related to 
regulation of gene expression in infected cells. Some of these functions, such as 
inhibition of cellular pre-mRNA processing and transport, by NS1 interacting with 
CPSF30 and PABPII, would result in inhibition of gene expression and possibily in shut-
off host protein synthesis (Alonso-Caplen et al., 1992; Fortes, Beloso, and Ortin, 1994; 
Lu, Qian, and Krug, 1994; Nemeroff et al., 1998; Qian, Alonso-Caplen, and Krug, 1994; 
Qiu and Krug, 1994).  
Various mutant influenza A viruses with corresponding loss of function in their NS1 
genes have been used to study the effects of the NS1 protein on host protein expression 
during influenza A virus infection. Therefore, the overall levels of cellular protein 
synthesis was examined in cells infected with wild-type virus and mutant viruses loss the 
ability to interact with CPSF30 or PKR, to bind to dsRNA or to activate PI3K. Results 
from radioactive host cell labelling of proteins showed no major differences in cellular 
protein synthesis were found among these viruses (Fig. 3.4), the conclusion being that the 
NS1 protein does not play a major role in the shutoff of host protein synthesis. Clearly, 
some other viral protein plays a more crucial role than NS1 in the shutoff of cell protein 
synthesis in influenza virus-infected cells. Recently it has been reported host RNA 
polymerase II (Pol II), a multiprotein complex composed of 12 subunits responsible for 
the transcription of mRNAs, is targeted for degradation by influenza viral polymerase 
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(Rodriguez, Perez-Gonzalez, and Nieto, 2007; Vreede et al., 2010). Therefore it has been 
proposed that the viral RNA polymerase-mediated inhibition of Pol II plays an important 
role in inhibiting host gene expression and may contribute to the shut-off of host protein 
synthesis.	  
 
4.4 Stages of influenza A virus replication blocked by IFN 
Influenza virus replication is highly sensitive to the antiviral action of IFN. The precise 
step of influenza virus life cycle that is inhibited in IFN-treated cells has been difficult to 
establish and to date, there is no consensus regarding which stage of influenza virus 
replication is inhibited. It has been reported that inhibition occurs at the level of primary 
transcription (Bean and Simpson, 1973; Ransohoff et al., 1985), however, Repick et al  
suggested that inhibition of viral replication occurs at a stage between primary 
transcription and secondary transcription (Repik, Flamand, and Bishop, 1974). Data 
presented here demonstrate that type I IFN triggers efficient inhibition of influenza virus 
replication. This inhibition appears to be at the stage of nuclear import of viral RNPs, 
since the nuclear translocation viral RNPs and subsequent synthesis of primary 
transcripts as well as viral proteins translation are absolutely essential virus replication. 
Subsequently, studies of FLUAV replication in cells in which MxA expression was 
knocked down clearly indicate that MxA is an essential component induced by IFN in 
blocking viral genome import, as the IFN-mediated inhibition is aborted in MxA-
knockdown cells.  
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4.5 MxA recognition of NP protein 
Exactly how MxA prevents nuclear import of viral RNPs is not clear, but it is 
conceivable that MxA recognizes influenza virus nucleocapsids and prevents their 
transport through the cells. Previous studies have shown that the human MxA protein 
blocks the genome import of Thogoto virus, an influenza virus-like orthomyxovirus, by 
recognizing the viral nucleocapsids (Kochs and Haller, 1999b). It was also reported that 
MxA targets influenza virus NP protein in minireplicon systems. Over-expression of NP 
effectively rescues viral transcriptional activity from the MxA inhibition (Turan et al., 
2004).  
Not only was MxA reported to target nucleocapsids of orthomyxovirus, it also targets 
bunyavirus N protein. MxA was found to recognize newly synthesized viral N protein 
and forms a complex in the perinuclear region, leading to a depletion of N protein, thus 
blocking virus genome amplification.  
Influenza virus NP is associated with the viral genome, and together with viral 
polymerases, forms the nucleocapsid. However, there is no solid evidence that MxA 
directly associates with influenza virus NP protein, the interaction was only demonstrated 
in cross-linking conditions (Turan et al., 2004). Nevertheless, how exactly MxA 
recognizes viral RNPs and prevents their nuclear translocation is not clear. It is thought 
that MxA can self-assemble into ring-structures and recognizes the multimeric lattice of 
NP in the vRNPs and wraps around them to cover the nuclear import signals that are 
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normally exposed. Alternatively, MxA may direct vRNPs to other places in the 
cytoplasm where they are subsequently degraded.  
 
4.6 Cell type and virus strain specificity of the antiviral function of MxA 
The antiviral function of MxA appears to be rather complicated. Previous studies have 
shown that MxA inhibits a poorly defined step after primary transcription, this was 
demonstrated by infecting murine 3T3 cells stably over-expressing MxA with fowl 
plague virus (FPV-B) (Pavlovic, Haller, and Staeheli, 1992). Results presented here, from 
in situ hybridization and immunofluorescence in A549 cells infected with H3N2 viruses, 
suggest that MxA is an essential molecule induced by IFN in blocking influenza virus 
genome import. The difference is difficult to reconcile, but it could have been due to the 
different cell types used. Over-expression of MxA in Vero cells appears to be more 
effective in reducing influenza virus plaque numbers than in A549 cells (data not shown). 
Circumstantial evidence indicates that the cell type-specific antiviral function of MxA is 
not unique to influenza viruses. Previous studies which showed that Measles virus 
transcription is inhibited only in certain human cell lines (Schneider-Schaulies et al., 
1994; Schnorr et al., 1993), strongly support the idea of the existence of auxiliary cellular 
factors that modulate the antiviral activities of MxA. Results presented here, from studies 
using MxA over-expressing cells, are in agreement with previous reports. As shown in 
the results section, constitutive expression of MxA in naïve A549 cells or introducing 
wobble MxA back into MxA knockdown cells is insufficient to block nuclear import of 
influenza virus RNPs (Fig. 3.15 and Fig. 3.17D), but wobble MxA was able to restore the 
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ability of IFN to block the nuclear import of FLUAV genome in the shMxA cells, 
suggesting that other molecules induced by IFN are required for MxA function. Thus, it 
may be that MxA recognition of NP is facilitated by one or more auxiliary proteins. It is 
very likely that IFN-induced molecules bridge the interaction of MxA with NP, or rather, 
IFN-induced modification of MxA may modulate its antiviral activity. Previous studies 
have shown that MxA is ISGylated (Dastur et al., 2006; Zhao et al., 2005), and it has also 
been showed that ISG15 and/or its conjugates play an important role in protecting cells 
from infection by several viruses. However, the mechanism by which ISGylation exerts 
antiviral activity has not been established. It is plausible that by targeting MxA, ISG15 
increases its stability or induces conformational change to form lattice strucrture for 
interaction with other proteins. 
 
The difference of antiviral functions of MxA seen may be a consequence of differences in 
sensitivity to MxA between strains of influenza A viruses. Previous studies have shown 
that avian FPV-B virus replication in MxA over-expressing 3T3 cells was significantly 
reduced (Pavlovic et al., 1990b). It was also reported that human H1N1 (1918) virus-
based mini-replicon system was almost insensitive to inhibition by MxA, whilst the avian 
H5N1 virus was significantly inhibited (Dittmann et al., 2008).  
 
4.7 Future prospects 
MxA belongs to the dymamin superfamily of GTPases that is involved in endocytosis 
and vesicle trafficking between intracellular membrane compartments. Mx GTPases have 
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a relatively low affinity for GTP and a intrinsic high rate of GTP hydrolysis. They 
consists of an N-terminal GTPase domain, the central interactive domain (CID), and a C-
terminal GTPase effector domain (GED) (Haller, Stertz, and Kochs, 2007). The CID and 
GED were proposed to form a stalk which mediates oligomerization and self-assembly. 
Recently, the crystal structure of the stalk region has been resolved (Gao et al., 2010), 
and it was shown MxA assembles in a criss-cross pattern to form higher-order structures. 
This provides new insights into the structural basis for MxA antiviral functions, thus it 
will be of great interest to unravel the precise mechanism of MxA antiviral action by 
mapping the domain(s) that mediate(s) the interaction of MxA with viral nucleocapsid 
protein. Currently, I am in the process of generating the Pk-tagged MxA aimed at finding 
the cellular factors that are associated with MxA by immunoprecipitations.  
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A.1 Plasmid map of the pLKO.1 with shRNA construct 
  
Description Vector Element 
U6 Human U6 promoter drives RNA Polymerase III transcription for generation of shRNA 
transcripts. 
cPPT Central polypurine tract, cPPT, improves transduction efficiency by facilitating nuclear 
import of the vector's preintegration complex in the transduced cells.  
hPGK Human phosphoglycerate kinase promoter drives expression of puromycin.  
Puro R Puromycin resistance gene for selection of pLKO.1 plasmid in mammalian cells. 
sin 3'LTR 3' Self-inactivating long terminal repeat. 
f1 ori f1 bacterial origin of replication. 
Amp R Ampicillin resistance gene for selection of pLKO.1 plasmid in bacterial cells 
pUC ori pUC bacterial origin of replication. 
5'LTR 5' long terminal repeat. 
RRE Rev response element. 
pLKO.1 is a cloning vector of 
shRNA. It contains the necessary cis 
elements for packaging, reverse 
transcription, and integration for 
subsequent production of the 
lentivirus particles. 	  
	   144	  
                       
Detail of shRNA insert. The U6 promoter directs RNA Polymerase III transcription of 
the shRNA. The shRNA contains 21 "sense" bases that are identical to the target gene, a 
loop containing an XhoI restriction site, and 21 "antisense" bases that are complementary 
to the "sense" bases. The shRNA is followed by a polyT termination sequence for RNA 
Polymerase III. 
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A.2 Plasmid map of the pdlNotI’IRESpuro vector  
 
                     
Plasmid generated by Dr. Yun-Hsiang Chen, University of St Andrews, UK.  
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A.3 pGEM-T Easy Vector Map and sequence reference points 
                      
 
The promoter and multiple cloning sequence of the pGEM-T easy vector. The top 
strand corresponds to the RNA synthesized by T7 RNA polymerase. The bottom strand 
corresponds to the RNA synthesized by SP6 RNA polymerase. 
Virus Mutation Comments 
rUd-NS1-R38A R38A Prevents binding of dsRNA to NS1 thereby preventing activation 
of 2’-5’OAS. Also known to be important in the co-precipitation 
of NS1 and RIG-I (Min and Krug, 2006; Wang et al., 1999). 
rUd-NS1-123/4 I123A / M124A Prevents binding of NS1 to PKR (Min et al., 2007). 
rUd-NS1-103/106 F103L / M106I Destabilisation of the NS1-CPSF30 interaction. 
rUd-NS1-184-8(L) Residues 184-188  
GLEWN → RFLRY 
(L28F/N29S in NS2) 
Prevents interaction of NS1 and CPSF30 (Noah, Twu, and Krug, 
2003). 
rUd-NS1-184-8(P) Residues 184-188  
GLEWN → RFPRY 
(L28F/N29Q in NS2) 
Recovered with rUd-NS1-ΔCPSF-RFLRY as a mixed virus 
population.  
rUd-NS1-Y89F Y89F in Udorn background Prevents interaction of NS1 with PI3-K (Hale et al., 2006).  
rUd-NS1-P164/7A P162A, P164A Double proline mutant Shin et al. (2007). Reported to prevent the 
interaction of NS1 with PI3-K. 
rUd-NS1-P162/4/7A P162A, P164A, P167A Triple proline mutant Shin et al. (2007) (although they reported it 
as a double mutant their sequence is a triple mutation). Causes 
increased apoptosis. 
rUd-NS1-Δ99 138 amino acid C-terminal truncation of 
NS1 due to stop codon at residue 99 
Recovered with rUd-NS1-P162/4/7A as a mixed virus population.  
Table 3.1. Amino acid mutations introduced into the A/Udorn NS1 protein of mutant viruses. 
Fig. 1.1. Recognition of viral PAMPs by cellular sensors. RIG-I rec-
ognize different RNA viruses by detecting short dsRNAs and ssRNAs 
with 5’-triphosphate ends, whilst MDA-5 recoginizes long dsRNAs. 
LGP2 functions as a positive regulator in RIG-I and MDA5-mediated 
virus recognition. Activation of RIG-I is positively and negatively regu-
lated by ubiquitin ligases TRIM25 and RNF125, respectively. RIG-I and 
MDA5 interact with a common downstream signalling molecule, MAVS 
through homophilic interactions between CARD domains. MAVS then 
activates signaling cascades leading to the expression of type I IFN genes 
(diagram adapted from Takeuchi & Akira, 2010). 
Fig. 1.2. Schematic representation of activation of IFN-β activation from RLRs sig-
nalling.  Viral RNA, generated during virus replication inside the cells, activates the RNA 
helicases MDA-5 and RIG-I, and they subsequently recruit the adaptor Cardif/VISA/
MAVS/IPS-1. This adaptor, in turn, recruits signalling components essential for the ac-
tivation and nuclear translocation of IRF- 3 or NF-kB. These transcription activators are 
essential in the assembly of transcription machinery for the activation of IFN-β promoter 
(Diagram adapted from Randall and Goodbourn, 2008).
Fig. 1.3. Type I and type II IFN signalling pathways. Type I signalling is initi-
ated by type I IFNs binding to a common receptor at the cell surface. This leads 
to the activation of the receptor-associated tyrosine kinases JAK1 and Tyk2, 
which phosphorylate STATs. Phosphorylated STAT1 and STAT2 form a het-
erodimer with each other by recognizing SH2 domains, and then translocated 
into the nucleus, where it interacts with the DNA-binding protein IRF-9, forming 
ISGF3. ISGF3 binds to a cis element, ISRE, located on in the promoter region 
of most ISGs. Type II IFN binds a distinct receptor, composed of IFNGR1 and 
IFNGR2, which are associated with JAK1 and JAK2, respectively. Activated 
JAKs phosphorylate STAT1, inducing the formation of STAT1 homodimers that 
translocate to the nucleus and bind to GAS elements of certain ISGs, thereby 
initiating their transcription (Diagram adapted from Platanias, 2005).
  
 
Fig. 1.4. Schematic representation of the Parainfluenza virus type 5 
(PIV5) virion structure. The spherical particle of PIV5 consists of an 
outer lipid membrane with membrane protein hemagglutinin-neuramini-
dase (HN) attachment glycoprotein, and the fusion (F) glycoprotein. The 
small integral membrane protein, SH, is unique for PIV5. Underneath the 
lipid bilayer is matrix protein, essential for maintaining virus integrity. 
Inside the virion is the single-stranded, negative-sense RNA genome en-
capsidated by nucleocapsids protein (NP). Associated with NP are the L 
and P proteins, which have the RNA-dependent RNA polymerase activ-
ity. V protein of PIV5 is found as a virion component, whilst V proteins 
of other members of paramyxoviruses are found only in virus-infected 
cells.
Fig. 1.5. Genetic map of a typical member of each genus of the Paramyxo-
viridae. The single-stranded, non-segmented, negative-sense RNA genome of 
paramyxoviruses consists of 6 to 10 tandem linked genes, depending on the spe-
cies. The genes are shown as boxes that are drawn to approximate scale. These 
genes are separated by intergenic regions. Flanking the genome is a 3’ extracis-
tronic region of ~50 nucleotides known as the leader and 5’ extracistronic region 
of 50 to 161 nucleotides known as the trailer.
Fig. 1.6. Schematic representation of the influenza A virus particle. Virions 
are decorated with two surface glycoproteins, HA and NA. M2 ion channel pro-
tein is also inserted into the lipid bilayer. Underneath the lipid envelope is M1 
protein. The genome is composed of eight segments of single-stranded negative-
sense RNA genome encapsidated by the nucleoprotein. These ribonucleoproteins 
(RNPs) are also associated with components of polymerase complex (PB2, PB1, 
PA). NS1 and PB1-F2 are only found in infected cells, therefore they are not 
displayed in the diagram. The proteins encoded by each genomic segment are 
indicated. Diagram adapted from Lamb & Krug, 2001.
Fig. 1.7. Schematic diagram of the influenza viral life cycle. Following receptor-
mediated endocytosis and fusion/uncoating process inside the endosome, the viral 
ribonucleoprotein (vRNP) complexes are released into the cytoplasm and subse-
quently transported to the nucleus, where replication and transcription occur. See 
text for more details. Diagram adapted from Neumann and Kawaoka, 2010.
Fig. 1.8. Replication and transcription of the influenza virus ge-
nome. (A) The major steps of replication and transcription of the in-
fluenza virus genome. See main text for more details. (B) The “pan-
handle” model of influenza virus ribonucleoprotein complex. Diagram 






Fig. 3.1. (A). Plaques of PIV5 or influenza A virus formed on monolayers of A549, 
A549/BVDV-Npro, or A549/BVDV-Npro pretreated with 1000u/ml IFN for 16h. 
note A549/BVDV-Npro cells cannot produced IFN in response to virus infection 
as BVDV-Npro targets IRF3 for degradation. influenza A virus infected cells were 
fixed at 5 days p.i. and immunostained with polyclonal anti-influenza A virus an-
tibody, whilst PIV5 infected cells were fixed at 10 days p.i. and immunostained 
with an antibody to PIV5 NP. The plaque numbers formed on monolayer of cells 
were shown on the top right corner of each well. (B). A549 cells were infected 
with influenza A virus at low MOI of 0.1 pfu/cell, cells were fixed at 16 hours post-
infection and double-stained with antibodies against influenza A virus NS1 protein 
and cellular protein MxA. The cells were also counter-stained with DAPI to reveal 
the nuclei. NS1, MxA and DAPI imaged were merged using SPOT software (v4.6).
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Fig. 3.2. Metabolic labelling of Influenza A virus and PIV5 infection of A549 
cells. (A). A549 cells were infected with PIV5  or mock-infected at an MOI 
of 5pfu/cell, and at different time point post-infection, cells were labelled with 
S35-Methionine for one hour and cell lysate were prepared at the end of label-
ling period. Viral proteins were analysed  with SDS-PAGE and phosphoimag-
ing. A549 cells were, or were not pretreated with IFN were either mock-infected 
or infected with PIV5 (B) or FLUAV (C), and at different time post-infection, 
cells lysate were prepared. PIV5 proteins were precipitated with a pool of mono-
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Fig. 3.3. Schematic diagram of the NS1 protein of recombinant mutant vi-
ruses. The NS1 protein of A/Udorn/72 virus is 237 amino acids (aa) in length. It 
is notionally divided into a 73 aa N-terminal RNA binding domain and a 164 aa 
C-terminal effector domain. The mutations introduced into the recombinant A/
Udorn/72 (rUd) viruses described in Table. 3.1 are shown. The NS1 and cellular 
protein/RNA interactions affected by each mutation is highlighted in the open 
boxes. The “stop sign” indicates the position of the termination codon introduced 





























































Fig. 3.4. Cell shut-off is not affected by mutations in NS1 
protein. Cultures of A549 cells were infected with the recom-
binant wild type rWSN virus, A/Udorn virus or mutant rUd vi-
ruses in which the interactions with dsRNA, PI3K, CPSF30 and 
PKR were inhibited. The mutations introduced into NS1 and the 
functions inhibited by each mutant are summarized in Table. 3.1. 
Cells were infected at a MOI of 5 PFU/cell. The cultures were 
labelled at 12 h p.i. with [35S]Met-Cys (200 Ci/ml) for 1 h and 
the cells were lysed with immunoprecipitations buffer. The cell 





Fig. 3.5. Immunofluorescence of PIV5 virus in cell pretreated or left 
untreated with IFN. A549 cells were either pretreated (+IFN) or left un-
treated (-IFN) with 1000u/ml IFN for 16h and infected with PIV5 at an MOI 
of 5pfu/cell, at 24h (A and C) and 48 h (B and D) post-infection, cells were 
fixed and immunostained with monoclonal PIV5 NP and P antibodies. The 








Fig. 3.6 Neutralization antibody was able to prevent PIV5 virus spread. A549 
cells were infected with PIV5 at low MOI of 0.1 pfu/cell. After virus binding to 
cells, the inoculum were washed away and cells were added with FBS free DMEM 
in the presence (B and D) or absence (A and C) of neutralizing antibody. Cells were 
fixed and immunostained with NP and P antibodies at different time post-infection.
The cells were also counter-stained with DAPI to show the localization of the nu-



















Fig. 3.7. PIV5 was able to overcome the antiviral state in the presence of neu-
tralizing antibody. A549 cells pretreated (+IFN) or left untreated (-IFN) with IFN 
O/N were infected with PIV5 at a high MOI of 10 pfu/cell. After virus binding to 
cells, the inoculum were washed away and cells were added with FBS free DMEM 
in the presence (A) or absence (B) of neutralizing antibody. Cells were fixed and im-
munostained with monoclonal NP/P antibodies at different time post-infection. The 
cells were also counter-stained with DAPI to reveal the localization of nuclei, and 









Fig. 3.8. (A). A549 cells were pretreated (+IFN) or left untreated (-IFN) with 
1000u/ml IFN for 16h and infected with A/Udorn at an MOI of 5 pfu/cell. cells 
were fixed at 12p.i. and stained with anti-NS1 antibody and DAPI. Images were 
captured and merged using Nikon SPOT software.
(B). A549 cells were pretreated (+IFN) or left untreated (-IFN) with 1000u/ml 
IFN for 16h and infected with A/Udorn at an MOI of 5 pfu/cell. cells were fixed 
at 12p.i. and double-stained with sheep anti-NS1 antibody and monoclonal anti-
MxA antibody. The cells were also counter-stained with DAPI and images of 








Fig. 3.9. IFN treatment after virus infection has no inhibitory effect on 
virus replication. A549 cells were infected with influenza A virus at MOI 
of 5 pfu/cell. one hour after infection, inoculum was removed, and cells 
were treated with 1000u/ml IFN (+IFN) or left untreated (-IFN). At differ-
ent time point post-infection cells were  fixed  and immunostained  with 
sheep  anti-NS1  antibody.
(A)
(B) Mock NS1
Fig. 3.10. The ability of influenza A virus to overcome the antiviral state 
depends on MOI. (A). Confluent A549 cells were pretreated with 1000u/ml 
IFNα and infected with influenza A virus at different MOI, cells were fixed 
and immunostained with anti-NS1 antibody 12 h p.i. and the percentage of 
NS1 positive cells was calculated by counting cells positive for NS1 versus the 
total number of cells per field of view under the microscope. (B). As a control, 
A549 cells untreated with IFN were infected with influenza A virus at MOI of 
0.5 pfu/cell, at 12h p.i. cells were fixed and stained with sheep NS1 antibody 
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Fig. 3.11a. IFN pretreatment blocks the nuclear import of viral nucleocapsids. A549 
cells pre-treated with IFN (+IFN) or left untreated (-IFN) were either mock-infected or 
infected with influenza A virus at a high MOI of 500 pfu/cell in the presence (+CHX) 
or absence (-CHX) of 100μg/ml cycloheximide (CHX) on ice for 45min to allow virus 
binding to cells. After that, virus inoculum was removed and unbound viruses were 
washed away with ice-cold PBS and virus infection was synchronized by adding pre-
warmed FBS-free medium onto the cells. CHX was kept the whole time during infec-
tion. At 2 hours p.i., the cells were fixed and stained with monoclonal anti-NP antibody. 
The cells were also counter-stained with DAPI to reveal the location of the nuclei.The 











Fig. 3.11b. IFN pretreatment blocks the nuclear import of viral genome. A549 
cells pre-treated with IFN (+IFN) or left untreated (-IFN) were either mock-in-
fected or infected with influenza A virus at a high MOI of 500 pfu/cell in the 
presence  of 100μg/ml cycloheximide (+CHX) on ice for 45 min to allow vi-
rus binding to cells. After that, virus inoculum was removed and unbound vi-
ruses were washed away with ice-cold PBS and virus infection was synchronized 
by adding pre-warmed serum-free medium onto the cells. CHX were kept the 
whole time during the infection. At 2 hours p.i., the cells were fixed and viral ge-
nome localization was revealed by in situ hybridization using DIG-labeled probes 
specific for genomic NS1. The cells were also counter-stained with DAPI to re-
veal the location of the nuclei.The subcellular localization of NS1 genome  was 
visulized using Nikon  Microphot FXA 20× (A) or with DeltaVision 60× (B). 
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Fig. 3.12. Knock down of MxA expression in A549 cells with lentivirus 
expressing shRNA against MxA.  Naive A549 cells or A549 cells trans-
duced with lentivirus expressing shRNA against MxA were treated or left 
untreated with 1000u/ml IFN. The level of MxA expressed was determined 
by western blot (A) or immunofluorescence (B) 16 hours after IFN treat-
ment. For western blot, cells were lysed using immunoprecipitation buffer 
and sonicated to reduce sample viscosity. MxA, STAT1 and actin expression 
was examined using rabbit anti-MxA, monoclonal anti-STAT1 and mon-
oclonal anti-actin, respectively. For immunofluorescence, MxA expres-
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Fig. 3.13. MxA is essential in blocking FLUAV genome import in cells in a 
pre-existing IFN-induced antiviral state. A549 cells (A549)                   and MxA 
knockdown cellss (shMxA), pre-treated (+IFN) or left untreated (-IFN) with 
1000u/ml IFN, were either mock-infected or infected with FLUAV at a very high 
MOI of 500 pfu/cell in the presence of 50μg/ml cycloheximide on ice for 45min 
to allow virus binding to cells. Subsequently, virus inoculum was removed and 
unbound viruses were washed away with ice-cold PBS and virus infection was 
synchronized by adding pre-warmed FBS-free medium onto the cells. CHX were 
kept the whole time during infection. At 2 h p.i., cells were fixed and stained with 
monoclonal anti-NP antibody. The cells were also counter-stained with DAPI to 
reveal the location of the nuclei. 
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Fig. 3.14. Generation of MxA over-expression cell line in A549 
cells. A549 cells were infected with lentivirus expressing MxA, or 
were left uninfected. Stable cell line were selected with puromycin 
2ug/ml. Cells were treated with 1000u/ml IFNα as indicated. The 
amount of MxA expressed was determined by western blot (A) or 
immunofluorescence (B) analysis using  monoclonal anti-MxA 16 







Fig.3.15. Over-expression of MxA is insufficient to block FLUAV genome 
import. A549 cells (A549) and MxA over-expression cells (A549-MxA), 
treated with 1000u/ml IFN (+IFN) or left untreated (-IFN), were either mock-
infected or infected with FLUAV at a high MOI of 500 pfu/cell in the pres-
ence of 50μg/ml cycloheximide on ice for 45min to allow virus binding to 
cells. Subsequently, virus inoculum was removed and unbound viruses were 
washed away with ice-cold PBS and virus infection was synchronized by add-
ing pre-warmed FBS-free medium onto the cells. CHX were kept the whole 
time during infection. At 2 h p.i., cells were fixed and stained with mono-




Fig. 3.16. Generation of wobble MxA over-expression cell line in 
shMxA cells. Lentivirus transduced, blasticidin-resistant shMxA cells 
were infected with lentivirus construct expressing wobble MxA, or were 
left uninfected. The amino acid sequence of wobble MxA is identical to 
endogenous MxA, but there is no complementary sequence to shRNA 
against MxA due to the introduction of synonymous substitutions. Sta-
ble cell line were selected with puromycin (2μg/ml). The level of MxA 
expression in naive A549 cells (A549), MxA knockdown cells (shMxA) 












Fig. 3.17. Effects of introducing MxA back into MxA-knockdown 












Fig. 3.17. Effects of introducing MxA back into MxA-knockdown cells 
upon virus genome import. A549 cells (B), MxA knockdown cellss (C), 
and shMxA knockdown cells over-expressing wobble MxA (D), pre-treated 
(+IFN) or left untreated (-IFN) with 1000u/ml IFN, were either mock-infected 
or infected with FLUAV at a very high MOI of 500 pfu/cell in the presence of 
50μg/ml cycloheximide on ice for 45min to allow virus binding to cells. Subse-
quently, virus inoculum was removed and unbound viruses were washed away 
with ice-cold PBS and virus infection was synchronized by adding pre-warmed 
FBS-free medium onto the cells. At 2 h p.i., cells were fixed and double-stained 

























Fig. 3.18.  Role of MxA in plaque reduction assay. Naïve A549 cells 
or cells with MxA knockdown (shMxA) or overexpression (A549-MxA) 
were treated with 1000u/ml IFN for 16 hours or left untreated. Monolayer 
of cells were infected with influenza A virus and the viruses were allowed 
to form plaques under 1% agarose. Plaque were visualized by immunos-
taining with polyclonal antibody against influenza A virus. Viral plaques 
were shown in Panel A, and the plaque numbers were plotted (Panel B).The 
number on the top left corner of  each well in Panel A indicates the folds of 









Fig. 3.19. Role of viperin in plaque reduction assay.  Naive A549 cells 
or viperin over-expressing A549 cell lines were treated with 1000u/ml IFN 
for 16 hours or left untreated. Monolayer of cells were infected with influ-
enza A virus and the viruses were allowed to form plaques under 1% aga-
rose. Plaque were visualized by immunostaining with polyclonal antibody 


























Fig. 3.20. Effect of ISG56 knockdown on plaque formation of PIV5 and 
FLUAV. (A) Plaques of PIV5 formed on monolayers of Hep2, Hep2/Npro, 
and Hep2/shISG56. Note Hep2/Npro cells cannot produce IFN in response 
to virus infection as BVDV-Npro targets IRF-3 for degradation (Hilton et al., 
2006Down).Hep2/shISG56 was generated by lentivirus expressing shRNA 
against ISG56. Cells were fixed at 6 days p.i., and plaques were visulized by 
staining with crystal violet. (B) FLUAV plaque formation on naïve A549 cells 
or cells with ISG56 knockdown (A549/shISG56) were treated with 1000u/
ml IFN for 16 hours or left untreated. Monolayer of cells were infected with 
FLUAV and the virus were allowed to form plaques under 1% agarose. Plaque 
were visualized by immunostaining with polyclonal antibody against FLUAV.
The number on the top left corner of  each well in Panel B indicates the folds 








Fig. 3.21.  Effects of ISGylation on IFN-mediated plaque reduc-
tion. Naïve A549 cells or cells knocking down E3 (shHerc5)  of IS-
Gylation pathway or cell line overexpressing influenza B NS1 gene 
(which prevent ISGylation) were treated with 1000u/ml IFNα for 16 
hours or left untreated. Monolayer of cells were infected with FLUAV 
and the virus were allowed to form plaques under 1% agarose. Plaque 







Fig. 3.22. IFNγ does not have an obvious effect on influenza virus 
plaque reduction in contrast to IFNα. Naïve A549 cells were treated 
with 1000u/ml IFNα, IFNγ for the indicated time or left untreated. Mon-
olayer of cells were infected with influenza A virus and the virus were al-
lowed to form plaques under 1% agarose. Plaque were visualized by im-
munostaining with polyclonal antibody against influenza A virus. Plaques 
numbers were counted and and plotted.
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